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ABSTRACT 
Telomere shortening is a major mechanism to induce telomere uncapping and thus to 
signal growth arrest and/ or apoptosis and can be caused by different mechanisms, one 
of which is damage to DNA, to which telomeres appear to be particularly sensitive. 
Contradictory data exists on the relationship between conventionally used 
chemotherapeutic drugs and the telomere/ telomerase complex. The aim of the work 
described in this thesis was to determine whether or not damage to telomeres played a 
significant role in the cytotoxic action of the anti-cancer drugs cisplatin and etoposide. 
Two cell lines were used with either short (neuroblastorna cell line SHSY5Y) or long 
(lymphoblastic T cell line 1301) telomeres. Cytotoxic effects of the drugs were 
assessed by growth inhibition assays and measurement of apoptosis and cell cycle 
progression by flow cytometry. Etoposide caused readily detectable DNA strand 
breakage and led to formation of nuclear foci of phosphorylated histone y-H2A. X. 
Cisplatin treatment did not induce strand breaks after initial drug exposure but strand 
breaks and DNA damage foci were detected after further incubation. 
For cells with either long or short telomeres, no detectable changes in total telomere 
length or overhang length were observed before apoptosis became manifest. 
Preferential occurrences of single strand breaks in the G-rich strand of telorneres were 
not found. Through the development of a dual staining method it was established that 
drug-induced histone H2A. X foci did not colocalise to the telomeres. Telomerase was 
transiently activated by lower concentrations of etoposide and its activity decreased 
only after onset of apoptosis. 
Taken together, the results show no indication that telorneres and/ or telomeric 
damage play any preferential role as signal transducers towards apoptosis and/ or 
growth arrest in either of these cell lines. Also, the protective function of telornerase &-I - 
seems to be telomere independent. The data are consistent with a model of drug- 
induced growth arrest and apoptosis being triggered by damage elsewhere in the 
genome. 
III 
ABBREVIATIONS 
(v/V) volume per volume 
(W/v) weight per volume 
ALT Alternative lengthening of telomeres 
AP Apurinic/ apyrimidinic 
BER Base excision repair 
Bp Base pairs 
BrdU 2-bromo-5-deoxuridine 
BSA Bovine serum albumin 
CDK Cyclin dependent kinase 
CKI Cyclin dependent kinase inhibitor 
CPD Cyclobutane pyrimidine dimers 
CSPD Chemiluminescent substrate 
D-loop Displacement loop 
DAPI 4'-6-Diamidino-2-phenylindole 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DNA-PK DNA dependent protein kinase 
DSB Double strand break 
ELISA Enzyme linked immunosorbent assay 
FADD Fas associated death domain 
FADU Fluorescence detected alkaline DNA unwinding 
FCS Foetal calf serum 
FISH Fluorescent in situ hybridisation 
FITC Fluorescein isothiocyanate 
HR Homologous recombination 
IV 
hTERT Catalytic subunit of telomerase 
hTR Telomerase RNA template 
ICP-MS Inductively coupled plasma- mass spectrometry 
IR lonising radiation 
T'I'L 
r..,. Up Kilobase pair 
Mb Megabase 
MMR DNA mismatch repair 
MW Molecular weight 
NER Nucleotide excision repair 
NHEJ Non homologous end joining 
NIMA Never in mitosis A 
NT Nucleotide 
OD Optical density 
P Phosphorus 
PARP Poly ADP ribose polymerase 
PAS Particle analysing system 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD Population doubling 
PFGE Pulsed field gel electrophoresis 
PIMMS Plasma ionisation multicollector mass spectrometer 
PIN2 Protein interacting with the never in mitosis A protein kinase 
PNA Peptide nucleic acid 
PNK Polynucleotide kinase 
PPB Parts per billion 
PPM Parts per million 
V 
PPT Parts per trillion 
POTI Protection of telomeresl 
Pt Platinum 
Rb Retinoblastoma 
RF Radio frequency 
RNA Ribonucleic acid 
SA- P Gal Senescence associated- Beta galactosidase 
SDS Sodium dodecyl sulphate 
SIPS Stress induced premature senescence 
SSC Sodium chloride, sodium citrate 
SRB Sulphorhodamine B 
SSB Single strand break 
TAP Telomeric associated proteins 
TBP TATA binding protein 
TCA Trichloroacetic acid 
TIN2 TRF I interacting protein 2 
TNF Tumour necrosis factor 
TRAP Telomeric repeat amplification protocol 
TRFI TTAGGG repeat binding factor I 
TRF2 TTAGGG repeat binding factor 2 
TTD Trichothiodystrophy 
UV Ultraviolet 
XP Xeroderma pigmentosum 
vi 
PUBLICATIONS 
Parts of the research in production of this thesis has led to the publishing of the 
following papers: 
Martin-Ruiz, C., Saretzki, G., Petrie, J., Ladhoff, J., Jeyapalan, J., Wei, W., Sedivy, J. 
and von Zglinicki T. (2004) Stochastic variation in telomere shortening rate causes 
heterogeneity of human fibroblast replicative life span. JBiol Chem., 17,17826-33. 
Jeyapalan, J., Leake, A., Ahmed, S., Saretzki, G., Tilby, M. and von Zglinicki, T. 
(2004) The role of telomeres in etoposide induced tumour cell death. Cell Cycle., 3, 
1169-74. 
Published abstracts: 
Ottley, C. J., Pearson, D. G., Jeyapalan, J. C., Tilby, M. J., Nowell, G. M. von Zglinicki, 
T. (2001) Determination of P and Pt in clinical DNA samples by ICPMS and PIMMS. 
1h International Conference ofPlasma Source Mass Spectrometry 8, p56. 
Jeyapalan, J. C., Tilby, M. J. and von Zglinicki, T. (2003) Cisplatin induced 
neuroblastoma cell death and the involvement of telomeres. British Journal of Cancer 
88 (Suppl 1), S39. 
Jeyapalan, J. C., Tilby, M. J. and von Zglinicki, T. (2004) The role of telomeres in 
etoposide induced cell death. Proceedings of the American Association for Cancer 
Research 45, A991. 
Awards: 
Cancer Research UK Student of the Year 2004 
Vil 
TABLE OF CONTENTS 
CHAPTER ONE 
INTRODUCTION 
1.1 Cancer ............................................................................................................... 1 
1.2 Cell Cycle Checkpoints .................................................................................... 3 
1.3 Apoptosis .......................................................................................................... 10 
1.4 DNA Repair ...................................................................................................... 14 
1.4.1 Introduction ........................................................................................ 
14 
1.4.2 Base excision repair ........................................................................... 14 
1.4.3 Nucleotide excision repair .................................................................. 
15 
1.4.4 Mismatch repair .................................................................................. 
15 
1.4.5 DNA double strand break repair ......................................................... 
16 
1.4.6 Direct damage reversal ....................................................................... 
16 
1.4.7 DNA repair deficiencies ..................................................................... 
17 
1.5 Telomeres ........................................................................................................ 18 
1.5.1 Historical background ........................................................................... 18 
1.5.2 Structure of telomeres ....................................................................... 19 
1.5.3 Telomeric associated proteins ........................................................... 21 
1.5.4 Function of telorneres ........................................................................ 
26 
1.5.4.1 End replication problem ...................................................... 
26 
1.5.4.2 Telomere shortening ........................................................... 
29 
1.6 Cellular Senescence and Immortalisation ..................................................... 30 
1.6.1 The Hayflick limit .............................................................................. 
30 
1.6.2 The telomere hypothesis of cell ageing and immortalisation ............. 
31 
1.6.3 Telornere capping/ uncapping ............................................................ 34 
1.7 Relationship between telomere-dependent and stress-induced 
senescence ....................................................................................................... 36 
1.8 Telomerase ...................................................................................................... 39 
1.8.1 Comi)onents of telomerase ................................................................ 39 
1.8.2 Alternative lengthening of telomeres ................................................ 40 
1.8.3 Telomere length independent survival function of telomerase ......... 42 
1.8.4 Telomerase as a prognostic marker .................................................. 43 
1.9 Conventional Anti-cancer Therapeutics ..................................... 0 .... 0 .... 0 ........ 45 
1.10 Cisplatin ......................................................................................................... a 
46 
1- 10.1 History of cisplatin ............................................................................ 
46 
1.10.2 Biochemical mechanism of action of cisplatin ................................. 47 
1.10.3 Cisplatin cytotoxicty ......................................................................... 48 
1.10.4 Cisplatin drug resistance .................................................................. 52 
1.11 Etoposide ........................................................................................................ 53 
1.11.1 Topoisomerase II poisons ................................................................. 53 
1.11.2 History of etoposide ........................................................................ 54 
1.11.3 Biochemical mechanism of action and cytotoxicty of etoposide ..... 54 
1.11.4 Etoposide drug resistance ................................................................. 55 
1.12 Telomerase Inhibition as a Potential Therapeutic ..................................... 56 
1.13 Aims and Objectives ....................................................................................... 58 
CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Chendcals and Reagents .............................................................. 60 
2.2 Buffers and Solutions ................................................................. 60 
2.3 Cell Culture ............................................................................ 62 
2.3.1 Tissue culture supplies ........................................................ 62 
2.3.2 Equipment ....................................................................... 62 
2.3.3 Cell lines/ strain ................................................................ 63 
2.3.4 Maintenance of cell lines/ strain ........................................................... 63 
2.3.5 Cryogenic storage ................................................................................. 63 
2.3.6 Resuscitation of frozen cells ................................................................. 64 
2.3.7 Routine cell culture ............................................................................... 64 
2.3.8 Calculation of cell density .................................................................... 65 
2.3.9 Calculation of population doubling ...................................................... 65 
2.4 Drug Preparation .............................................................................................. 66 
2.4.1 Safety procedures ................................................................................. 66 
2.4.2 Cisplatin ............................................................................................... 66 
2.4.3 Etoposide ............................................................................................. 66 
2.5 Sulphorhodamine B (SRB) Growth Inhibition Assay ................................... 67 
2.5.1 Introduction 
......................................................................................... 67 
2.5.2 SRB staining procedure ....................................................................... 67 
2.5.2.1 Trichloroacetic acid (TCA) fixation ..................................... 67 
2.5.2.2 SRB staining ......................................................................... 68 
2.5.3 Establishment of optimal inoculum conditions .................................... 68 
2.5.4 DeterminationOf IC50values ............................................................... 69 
2.6 DNA Extraction ................................................................................................. 70 
2.6.1 Materials .............................................................................................. 70 
2.6.2 Method ................................................................................................. 72 
2.6.3 Concentration of DNA ......................................................................... 72 
2.7 Telomeric DNA Isolation ................................................................................. 72 
2.7.1 Introduction ......................................................................................... 73 
2.7.2 Hinfl restriction digestion of genomic DNA ...................................... 73 
2.7.3 Mixing of biotinylated oligonucleotides and DNA ............................. 
73 
2.7.4 Elution of telomeres ............................................................................ 
75 
2.7.5 Pulsed field gel electrophoresis (PFGE) .............................................. 
75 
2.7.6 Southern blotting 
................................................................................. 
75 
2.7.7 Membrane hybridisation ..................................................................... 
76 
2.7.7.1 Using an alkaline phosphatase labelled probe ..................... 
76 
2.7.7.2 Using a digoxigenin labelled probe ..................................... 
76 
2.8 Inductively Coupled Plasma- Mass Spectrometry (ICP-MS) ...................... 77 
2.8.1 Equipment ........................................................................................... 
77 
2.8.2 Introduction ......................................................................................... 
78 
2.8.3 Preparation of DNA samples ............................................................... 
78 
2.8.4 Method ................................................................................................. 
78 
2.9 Telomere Restriction Fragment Lengths ....................................................... 81 
2.9.1 Production of agarose plugs ................................................................ 81 
2.9.2 Hinfl digestion ................................................................................... 
81 
2.9.3 Pulsed field gel electrophoresis ........................................................ 81 
2.9.4 Hybridisation ....................................................................................... 82 
2.9.4.1 Preparation of 32P-y-ATP labelled oligonucleotide probes.. 82 
2.9.4.2 Hybridisation of dried gels .................................................... 82 
2.9.4.3 Hybridisation of membranes ................................................. 83 
2.9.5 Evaluation of telomere length by fragment size determination ............ 83 
2.9.6 Minisatellite Probing ............................................................................. 84 
2.10 Telomeric Single Stranded Overhangs .......................................................... 84 
2.11 G Rich Single Stranded Telomeric DNA Damage ........................................ 85 
2.12 Telomerase Activity ......................................................................................... 86 
2.12.1 Introduction ........................................................................................ 86 
2.12.2 Lysis ................................................................................................... 86 
2.12.3 Determination of protein concentration by Bradford assay ............... 88 
2.12.4 Telomeric repeat amplification protocol (TRAP) ........................... 88 
2.12.5 Hybridisation & ELISA ..................................................................... 89 
2.13 Flow Cytometry ............................................................................................... 90 
2.13.1 Equipment .......................................................................................... 90 
2.13.2 Introduction ........................................................................................ 91 
2.13.3 Setting up the flow cytometer ............................................................ 92 
2.13.4 Measuring apoptosis ......................................................................... 93 
2.13.4.1 Introduction ......................................................................... 93 
2.13.4.2 Method ................................................................................ 93 
2.13.5 Cell Cycle Analysis ........................................................................... 93 
2.13.5.1 Introduction ......................................................................... 93 
2.13.5.2 Method ................................................................................ 94 
2.13.6 BrdU Incorporation ............................................................................ 95 
2.13.6.1 Introduction ......................................................................... 95 
2.13.6.2 Method ................................................................................. 95 
2.14 Fluorescence Detected Alkaline DNA Unwinding Assay (FADU) .............. 96 
2.14.1 Introduction ........................................................................................ 96 
2.14.2 Determination of strand damage ....................................................... 97 
2.14.3 Determination of repair ..................................................................... 97 
2.15 Senescence Associated-P galactosidase (SA- P gal) ...................................... 98 
2.15.1 Introduction ........................................................................................ 98 
2.15.2 Method ................................................................................................ 98 
2.16 Histone H2A. X Phosphorylation (y- H2A. X) ............ 0 ................................... 99 
2.16.1 Introduction ........................................................................................ 99 
2.16.2 Method ................................................................................................ 99 
2.17 ImmunoFISH ................................................................................................... 100 
2.17.1 Introduction 
........................................................................................ 100 
2.17.2 Method ............................................................................................... 101 
CHAPTER THREE 
NEUROBLASTOMA APOPTOSIS INDUCTION AFTER CISPLATIN 
TREATMENT IS NOT TELOMERE, DEPENDENT 
3.1 Introduction ...................................................................................................... 103 
3.2 Methods ............................................................................................................. 105 
3.3 Results ................................................................................................................ 105 
3.3.1 Growth inhibitory effect of cisplatin on SHSY5Y cells ...................... 105 
3.3.2 Cisplatin induces apoptosis and S phase arrest in SHSY5Y cells ...... 109 
3.3.3 Cisplatin induces DNA strand breaks as a result of attempted 
repair ................................................................................................... 118 
3.3.4 Cisplatin does not shorten telomeres in SHSY5Y cells ...................... 122 
3.3.5 Effects of cisplatin on telomeric overhangs ........................................ 129 
3.3.5.1 In-gel hybridisation .............................................................. 129 
3.3.5.2 Telornere isolation ............................................................... 129 
3.3.6 Attempt to determine whether cisplatin preferentially targets the 
telomeres by direct measurement of platinum-DNA adducts ............. 135 
3.3.7 Cisplatin decreases telomerase activity in SHSY5Y cells .................. 143 
3.3.8 Response of 1301 cells after cisplatin treatment ................................ 145 
3.3.9 DNA damage foci are not localised at the telomeres after 
cisplatin treatment ............................................................................... 155 
3.4 Discussion ......................................................................................................... 157 
3.5 Conclusions ....................................................................................................... 160 
CHAPTER FOUR 
THE ROLE OF TELOMERES IN ETOPOSIDE INDUCED TUMOUR 
CELL DEATH 
4.1 Introduction ....................................................................................................... 161 
4.2 Methods ............................................................................................................. 163 
4.3 Results ................................................................................................................ 163 
4.3.1 Growth inhibition effect of etoposide .................................................. 163 
4.3.2 Etoposide induces apoptosis ................................................................ 168 
4.3.3 Etoposide causes S phase arrest with features of senescence .............. 174 
4.3.4 Etoposide triggers a DNA damage response ....................................... 182 
4.3.5 Etoposide does not influence telomere length ..................................... 185 
4.3.6 Etoposide does not influence the length of telomeric single 
stranded G-rich overhangs .................................................................. 191 
4.3.7 Etoposide does not induce single strand breaks in the 
G- rich telomeric strand ...................................................................... 196 
4.3.8 Etoposide decreases telomerase activity only after onset 
of apoptosis ......................................................................................... 199 
4.3.9 DNA damage foci do not colocalise to the telorneres after 
etoposide treatment ............................................................................. 201 
4.4 Discussion ......................................................................................................... 203 
4.5 Conclusions ....................................................................................................... 206 
CHAPTER FIVE 
FINAL DISCUSSION 
5.1 Introduction ...................................................................................................... 207 
5.2 Aim .................................................................................................................... 208 
5.3 Outline of Results ............................................................................................ 208 
5.3.1 Cisplatin ............................................................................................. 208 
5.3.2 Etoposide ........................................................................................... 210 
5.4 Summary .......................................................................................................... 211 
5.5 Conclusions ...................................................................................................... 212 
REFERENCES .............................. --o-o-o-o-o ..... o-o-o ... 0 .... o-oo ......... ooo ... oo-oo ..... o ..... 214 
LIST OF TABLES 
Table 2.1 Characteristics of cell lines/ strain ..................................................... 
63 
Table 2.2 Telomeric repeat amplification PCR procedure ................................ 88 
Table 3.1 Combination of buffers tested in the telomere isolation 
procedure ........................................................................................... 138 
Table 3.2 Measurement of phosphorus levels in buffers used in 
telorneric DNA isolation procedure using lCP-MS .......................... 139 
Table 3.3 Total Pt concentration determined from measurement of 
Pt 195 and P concentration on cisplatin treated and untreated 
telomeres/ supernatant using a combination of buffers .................... 141 
Table 4.1 Growth inhibitory concentrations(IC5o) after etoposide 
treatment ............................................................................................ 164 
LIST OF FIGURES 
Figure 1.1 Schematic diagram of the cell cycle .................................................. 4 
Figure 1.2 The ATM pathway ............................................................................ 
6 
Figure 1.3 p53 stress pathways ........................................................................... 8 
Figure 1.4 Apoptotic pathway induced by non repaired DNA double strand 
breaks ................................................................................................ 13 
Figure 1.5 Structure of a human telomere .......................................................... 22 
Figure 1.6 The end replication problem .............................................................. 28 
Figure 1.7 The telomere hypothesis of cell ageing and immortalisation ............ 33 
Figure 1.8 Relationship between telomere-dependent and stress-induced 
senescence ........................................................................................ 38 
Figure 1.9 Telomere elongation ......................................................................... 41 
Figure 1.10 Structure of cisplatin ......................................................................... 46 
Figure 1.11 Formation of reactive cisplatin complexes in vivo ............................ 49 
Figure 1.12 Spectrum of cisplatin- DNA adducts ................................................ 50 
Figure 1.13 Structure of etoposide ....................................................................... 54 
Figure 2.1 DNA extraction using Qiagen columns ............................................. 71 
Figure 2.2 Isolation of telomeric DNA ............................................................... 74 
Figure 2.3 Inductively Coupled Plasma- Mass Spectrometry (ICP-MS) ........... 80 
Figure 2.4 TeloTAGGG Telomerase PCR Elisa ................................................ 87 
Figure 2.5 Principle of the Partec Particle Analysing System (PAS) ................. 90 
Figure 2.6 Calibration pasbeads ......................................................................... 92 
Figure 2.7 DNA cell cycle histogram ................................................................. 94 
Figure 3.1 Determination Of IC50 of SHSY5Y cells after cisplatin treatment.... 106 
Figure 3.2 Cell numbers of SHSY5Y cells after a short and continuous 
exposure to cisplatin .......................................................................... 108 
Figure 3.3 Levels of apoptosis after short exposure cisplatin treatment on 
SHSY5Y cells ................................................................................... 110 
Figure 3.4 Levels of apoptosis after continuous exposure cisplatin treatment 
on SHSY5Y cells .............................................................................. III 
Figure 3.5 Cell cycle analysis of SHSY5Y cells exposed to cisplatin after a 
short exposure ................................................................................... 113 
Figure 3.6 Stages of SHSY5Y cells in the cell cycle after a short exposure 
to cisplatin ........................................................................................ 114 
Figure 3.7 Cell cycle analysis of SHSY5Y cells exposed to cisplatin 
continuously ...................................................................................... 115 
Figure 3.8 Stages of SHSY5Y cells in the cell cycle after a continuous 
exposure to cisplatin ......................................................................... 116 
Figure 3.9 BrdU incorporation of cisplatin treated SHSY5Y cells .................... 117 
Figure 3.10 DNA strand breaks in cisplatin treated SHSY5Y cells ................... 120 
Figure 3.11 DNA damage response in cisplatin treated SHSY5Y cells ............ 121 
Figure 3.12 Telomere restriction fragment lengths after short exposure 
cisplatin treatment on SHSY5Y cells .............................................. 124 
Figure 3.13 Detennination of unspecific DNA degradation ............................... 125 
Figure 3.14 Denaturing gel to detect G rich telomeric strand breaks after short 
exposure cisplatin treatment .............................................................. 126 
Figure 3.15 Telomere restriction fragment lengths after continuous exposure 
cisplatin treatment on SHSY5Y cells ................................................ 127 
Figure 3.16 DNA degradation after continuous cisplatin treatment ..................... 128 
Figure 3.17 Telomeric G rich overhangs in SHSY5Y cells after short 
exposure cisplatin treatment .............................................................. 130 
Figure 3.18 Telomeric DNA isolation .................................................................. 132 
Figure 3.19 Modification of telomeric DNA isolation ......................................... 133 
Figure 3.20 Telomeric DNA isolation after treatment with short exposure to 
cisplatin ............................................................................................. 134 
Figure 3.21 Telomerase activity in SHSY5Y cells after short exposure 
to cisplatin ......................................................................................... 
144 
Figure 3.22 Cell numbers of 1301 cells after cisplatin treatment ......................... 146 
Figure 3.23 Levels of apoptosis after short exposure cisplatin treatment on 
1301 cells ........................................................................................... 
147 
Figure 3.24 Levels of apoptosis after continuous exposure cisplatin treatment 
on 1301 cells ...................................................................................... 148 
Figure 3.25 Telomere restriction fragment lengths after short exposure 
cisplatin treatment on 1301 cells ....................................................... 150 
Figure 3.26 Telomere restriction fragment lengths after continuous exposure 
cisplatin treatment on 1301 cells ....................................................... 151 
Figure 3.27 Denaturing gels to detect G rich telomeric strand breaks after 
cisplatin treatment on 1301 cells ....................................................... 152 
Figure 3.28 Telomeric G- rich overhangs in 1301 cells after short exposure 
cisplatin treatment .............................................................................. 153 
Figure 3.29 Telomeric G- rich overhangs in 1301 cells after continuous 
exposure cisplatin treatment .............................................................. 154 
Figure 3.30 DNA darnage foci do not colocalise with telomeres after a short 
exposure cisplatin treatment .............................................................. 156 
Figure 4.1 Cell numbers of SHSY5Y and 1301 cells after a short exposure 
etoposide treatment ............................................................................ 166 
Figure 4.2 Cell numbers of SHSY5Y and 1301 cells after a continuous 
exposure etoposide treatment ............................................................. 167 
Figure 4.3 Levels of apoptosis after short exposure etoposide treatment 
on SHSY5Y cells ............................................................................... 169 
Figure 4.4 Levels of apoptosis after short exposure etoposide treatment 
on 1301 cells ..................................................................................... 170 
Figure 4.5 Levels of apoptosis after continuous exposure etoposide 
treatment on SHSY5Y cells ............................................................... 172 
Figure 4.6 Levels of apoptosis after continuous exposure etoposide 
treatment on 1301 cells .................................................................... 
173 
Figure 4.7 Cell cycle analysis of SHSY5Y cells exposed to etoposide for 
four hours 
......................................................................................... 
175 
Figure 4.8 Stages of SHSY5Y cells in the cell cycle after a four hour 
exposure to etoposide ...................................................................... 176 
Figure 4.9 Cell cycle analysis of SHSY5Y cells exposed to etoposide 
continuously .................................................................................... 177 
Figure 4.10 Stages of SHSY5Y cells in the cell cycle after a continuous 
exposure to etoposide ....................................................................... 178 
Figure 4.11 BrdU incorporation of short exposure treated SHSY5Y cells ......... 180 
Figure 4.12 Senescence Associated -0 galactosidase (SA- P gal) of SHSY5Y 
cells after a short exposure etoposide treatment ............................... 181 
Figure 4.13 Measurement of DNA strand breaks in etoposide treated cells ....... 183 
Figure 4.14 DNA damage response in etoposide treated SHSY5Y cells ............ 184 
Figure 4.15 Telomere restriction fragment lengths after short exposure 
etoposide treatment on SHSY5Y cells ............................................ 187 
Figure 4.16 Telomere restriction fragment lengths after short exposure 
etoposide treatment on 1301 cells ..................................................... 188 
Figure 4.17 Telomere restriction fragment lengths after continuous exposure 
etoposide treatment on SHSY5Y cells ............................................. 189 
Figure 4.18 Telomere restriction fragment lengths after continuous exposure 
etoposide treatment on 1301 cells .................................................... 190 
Figure 4.19 Telomeric G-rich overhangs in SHSY5Y cells after short exposure 
to etoposide ....................................................................................... 192 
Figure 4.20 Telorneric G-rich overhangs in 1301 cells after short exposure to 
etoposide . ......................................................................................... 193 
Figure 4.21 Telomeric G-rich overhangs in SHSY5Y cells after continuous 
exposure to etoposide ...................................................................... 194 
Figure 4.22 Telomeric G-rich overhangs in 1301 cells after continuous 
exposure to etoposide ....................................................................... 
195 
Figure 4.23 Denaturing gel to detect G rich telomeric strand breaks after short 
exposure etoposide treatment ........................................................... 197 
Figure 4.24 Denaturing gel to detect G rich telomeric strand breaks after 
continuous exposure etoposide treatment ........................................ 198 
Figure 4.25 Telomerase activity in SHSY5Y cells after continuous etoposide 
treatment ........................................................................................... 200 
Figure 4.26 DNA damage foci do not colocalise with telomeres after a short 
exposure etoposide treatment .......................................................... 
202 
I 
CHAPTER ONE 
INTRODUCTION 
1.1 Cancer 
Cancer is a complex genetic disease that is the most common cause of death in the 
UK (26% of all deaths) and the lifetime risk of developing cancer is over one in three. 
270,000 new cases were diagnosed in 2000 in the UK. Cancer is more likely to 
develop later on in life with 65% of cases diagnosed in people over the age of 65 
(Cancer Research UK, Scientific Yearbook, 2003-2004). 
Cancer is a disease which is distinguished by uncontrolled cell growth. During the 
early years of a person's life, normal cells divide more rapidly until the person 
becomes an adult then cells divide only to replace wom-out or dying cells and to 
repair injuries. As cancer cells continue to grow and divide, they differ from normal 
cells and they can travel to other parts of the body where they begin to grow and 
replace normal tissue which is called metastasis. This process occurs as the cancer 
cells get into the bloodstream or lymph vessels of our body. Cancer cells must not 
only be capable of dividing indefinitely but need to live as well by gaining nutrients 
and move through the extracellular matrix to metastasize (Hanahan and Weinberg, 
2000). There are more than two hundred types of cancer but four of them account for 
half of all new cases (breast, lung, colorectal. and prostate). Different types of cancers 
behave differently and therefore have to be treated individually. Cancer usually fon-ns 
as tumours. Exceptions exist for example leukaemia which involves the blood and 
blood-forming organs. Though not all tumours are cancerous, non cancerous tumours 
are known as being benign. Benign tumours are generally slow growing expansive 
masses that compress rather than invade surrounding tissue. 
I 
Chapter I 
There are many different types of cancer and more than one cause can often be 
involved (multi-factorial). Cancer causing agents (carcinogens) are widespread and 
can be present in food, air, water, chemicals or the sunlight. There are many risk 
factors that can increase the chance of getting cancer which includes age, sex, genetic 
makeup and family medical history. Other risk factors are linked to lifestyle and 
environment such as smoking, alcohol, diet and sun exposure. Certain virus infections 
can increase the risk of getting associated cancers e. g. Epstein Barr Virus. 
Tumour development is a complex process that arises as a result of genetic alteration 
that leads to loss of control over cellular proliferation. This can occur by the gain of 
function of a gene (proto-oncogene) that is involved in signalling pathways governing 
cell survival, proliferation and differentiation. When a proto-oncogene function has 
been deregulated or is altered by being mutated or expressed at abnormally high 
levels (oncogene) this contributes to converting a normal cell into a cancer cell 
leading to uncontrolled mitosis. 
Typical oncogenes have dominant activity and may be viral or cellular in origin. DNA 
viruses and retroviruses can carry oncogenes which are similar to cellular genes, 
however they only play a part to a small fraction of cancers but have greatly 
contributed to the understanding of oncogenes. Most oncogenes are cellular genes that 
have either been altered in their coding sequence by mutation, had their copy number 
increased or had chromosomal rearrangements. These include growth factors and 
receptors, membrane transducers, cell cycle regulators and inhibitors of apoptosis. 
Another mechanism to deregulate cellular proliferation is through the loss of genes. 
Turnour suppressor genes are genes whose loss or downregulation contributes to the 
fon-nation of malignancy. There are multiple genetic mechanisms that can account for 
this loss, including deletion, mutation and chromosomal silencing, but the common 
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end feature is lack of gene function which is thought to produce a physiological state 
that enhances the process of tumorigenesis. One of the best known tumour suppressor 
genes is p53. 
Initially the conversion of normal cells into turnour cells (transformation) was 
achieved in rodents by introduction of several cooperating oncogenes (Land and 
Weinberg, 1983; Ruley, 1983). In humans, transformation was achieved by physical 
or chemical agents (Kang et al., 1998), the use of an entire viral genome (Flore et al., 
1998) and the selection of rare, spontaneously arising immortalised cells (Yoakum et 
al., 1985; Rhim et al., 1985; Hurlin et al., 1989; Burger et al., 1998). This was until 
the cloning of the catalytic component of human telornerase (hTERT) was achieved 
(See Section 1.8). Using this subunit the immortalisation of cells by the extension of 
telomeric repeats was accomplished (Bodnar et al., 1998; Vaziri and Benchimol, 
1998). The ectopic expression on the catalytic subunit of hTERT in combination with 
two oncogenes (SV40 large T oncoprotein and H-ras) directly converted nonnal 
epithelial and fibroblast cells into tumour cells (Hahn et al., 1999). This suggests that 
telomere maintenance, allowing cells to proliferate indefinitely contributes to 
transformation. 
1.2 Cell Cycle Checkpoints 
One important role of certain tumour suppressor genes involves regulation of the cell 
cycle. During development from stem to fully differentiated cells in the body divide 
(mitosis) and enter a stage between two successive cell divisions (interphase). 
Interphase is indispensable for the next mitosis, as cells in this stage are constantly 
synthesizing RNA, producing protein and growing in size. This sequence of activities 
exhibited by the cell is called the cell cycle (Figure 1.1). 
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Figure 1.1 Schematic diagram of the cell cycle. The cell cycle is an ordered set of 
events that culminating in cell growth and division into two daughter cells. 
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During the cell cycle it is essential that the cells genome is copied, fully and 
accurately and segregation of the sister chromatids is error free. Many of the risk 
factors described in Section 1.1 increase the risk of obtaining cancer by interacting 
and modifying DNA. DNA contains cell's genetic information, in the form of a 
sequence of bases which are copied and transcribed into messenger RNA that are 
subsequently used to synthesise proteins. Therefore if DNA is modified by damage or 
copied incorrectly this will not allow the cell to function correctly increasing the risk 
of many human pathologies, including cancer. 
DNA is highly susceptible to damage which can lead to mutation or cell death. 
Sources of DNA damage consist of chemical or physical agents found outside the 
cells or also agents that arise inside cells e. g. reactive oxygen species. Different types 
of DNA damaging agents produce different kinds of lesions in DNA. For example 
ultraviolet light produces DNA dimers in which chemical bonds are formed between 
adjacent cytosines or thyrnines, whereas cisplatin cross-links the DNA. 
Damage to DNA causes several cellular responses. The ATM gene is activated by 
DNA double strand breaks (of different origins) in an early response and activates cell 
cycle checkpoints, DNA repair, stress response genes and apoptosis through signal 
transduction cascades (Figure 1.2). ATM is a serine/ threonine protein kinase whose 
phosphorylation targets and downstream effector molecules include p53, MDM2, 
CHK2, NBSI and BRCAI. CHK2 is a protein kinase which is activated by post 
translational modifications, after DNA damage. CHK2 is phosphorylated in an ATM 
dependent and independent manner. 
Multiple pathways are involved in the maintenance of genetic integrity, most of which 
link to the cell cycle. The inactivation of these pathways as part of a multi-step 
process contributes significantly to the origin of cancers. 
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Figure 1.2 The ATM pathway. The ATM signalling pathway in response to double 
strand breaks induced for example by ionising radiation (IR) (Adapted from Daboussi 
et al., 2002). 
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Cells can arrest in the cell cycle at Go/ G, and/ or G2/ M and by arresting the cell cycle, 
checkpoints allow the cells to repair DNA. Some cell types may primarily undergo 
apoptosis to avoid the risk of generating altered progeny. The turnour suppressor 
protein p53 is an important component of the DNA damage response (Lane, 1992) 
and acts as a cellular gatekeeper (Levine, 1997). 
p53 is pivotal in the cells response to stress by protecting the cell from further stress 
through the activation of genes that play a role in cell cycle checkpoints, apoptosis, 
DNA repair or cellular senescence (Figure 1.3). p53 was identified in 1979 as a 
cellular protein that bound to the simian virus (SV40) large T antigen and 
accumulated in the nuclei of cancer cells (DeLeo et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979). p53 has multiple functions in cell cycle regulation, 
apoptosis, development, differentiation, gene amplification, DNA recombination, 
chromosomal segregation and cellular senescence (Oren and Rotter, 1999). More 
recently wildtype p53 has been shown to facilitate DNA repair and base excision 
repair (Adimoolam and Ford, 2003; Offer et al, 1999; Zhou et al., 2001). 
p53 is activated and regulated by a number of mechanisms and pathways which 
include for example post translational modification including phosphorylation/ 
dephosphorylation (Scheidtmann et al., 1991) and acetylation (Gu and Roeder, 1997). 
p53 is mutated or lost in -50% of all human cancers (Hollstein et al., 1991; Levine et 
al., 1991) and mice deficient in the gene encoding p53 (TP53) are susceptible to 
spontaneous turnour formation (Donehower et al., 1992). Whereas in humans, 
gen-nline mutations in the p53 gene lead to the cancer prone Li- Fraumeni syndrome 
(Malkin et al., 1990; Srivastava et al., 1990). 
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Figure 1.3 p53 stress pathways. Once p53 has been activated through stress it in 
turn activates genes to encode proteins (examples listed above) involved in cell cycle 
checkpoints, DNA repair, apoptosis and senescence (Adapted from Hofseth et al., 
2004). 
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Progression through the cell cycle is controlled by a family of proteins found in the 
cytoplasm termed cyclin dependent kinases (CDK). CDK holoenzymes are comprised 
of a catalytic subunit, the CDK and a member of a family of regulatory subunits, the 
cyclins. CDK are inactive in their monomeric form and require association with the 
cyclins for activation. The CDK- cyclin complex is both negatively and positively 
regulated by phosphorylation and can be further regulated by binding to cyclin 
dependent kinase inhibitors (CKI). The CKI compromise of two families, one 
WAFI/CIPI KWI 2 INK4B INK4A INK4C including p2l , p27 and p57K'p , the other of p 15 , p16 3 P18 
and P191NII, 
4D. 
At the GI/ S boundary cells are checked on whether or not they can continue onto 
DNA replication. DNA damage leads to arrest in G, via p53 dependent transactivation 
of genes, primarily p21CW1. The CIP/ KIP family members share broad specificity for 
binding to and inhibition of most CDK/ cyclin complexes (Zhu et al., 1995; Chen et 
al., 1996; Adams et al., 1996) but only p2l is involved in the DNA damage induced 
arrest. DNA damage is also linked to the CDC25A- CDK2 pathways, which has 
recently been reported (Falck et al., 2001). Nonually CDC25A activates CDK2, a 
kinase essential for S phase. CHK2 phosphorylates and promotes the destruction of 
CDC25A and this constitutes an S phase checkpoint. 
A G2/ Mcheckpoint exists which prevents cells from entering mitosis in response to 
DNA darnage, providing an opportunity for repair and stopping the proliferation of 
damaged cells. This checkpoint is less clearly defined and its control has been shown 
to be either p53 dependent (Agarwal et al., 1995; Stewart et al., 1995) or independent 
(Kastan et al., 199 1). 
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There are three different outcomes of checkpoint activation; 
(i) arrest to allow repair to occur or senescence if pennanent (Section 1.6) 
(ii) DNA repair to remove DNA damage (Section 1.4) 
apoptosis to eliminate seriously damaged cells (Section 1.3) 
1.3 Apoptosis 
DNA damage can lead to cell death by creating too many DNA strand breaks, by 
cross-linking DNA strands, by introducing large number of mutations or creating 
lesions that block replication. DNA damage can also cause cell death indirectly by 
triggering a fonn of cellular suicide called apoptosis. 
Apoptosis is a programmed cell death, that is an active, metabolic pathway that occurs 
under a variety of physiological and pathological conditions. Apoptosis has an 
important role in tissue homeostasis and the immune system. Apoptotic cells can be 
distinguished by their morphological characteristics which include blebbing of the 
plasma membrane, cell shrinkage and condensation of chromatin (Arends and Wyllie, 
1991). An endonucleolytic pathway is activated which leads to cleavage of the DNA 
resulting in a distinct nucleosomal ladder of fragments (Wyllie et al., 1980). This is 
followed by cell shrinkage and disintegration of the cell into multiple membrane 
enclosed vesicles 'apoptotic bodies' which are targets for phagocytes to remove 
(Wyllie, 1997). 
Apoptosis can be triggered by several stimuli, including intracellular stress and 
receptor mediated signalling. A large number of genes and proteins have been 
implicated in the control of apoptosis. Caspases (cysteine aspartate proteases) play 
central roles in apoptotic signalling and execution (Thomberry, 1999). Caspases are 
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synthesized as zymogens and upstream signals convert these precursors into mature 
proteases. 
There are two types of caspases; initiator caspases which are activated via 
oligomerisation induced autoprocessing (Butt et al., 1998; Li et al., 1997) and effector 
caspases which are activated by other proteases including initiator caspases. The 
initiator caspases transduce various signals into protease activity and are linked to 
death inducing signalling complexes. Effector capases cleave various cytoplasmic or 
nuclear substrates which gives many of the morphological features of apoptotic cell 
death (Degen et aL, 2000). There are two major pathways that have been identified 
according to their initiator caspase: the death receptor (Medema et al., 1997) and the 
mitochondrial pathway (Green and Reed, 1998). 
Stimulation of death receptors of the turnour necrosis factor (TNF) receptor 
superfamily such as CD95 (apo-l/ Fas) or TRAIL receptors results in receptor 
aggregation and recruitment of the adaptor molecule Fas- associated death domain 
(FADD) and caspase 8. Upon recruitment caspase 8 becomes activated and initiates 
apoptosis by direct cleavage of downstream effector caspases (Schulze-Osthoff et al., 
1998). The mitochondrial pathway is initiated by the release of apoptogenic factors 
such as cytochrome c from the mitochondrial intermembrane space (Kroemer and 
Reed, 2000). The release of cytochrome c into the cytosol triggers caspase-3 
activation through fonnation of the cytochrome-c/Apaf-1/caspase 9 containing 
apoptosome complex (Adrain and Martin, 2001). Both pathways are interconnected at 
different levels (Roy and Nicholson, 2000). 
Apoptosis can be induced by a variety of DNA damaging agents whereby p53 plays a 
critical role. One of its roles is to act as a transcriptional activator of genes encoding 
apoptotic effectors. For example human p53 directly activates transcription of several 
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genes encoding members of the Bcl-2 family, which include multidomain pro- and 
anti-apoptotic proteins (Cory and Adams, 2002). Loss of apoptosis due to loss of p53 
has been implicated in turnourigenesis (Igney and Krammer, 2002) and also to the 
resistance of cancer cells to therapies that induce DNA damage (Lowe et al., 1993). 
Overexpression of anti- apoptotic proteins such as Bcl-2 can additionally favour 
tumour cell survival following DNA damage based therapy. 
The mitochondrial apoptotic pathway is thought to be the major pathway induced by 
DSB by decline of Bcl-2 and stabilisation of p53, which stimulates the promoter of 
the Fas receptor gene thus activating the FAS/CD95/Apo- I apoptotic pathway (Figure 
1.4). Damage may also activate the MAPK pathway leading to upregulation of Fos 
and Jun (Ap- 1). 
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Figure 1.4 Apoptotic pathway induced by non repaired DNA double strand 
breaks. This occurs via the mitochondrial pathway. It is unknown whether Fos/ Jun 
upregulation is directly activated by DSB (Adapted from Bernd, 2003). 
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1.4 DNA repair 
1.4.1 Introduction 
DNA damage in a cell can cause mutations and cell death. Cells that have lost the 
ability to repair DNA damage are very sensitive to mutations and killing by DNA 
damaging agents. Many types of damage can occur in cells which include loss of 
bases, changes in the structure of bases and DNA strand breaks. Different DNA 
damaging agents induce different kinds of lesions in DNA therefore a variety of 
mechanisms exist to repair specific types of damage and these are described below. 
1.4.2 Base excision repair 
Base excision repair (BER) involves the damaged base being excised from the DNA. 
The main types of damage recognised by BER are oxidative, DNA alkylation and 
single strand breaks (SSB). BER is a multistep process and the repair pathway can be 
divided into five steps (i) base removal by a specific DNA glycosylase, (ii) incision at 
the resulting abasic site by an apurinic/ apyrimidinic (AP) endonuclease, (iii) 
processing of the produced blocked termini, (iv) filling in the gap and (v) resealing of 
the damaged DNA strand. The first step is characterised by the action of a DNA 
glycosylase, which after recognition of the specific modified base, cleaves the N- 
glycosidic bond giving rise to an AP site. This lesion is acted upon by AP 
endonucleases or an AP lyase which generates a single strand break. The BER can 
then proceed through two pathways a short and long patch BER, which are 
differentiated by the repair gap size and enzymes involved. 
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1.4.3 Nucleotide excision repair 
Nucleotide excision repair (NER) deals with a wide range of structurally unrelated 
lesions and it acts on removing lesions that distort the DNA double helix which 
interferes with base pairing and blocks DNA replication and transcription. For 
example, NER repairs damage induced by UV light which induces pyrimidine dimers 
that cause a kink or bend in the DNA molecule. Cross-linking agents such as cisplatin, 
also distort DNA and are substrates for repair by NER. NER is a complicated 
multistep process that requires numerous proteins. NER involves recognition of 
damaged DNA, the sequential action of helicases and endonucleases open the double 
helix and enzymes cleave the damaged strand a few bases away from the lesion. This 
is followed by removal of the DNA segment containing the lesion and gap 
polymerisation using the intact strand as a template, with DNA ligase sealing the 
newly made patch into the DNA. 
1.4.4 Mismatch repair 
DNA mismatch repair (MMR) corrects mismatched bases which DNA polymerases 
have inserted opposite normal bases which can cause mutations if not corrected 
(Kolodner and Marsischky, 1999). Like BER and NER, MMR is an excision repair 
process and it targets newly synthesized DNA strands. MMR is clearly defined in E 
coli, though less is known about the mechanism in humans. At least six genes have 
been identified which are implicated in MMR. hMSH2, hMSH3, hMSH6 are involved 
with primary recognition of the mismatched DNA. hMLH 1, hPMS2 and hPMS I are 
recruited after the initial DNA recognition (Fink et al., 1998). 
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1.4.5 DNA double strand break repair 
DNA double strand breaks (DSB) can arise spontaneously or by DNA damaging 
agents for e. g. ionising radiation and is thought to be the most lethal type of DNA 
lesion. There are two main DSB repair pathways, homologous recombination (HR) 
and non homologous end joining (NHEJ). The difference between the processes is the 
fact that NHEJ requires little or no sequence homology and is a process that may or 
may not be error free, whereas HR requires DNA homology. The contribution of both 
processes to human DSB repair is controversial (Kanaar et al., 1998; Haber, 2000; 
Johnson and Jasin., 2001) but is generally believed that NHEJ plays a more important 
role than HR in mitotically replicating cells (Jackson and Jeggo, 1995), especially 
during G, and early S phase (Lee et al., 1997; Takata et al., 1998). NHEJ is a damage 
tolerance mechanism because it does not result in the physical removal of the damage 
r__ - from the DNA but allows cells with unrepaired lesions to replicate their DNA without 
stalling. Many proteins take part in the NHEJ mechanism and once at the site of the 
damage, DNA is aligned and endonucleases remove incompatible sites, which is 
followed by polymerisation, ligation then replication. After replication, the damage 
can be removed from the DNA by repair mechanisms such as NER. 
1.4.6 Direct damage reversal 
Two well known examples of direct reversal of damage are the repair of UV induced 
DNA dimers by photolyases and the repair of mutagenic methyl. lesions by 
methyltransferases. DNA photolyases are monomeric proteins and two different types 
have been distinguished according to the type of DNA lesion they repair (Todo et al., 
1996), though none have been discovered in mammals. The major lesion induced by 
UV light are cyclobutane pyrimidine dimers (CPD) which are repaired by CPD 
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photolyases (Taylor and Nadji, 1991). Minor UV light induced lesions are 6,4 
photoproducts which are repaired by 6,4 photolyases (Zhao et al., 1997). Photolyases 
work in concert with chromophores and use the energy of visible light. 
DNA repair methyltransferases remove mutagenic alkyl lesions from oxygens on the 
bases guanine (06 -methylguanine) and thyrnine 
(04 
-methylthymine) by transfer of a 
methyl group from the DNA to themselves, restoring the base to normal. The methyl 
group remains on the methyltransferase and inactivates the protein allowing the 
enzyme to repair only one lesion. Therefore the enzymes are known as suicide 
enzymes. 
1.4.7 DNA repair deficiencies 
Deficiencies in DNA repair can have serious consequences for cells as it can lead to 
increases in mutation, genetic instability and cancer. At least 15 human diseases have 
been linked to inherited deficiencies in DNA repair. These disorders represent defects 
in -35 different genes. In most but not all there is greatly elevated cancer incidence 
and have multi- system defects. The first DNA repair disease to be identified in 
humans was Xeroderma Pigmentosum (XP) (Kraemer et al., 1987). The defining 
characteristics of XP patients are extreme sensitivity of the eyes and skin to sunlight, 
n, k abnormal pigmentation and drying of the skin and increased rate and incidence of 
cancer. XP patients have a defect in at least 8 different genes related to NER. 
Mutations in some of the genes cause two other DNA repair related disorders 
Cockayne syndrome and Trichothiodystrophy (TTD). 
An elevated risk of cancer has been shown in an inherited defect in mismatch repair, 
which causes a syndrome called hereditary nonpolyposis colorectal cancer in which 
patients have a higher risk of developing colon cancer. People with defects in other 
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DNA repair related genes like BRCAI, BRCA2 and p53 also have a higher risk of 
developing cancer. Additionally during the course of tumour development, mutations 
in DNA repair genes can occur. 
1.5 Telomeres 
1.5.1 Historical background 
In the 1930s from a combination of genetic and cytological observations the proposal 
that the natural ends of chromosomes had specialised structures came about. From 
light microscope studies of Drosophila melangaster in 1938 Miller detected that 
tenninal deletions and inversions were not recovered following x-irradiation, though 
interstitial deletions and inversions were easily recovered (MOller, 1938). This 
suggested a unique structure at the end of linear chromosomes which causes them to 
behave differently from a free end. MUller named this hypothetical structure telomeres 
as telo= end and mere = segment. Millers original experiments were many years later 
confirmed in wildtype Drosophila (Roberts, 1974). 
Mifflers work was also verified and extended by the work of McClintock, who studied 
the fate of broken chromosomes in maize (McClintock, 1941). McClintock discovered 
that the end of broken chromosomes were very reactive and underwent aberrant 
recombination and fusion reactions with other chromosomes, frequently to form 
dicentrics. 
McClintocks results were validated 50 years later in yeast and mice when it was 
demonstrated that without telomeric ends, chromosomes undergo aberrant end-to-end 
fusions forming multicentric chromosomes. These have a propensity to break during 
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mitosis, activating DNA damage checkpoints and in some cases leading to widespread 
cell death (Zakian, 1989). 
1.5.2 Structure of telomeres 
Telomeres were first sequenced in 1978 from the ciliate protozoan Tetrahymena 
thermophila (Blackburn, 1984) and then Oxytricha (Oka et aL, 1980; Klotbutcher et 
al., 1981). This was due to the fact that ciliate chromosomes have a vast number of 
telomeres per cell as a result of genome fragmentation and telomere addition. 
Therefore giving a rich source of both telorneric DNA and the structural proteins and 
enzymes that protect and replicate this DNA. Since then the DNA sequence of the 
telomeres of a number of protozoans, yeasts, vertebrates and plants have been 
determined. There is considerable conservation of both structure and function of 
telomeres from ciliated protozoans to plants and animals. 
In most organisms telomere DNA consists of a very simple short tandem repeat that is 
G rich in one strand and whose orientation and sequence is highly conserved within 
species. For example in Tetrahymena the telomere consists of the repeat TTGGGG. In 
humans, other vertebrates, slime moulds and some protozoans the hexameric repeat 
unit is almost exclusively TTAGGG (Brown, 1989; Cross et aL, 1989). Yeast has 
irregular repeat sequence for example aT is followed by one, two, or three G's 
(abbreviated TGI-3). Drosophila the organism in which telomeres were first defined 
though has a different kind of telomere repeat sequence than most other eukaryotes. 
The 6 kilobase pair (kbp) repeated elements found on Drosophila chromosome ends 
are telornere specific retrotransposable elements that can be lost and readded onto 
chromosome ends (Mason and Biessmann, 1995). 
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The length of the telomeric repeat sequence also varies depending on the organism 
ranging from 24 base pairs (bp) to 150 kbp. Each organism has a characteristic mean 
length. In humans they are between 10-15 kbp in germline cells to 5-12 kbp in 
peripheral blood leucocytes. Though there is much heterogeneity and spontaneous 
changes in telomere length even for example in human cells (Lansdorp et aL, 1996) as 
telomeres do not carry genetic infonnation thus being able to act as a disposable part. 
It has been suggested that human cells are unique among primates in having relatively 
short (-10- 15 kbp) telomeres in somatic tissue (Kakuo et aL, 1999). 
The DNA sequences adjacent to the tandem repeats are known as subtelomeric 
regions or telomere associated DNA (Blackburn and Szostak, 1984) which generally 
contain repetitive but more variable sequences than those of telomeres. 
The 3' of telomeres, the G rich strand forms an overhang of about 100-200 
nucleotides (nt) in length (Makarov et al., 1997; Wright et al., 1997). According to 
one analysis (Makarov et aL, 1997), G strand overhangs appear to be present at most 
chromosome ends. However, other experiments suggest that in cells lacking 
telomerase long G strand tails are only present on half of the chromosome ends, 
consistent with their being generated by incomplete lagging strand synthesis during 
DNA replication (Wright et al., 1997). 
Originally, telomeres were thought to be linear structures with the repeat sequence 
and 3' single strand G rich overhang. Though they contain many telomeric proteins 
and it has been proposed that mammalian telomeres develop a loop structure at the 
end (Griffith et al., 1999) known as t or telomere loop. This telomere loop is thought 
to back up on itself forming the t-loop and a single strand overhang invades the 
telomeric double strand resulting in a displacement loop (d-loop). This loop is 
stabilised by telomenc associated proteins (Figure 1.5). The loop structure protects 
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the single stranded overhang from degradation and/ or interaction with signalling 
proteins and this protection is referred to as telomere capping (Blackburn, 2000). 
1.5.3 Telomeric associated proteins 
A number of telomeric associated proteins (TAP) have been identified that associate 
with telomeres (Figure 1.5). Some of these proteins associate exclusively with 
telomeres (telomere binding proteins) whereas others localise to additional subnuclear 
or subcellular sites. Although the functions of many of the proteins associated with 
telorneres are not fully known some may assist in the spatial organisation and 
packaging of telorneric sequences e. g. as heterochromatin (Hazelrigg et aL, 1984; 
Gottschling et aL, 1990) and it is thought that for example in yeast, telomeres 
participate in transcriptional activation or repression for instance by altering 
chromatin confonnation (Reuter and Spierer, 1992). It has been proposed that 
telomeric associated proteins may also be involved in the control of telomere length 
(Hardy et aL, 1992) whereas others may aid in attaching telomeres to the nuclear 
matrix (de Lange, 1992). Evidence has been published indicating that telomeres are 
linked to the nuclear envelope in a manner involving components of DNA-PK (de 
Lange, 1992; Laroche et al., 1998; Bianchi and de Lange, 1999; Smith and Jackson, 
1999). 
In mammalian cells double strand telomeric repeats are bound directly by two 
ubiquitously expressed proteins, TRF I (TTAGGG repeat binding factor 1) (Smith and 
de Lange, 1997) and TRF2 (TTAGGG repeat binding factor 2) (Bilaud et al., 1997). 
They both bind double stranded telomeric DNA via a DNA binding motif related to 
the proto-oncogene Myb (Broccoli et al., 1997). 
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Figure 1.5 Structure of a human telomere. The human telomere has many telomenc 
associated proteins including proteins which bind to the telomeric DNA (Adapted 
from Harrington,, 2004). 
TIN2/ PINXI/ Tankyrase 
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Overexpression of wildtype TRFI reduces telomere length, whereas overexpression 
of dominant negative TRFI increases telomere length in telomerase positive cells 
(van Steensel and de Lange, 1997). It is also thought TRFI might contribute to 
formation of t loops because it was shown to catalyse telomeric synapsis resulting in a 
coiled telomeric structure (Griffith et al., 1998). These results suggest that when 
TRF I is bound to telorneres it inhibits telornere elongation. 
Overexpression of a wildtype TRF2 reduces telomere length seemingly in a 
telomerase independent manner. However overexpression of dominant negative TRF2 
induces unique phenotypes including loss of G rich overhangs, end to end fusions 
and ATM/ p53 dependent apoptosis or senescence depending on the cell type (van 
Steensel et aL, 1998). Inhibition of TRF2 leads to dysfunctional telomeres which are 
processed by DNA damage machinery (van Steensel et al., 1998; Takai et al., 2003; 
d'Adda di Fagagna et al., 2003; Karlseder et al., 1999). Therefore TRF I is thought to 
function to regulate telomere length possibly by facilitating telomerase activity at 
telomeres, whereas TRF2 is thought to function independently to protect telomeres 
from non homologous end joining and other DNA repair or DNA damage response 
pathways. Though recent data suggests that TRF I and TRF2 are linked and TRF I also 
plays a role in telomere protection (Ye et al., 2004). 
TRFI recruits a number of other proteins to the telomeres (Smogorzewska and de 
Lange, 2004). Two TRFI interacting proteins were discovered by two hybrid 
interaction assays in yeast, tankyrase (Smith et aL, 1998) and TRFI interacting 
protein 2 (TIN2) (Kim et al., 1999). Tankyrase appears to have both telomeric and 
non telomeric functions in cells. Tankyrase under some circumstances interacts with 
acidic amino terminal region of TRF I and a related TRF I interacting protein TANK2 
which is most abundant at the nuclear periphery and in the Golgi apparatus (Chi and 
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Lodish, 2000; Smith and de Lange, 2000; Karninker et aL, 2001). The sequence of 
tankyrase includes 24 ankryin repeats responsible for protein-protein interactions and 
has homology to poly ADP ribose polymerase (PARP) catalytic domain. As 
recombinant tankyrase has PARP activity, as TRF I was shown to be a target, it seems 
likely that post translational ADP ribosylation regulates some aspect of telomere 
dynamics (Smith et aL, 1998). This has been shown, as ADP-ribosylation of TRFI 
impedes its DNA binding activity in vitro and tankyrase overexpression removes 
TRF I from the telomeres and promotes it degradation. This in vitro ADP ribosylation 
of TRF I by tankyrase is inhibited by TIN2 (Ye and de Lange, 2004; Kim et al., 1999). 
TIN2 is thought to protect TRF I from tankyrase in vivo (Ye and de Lange, 2004; Kim 
et aL, 1999). TIN2 interacts with the homodimerisation region of TRFI and has 
similar phenotypes as observed with overexpression of TRFI. Overexpression of 
wildtype TIN2 reduces telomere length, overexpression of truncated dominant 
negative TIN2 increases telomere length. TIN2 functions to recruit PIP I (also known 
as PTOP) to the TRF1 complex (Liu et al., 2004; Ye et al., 2004a). PIPI is a POTI 
(protection of telomeres) interacting protein that mediates the binding of POTI to the 
TRFI complex (Liu et al., 2004; Ye et al., 2004a). POTI binds the G rich telomeric 
single strand overhang (Baumwm and Cech, 2001). An alternative splicing product of 
TRF II PIN2 (protein interacting with the never in mitosis A (NfN4A) protein kinase) 
contains an internal 20 amino acid deletion and forms homo and heterodimers, with 
TRF I (Shen et al., 1997). TRF I has also been shown to interact with Ku (Hsu et al., 
2000), PINXI (Zhou and Lu, 2001), the BLM RecQ helicase (Opresko et al., 2002) 
and ATM kinase (Kishi et al., 2001). TRFI, TIN2, PIPI AND POTI are thought to be 
involved in telornere length horneostasis (Smogorzewska and de Lange, 2004). 
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TRF2 interacts directly with human RAP1 (Li et al., 2000). It also interacts with 
RAD50/MREI I/NBSI complex (Zhu et al., 2000), ERCCI/ XPF (Zhu et al., 2003), 
ATM kinase (Karlseder et al., 2004), Ku (Song et al., 2000) and WRN/ BLM 
helicases (Opresko et al., 2002). A recent study has reported that TIN2 mediates an 
interaction between TRF I and TRF2 (Ye et al., 2004b). 
RAD50/MREI INBS I complex is a trimeric complex involved in the repair of double 
strand DNA breaks, which may also have a role in telomere maintenance as it 
associates with the telomeres at least during S phase which is thought to be due to an 
interaction between NBS I and TRF2 (Zhu et aL, 2000). 
Ku is a protein known to participate in specific DNA repair processes, particularly the 
repair of DNA double strand breaks, also associates with telomeres. Ku is a 
heterodimer and is abundantly localised throughout the nucleoplasm. It is a critical 
component of DNA dependent protein kinase (DNA-PK), a trimeric complex that is 
essential for the repair of double strand breaks by non homologous end joining and is 
thought to have a role to protect the tenninal telomeric structure. Cells deficient in 
either of the two ku subunits are genomically unstable owing to frequent telomere- 
telomere fusions (Bailey et aL, 1999). Ku binds and stabilises the ends of broken 
DNA whereupon it recruits the catalytic subunit of DNA-PK (Smith and Jackson, 
1999). Ku interacts with a number of nuclear proteins, the 70 kD ku subunit (ku70) 
specifically binds TRF I (Hsu et al., 2000) and TRF2 (Song et al., 2000). Most Ku is 
recruited to the mammalian telomere by its binding to TRF I (Hsu et aL, 1999). 
One of the first responses of eukaryotic cells to oxidative and other types of DNA 
damage is the covalent post translational modification of nuclear proteins with poly 
(ADP-ribose). Poly (ADP) ribosylation is to a large extent catalysed by the nuclear 
enzyme PARP now called PARPI, which is a 113 kDa enzyme which utilises NAD+ 
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as a substrate. PARP I is constitutively expressed at a level depending on the type of 
tissue or cell. However it is the contact with DNA single or double strand breaks, 
mediated by two zinc fingers located in the amino terminal DNA binding domain of 
the enzyme that causes activation of the catalytic centre, residing within the carboxy 
terminal NAD+ binding domain. PARPI has also been shown to have a role in 
controlling telomere length as mice lacking PARP display telomere shortening 
compared with wildtype mice (d'Adda di Fagagna et al., 1999). 
There may be many more TAP that have not yet been identified. As TAP function 
cooperatively to establish and maintain the telomere structure, it has been proposed 
that TAP are more important than telomere length in detennining fate and phenotype 
of cells (Blackbum, 2000). 
1.5.4 Function of telomeres 
Telomeres play a number of important roles in the functioning and organisation of the 
genome. They protect the ends of eukaryotic chromosomes by having a capping 
function to protect from chromosomal fusion which would lead to genomic instability 
(Blackburn, 1999). Telomeres also protect the ends of chromosomes from being 
recognised as damaged DNA and from degradation. Telomeres are additional 
involved in chromosome pairing in meiosis and shield them from engaging in 
inappropriate kinds of recombination. More importantly, telomeres act as triggers of a 
checkpoint leading to growth arrest/ apoptosis/ senescence. 
1.5.4.1 End replication problem 
One of the most important roles of telomeres is that they ensure the complete 
replication of chromosomal DNA by recruiting a telomere specific DNA polymerase 
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to chromosome ends. Telomeric DNA is not completely replicated by the normal 
DNA replication machinery. In 1971 Olovnikov published a theoretical paper that in 
somatic cells the ends of the chromosomes are not fully replicated during DNA 
synthesis resulting in the shortening of linear DNA molecules with each cell division 
and that this may be the cause of progressive loss of essential genes and cell arrest in 
senescent cells (Olovnikov, 1971). In 1972 Watson also suggested that the termini of 
linear eukaryotic chromosomes could not be replicated known as the end replication 
problem (Watson, 1972). 
In semi conservative DNA replication, DNA polymerase oc synthesizes DNA in a 5' 
to 3' direction and requires a RNA primer to initiate DNA synthesis. Although one 
template strand can be copied in a continuous process, the other (the template for the 
lagging strand) is copied as a set of discrete Okazaki fragments. A problem occurs at 
the 3' end of the template for the lagging strand since there are no additional 
sequences beyond the end to which primers can anneal. DNA polymerase cc is thus 
unable to fill in the gap between the last Okazaki fragment and the very 3' end of the 
template. The 5' end of the lagging daughter strand is consequently shorter than its 
template (Figure 1.6). The consequence of incomplete replication of terminal DNA 
fragment has been modelled and predicted to a form of the binomial distribution of 
deletion events at each independent chromosome end (Levy et al., 1992). 
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Figure 1.6 The end replication problem. A simple diagram showing that during 
each round of replication, the DNA molecules get shorter (Adapted from Greider, 
1991). 
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1.5.4.2 Telomere shortening 
The possibility that human somatic cells might show telornere loss stemmed from the 
observation that human telomeres are longer in spenn than in blood (Cooke and Smith, 
1986; Allshire et al., 1988; Allshire et al., 1989; Cross et al., 1989; de Lange et al., 
1990; Hastie et aL, 1990). 
In 1990 Harley and colleagues provided evidence for the end replication problem by 
demonstrating in normal human somatic cells that telomeres shorten by 50-200 bp for 
each cell doubling (Harley et aL, 1990). Though the end replication problem can only 
account for the large loss of bp observed if one assumes that the last primer is located 
at a large distance to the end. Therefore other considerations came into account and as 
human telomeres contain a 100-200 nt G rich overhang, the action of aC strand 
specific exonuclease was suggested (Makarov et aL, 1997), which would shorten each 
telomere by half the overhang length per round of replication. 
Alternatively telomeres are sensitive to DNA damage and telomere lengths have also 
seen to be affected by external influences particularly oxidative stress (Petersen et aL, 
1998; von Zglinicki, 2000) which has been proposed to be responsible for the greater 
part of telomere loss in most cell strains. The G triplet is especially sensitive to 
modification by oxidative damage and telomeres are lost five to ten times faster than 
non-nal. if fibroblasts are subjected to chronic hyperoxia (von Zglinicki et aL, 1995; 
Vaziri et aL , 1999) or to concentrations of 
H202 (von Zglinicki et aL, 2000). 
The mitochondrial respiratory chain is a major source of reactive oxidative species 
internally and externally they are produced by ionising radiation e. g. x rays, cosmic 
radiation etc. Telomeres are deficient in repair of oxidatively generated single strand 
breaks (Petersen et al., 1998) and these single strand breaks translate into accelerated 
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telomere shortening as soon as the cells replicate their DNA (Sitte et aL, 1998). DNA 
polymerases have a major problem if single strand breaks are present as replication 
fork stalls. Additionally DNA repair in telorneres by nucleotide excision repair was 
seen to be less efficient than in the endogenous gene dihydrofolate reductase but more 
efficiently repaired than the inactive non coding X chromosome associated 754 region 
(Kruk et aL, 1995). 
A dramatic effect of telomere shortening is the arrest of cell proliferation (Section 1.6) 
or apoptotic cell death (Section 1.3). 
1.6 Cellular Senescence and Immortalisation 
1.6.1 The Hayffick limit 
Hayflick established that human diploid fibroblast show a spontaneous decline in 
growth rate on continuous culture related not to time but to an increasing number of 
population doublings (PD) eventually terminating (after 50-70 PD) in a quiescent but 
viable state termed replicative senescence (Hayflick, 1965). Senescent cells have a 
characteristic morphology, with an increase in volume, they lose their original shape 
and gain a flattened cytoplasm. This is accompanied by changes in nuclear structure, 
gene expression, protein processing and metabolism (Campisi, 2000; Narita et al., 
2003). Senescent cells show beta galactosidase activity at a more neutral pH i. e. pH 6 
than young cells (Dimri et al., 1995). There is evidence now showing that replicative 
senescence is an irreversible cell cycle block in Go triggered via a concerted activation 
of the p53/ p2 I/p 19 and p 16/ pRb pathway (Stein et al., 1999). 
The cells in a population fail to divide in response to a variety of non-nal growth 
stimuli after a charactenstic number of divisions and they remain metabolically active 
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but with an aberrant pattern of gene expression (West et al., 1989). Although the 
maximum division capacity in culture of a human somatic cell population from a 
young normal individual varies significantly from donor to donor and cell type to cell 
type, it typically falls in the range of 50-100 PD. This limit decreases as a function of 
donor age and there is evidence to support the notion that replicative senescence is 
related to in vivo ageing (Campisi, 2000). Ageing is usually defined as the progressive 
loss of function accompanied by decreasing fertility and increasing mortality with 
advancing age (Kirkwood and Austad, 2000). A positive correlation can also be 
drawn between species longevity and cell lifespan (Goldstein and Singal, 1974). 
1.6.2 The telomere hypothesis of cell ageing and immortalisation 
The shortening of telomeres gave rise to the telomere hypothesis of cell ageing and 
immortalisation (Figure 1.7) proposing that critically short telomeres may act as a 
mitotic clock to signal the cell cycle at senescence as it utilises cell divisions as the 
unit of time rather than chronological or metabolic age (Harley, 1991) and it has been 
suggested this may be adaptive in long lived species as a mechanism for turnour 
suppression (Campisi, 1997). 
When cells reach the Hay-flick limit or MI (mortality stage 1) stage, cells irreversibly 
enter senescence. Some rare events can abolish the MI barrier of proliferation, the 
best studied alterations are the expression of viral oncogenes that inactivate p53 and 
retinoblastorna (Rb) (Shay et al., 1991; Shay et aL, 1993). Though the infrequent 
accumulation of these genetic aberrations leaves only a few cells that proliferate 
beyond the Hayflick limit (Harley, 1991) resulting in further telomere shortening. 
A second checkpoint is reached at a critical telomere length called crisis (mortality 
stage 2 or M2). At this stage almost all cells die due to extensive chromosomal 
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n, k aberrations caused by very short and dysfunctional telomeres. However some 
immortal cells activate telomerase (Harley, 1991) and these subpopulation of cells 
escape from crisis giving rise to cells which now have an unlimited proliferative 
capacity (immortalised). The characteristic feature of such immortal cells is the ability 
to maintain their telomeres. Evidence to support this hypothesis was achieved with the 
cloning of the catalytic component of human telomerase (hTERT) (See Section 1.8). 
Using this subunit the immortalisation of cells by the extension of telomeric repeats 
was accomplished (Bodnar et al., 1998; Vaziri and Benchimol, 1998) rescuing some 
cell types from senescence. 
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Figure 1.7 The telornere hypothesis of cell ageing and immortalisation. Telomeres 
shorten with every cell division until MI (Hayflick limit). Some cells proliferate 
beyond MI until they reach crisis or M2. Cells that escape M2 acquire an indefinite 
growth capacity (Harley, 199 1). 
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Though even in replicating human cells there is evidence that telomeric length does 
not necessarily detennine whether cells senescence (Ouellette et al., 2000). The 
shortest telomere on any chromosome does not signal immediate arrest because very 
short telomeres are seen on chromosome 17 for many PD before senescence occurs 
(Martens et al., 2000) and it was suggested that average telomere length plays an 
important role. Others indicate that one or few telomeres signal arrest (Hemann et aL, 
2001). There is recent data (d'Adda di Fagagna et al., 2003) suggesting that >1 but 
less than all telomeres together signal arrest. 
As cultures grow there is an ever increasing fraction of senescent cells (Kill et al., 
1994). This early senescence is caused by faster telomere shortening and heterogenity 
of human fibroblasts replicative lifespan exists due to stochastic cell to cell variation 
in telomere shortening rates (Martin Ruiz et al., 2004). Other evidence suggests that at 
the single telomere level there is stochastic variation in telomere length with ultrashort 
telomeres present in cells (Baird et al., 2003). It has now been established that the 
length of telomeres does not directly trigger senescence but a concept known as 
telornere uncapping (Blackburn, 2000) and dysfunctional telorneres (Chin et al., 
1999). 
1.6.3 Telomere capping/ uncapping 
Expression of a dominant negative form of TRF2 protein causes loss of the overall 
telomere length in the double stranded region (van Steensel et al., 1998; Takai et al., 
2003). When this protein is overexpressed in normal fibroblasts the result is the 
induction of rapid senescence (Smogorzewska and de Lange, 2003). TRF2 has been 
suggested to be required for telomere capping in mammals (de Lange, 2001) as it 
enables the telomeres to fonn the loop structure (Griffith et al., 1999). The ends of 
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telomeric DNA fonn a structure which is tenned the T loop which is stabilised by a 
number of telomere binding proteins (Griffith et al., 1999). It has been suggested that 
a minimum number of telomere repeats is required to form this T loop and maintain a 
functional telomere (Martens et al., 2000). This loop structure is thought to serve as a 
protective 'cap' allowing cell division to proceed and if this loop structure is disrupted 
or opened this is referred to as uncapping (Blackburn, 2000). 
Blackburn suggests that the probability of telomere uncapping increases as it length 
shortens which corresponds to the fact that different strains of fibroblasts undergo 
senescence at different average telomere lengths (Martens et al., 2000; Serra and von 
Zglinicki, 2002). Using TRF2, evidence suggests that the forced uncapping of 
telomeres activates the senescence program (Smogorzewska and de Lange, 2002). 
Senescence has been shown to be signalled and maintained via formation of DNA 
damage foci at telomeres which means telomeres remain in an uncapped state in 
senescent cells (d'Adda di Fagagna et al., 2003). 
The telomeric loop structure protects the single stranded G rich overhang from 
degradation or interaction with signalling protein (von Zglinicki, 2000). The 
uncapping of the telorneres exposes the single stranded telomeric overhang which 
could instigate the signal transduction pathway towards senescence (Saretzki et al., 
1999; von Zglinicki, 2001). Studies have shown that it is not only telomeres that 
shorten during every PD but also telomeric overhangs (Stewart et al., 2003; Keys et 
al., 2004) and this exposure of the chromosme end could lead to activation of the 
DNA damage machinery (dAdda di Fagagna et al., 2003). 
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1.7 Relationship Between Telomere-Dependent and Stress-Induced 
Senescence 
There are many instances whereby senescence like growth arrest is induced in a 
telomere independent mechanism after stress, which is thought to be a form of a 
premature senescence (Toussaint et al., 2000). This has been termed stress induced 
premature senescence (SIPS). For example, overexpression of oncogenes such as 
activated RAS induce senescence like arrest in primary or mouse cells (Lin et al., 
1998; Dirnri et al., 2002; Ferbeyre et al., 2002). This has ap 16 dependency (Benanti 
and Galloway, 2004), which corresponds with an arrest in human epithelial cells in 
response to suboptimal culture conditions (Stampfer and Yaswen, 2003). DNA 
damaging stresses can induce a senescence like growth arrest including drugs 
generating DNA double strand breaks (Robles and Adami, 1998). lonising radiation 
and a number of chemotherapeutic agents induce a senescence like phenotype in cell 
lines derived from human tumours (Wang et al., 1998; Chang et al., 1999; Michishita 
et al., 1999; Park et al., 2000; Suzuki et al., 2001; Elmore et al., 2002; Han et al., 
2002; Haq et al., 2002). Typically these forms of senescence do not involve 
significant telomere shortening and cannot be prevented by ectopic hTERT expression 
(Wei and Sedivy, 1999; Gorbunova et al., 2002). This form of stress induced 
senescence which is telomere independent has phenotypic markers of replicative 
senescence in the fact that they express senescence associated beta galactosidase and 
express senescence associated proteins (Dierick et al., 2002). 
Telomeres are also particularly sensitive to stress/ DNA damage and have lower 
repair efficiencies (Kruk et al., 1995; Petersen et al., 1998). There is much evidence 
to suggest a link between the interaction of DNA damaging drugs and telomeres. 
Firstly, telomeres are specifically sensitive to DNA damage induced by UV (Kruk et 
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1995), oxidative stress (von Zg1inicki et al., 1995; Stewart et al., 2003) and 
possibly, chemotherapeutic drugs (Yoon et al., 1998). Second, dysfunctional 
telomeres trigger growth arrest and/ or apoptosis via telomere-specific induction of 
DNA damage foci, also termed senescence- associated DNA damage foci (d'Adda di 
Fagagna et al., 2003). Third, inhibition of telomerase sensitises mice cells (Lee et al., 
2001) and human cells (Ludwig et al., 2001; Misawa et al., 2002) towards cytotoxic 
drugs. Accordingly, overexpression of the catalytic subunit of telomerase increased 
the resistance of cells against chemotherapeutic drugs (Ludwig et al., 2001; Zhang et 
al., 2003). The modification of telomerase expression and/ or activity was detected 
after drug induced DNA damage (Spiropoulou et al., 2004). Therefore, as telomeres 
are also influenced by stress it has been suggested that telomere dependent senescence 
is also a stress response (von Zglinicki, 2002) (Figure 1.8). 
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Figure 1.8 Relationship between telomere-dependent and stress-induced 
senescence. The diagram indicates the different categories and how they interlink. 
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1.8 Telomerase 
1.8.1 Components of telomerase 
A compensatory system exists for telomere shortening due to the end replication 
problem, sensitivity to DNA damage and other mechanisms by the activation of 
telomerase, a reverse transcriptase enzyme. Telomerase is an RNA-protein complex 
which utilises its RNA as a template for the addition of TTAGGG repeats in human 
cells (Figure 1.9). First discovered in Tetrahymena (Blackburn and Greider, 1985) 
telomerase has now been detected in extracts from almost all organisms with the 
exception of bacteria and viruses which have circular genomes and Drosophila which 
have retrotransposons instead of telomeres (Mason and Biessmann, 1995). 
In humans telomerase is composed of two essential components an integral RNA 
(hTR) which provides the template for the synthesis of telomere repeats, as it contains 
a domain that is complementary to one hexameric unit of the DNA telomeric repeat 
sequence TTAGGG and a protein subunit (hTERT) which provides catalytic activity 
and is homologous to the reverse transcriptases (Feng et al., 1995; Harrington et al., 
1997; Nakayama et al., 1998). Telomerase binds to the 3' of DNA strands and 
extends them by copying its own RNA template in multiples of the hexamer repeat 
sequence. 
Both hTR and hTERT are necessary for reconstitution of telomerase activity in vitro 
(Weinrich et al., 1997; Beattie et al., 1998). While hTR is widely expressed in 
embryonic and somatic tissue, hTERT is highly regulated and it was thought that it 
was not detectable in most somatic cells (Meyerson et al., 1997; Nakamura et al., 
1997). Though a recent study indicated that maintenance of proper telomere structure 
is performed by telomerase operating in presenescenct cells (Masutomi et al., 
2003). 
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This work has shown that hTERT is expressed (only during S phase) and active in 
normal human fibroblasts. When the hTERT was eliminated from these cells, the cells 
underwent premature senescence (Masutomi et al., 2003). 
There is evidence showing that ectopic expression of hTERT is sufficient for 
restoring telomerase activity in a number of telomerase negative cell lines including 
foreskin fibroblasts, mammary endothelial cells and umbilical endothelial cells 
(Weinrich et al., 1997; Bodnar et al., 1998; Counter et al., 1998; Vaziri and 
Benchimol, 1998; Wen et aL. 1998). Although the additional inactivation of the Rb/ 
p16 pathway is required for the hTERT mediated immortalisation of keratinocytes 
(Kiyono et aL, 1998). 
Telomerase maintains a dynamic equilibrium and prevents the chromosomes from 
shortening to a critical length and prevents cells from receiving the signal to stop 
dividing. Cells that produce telomerase include genn cells and cancer cells, these cells 
are essentially immortal whereas normal somatic cells lack telomerase activity. The 
introduction of telornerase prior to either MI or M2 is sufficient for immortalisation 
indicating that telorneres are associated with both Ml and M2 stage of growth arrest 
in human fibroblasts (Morales et aL, 1999). 
1.8.2 Alternative lengthening of telomeres 
Cells exist which are telornerase negative but are still able to maintain the length of 
their telomeres and have unlimited replicative potential, indicating the existence of 
one or more non telomerase mechanisms for telomere maintenance termed Alternative 
Lengthening of Telomeres (ALT) (Bryan and Reddel, 1997). 
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Figure 1.9 Telomere elongation. Telomeres are extended by the enzyme telomerase. 
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ALT cells have a heterogeneous telornere length phenotype with long telomere length 
and wide length distribution (Bryan et al., 1995; Grobelny et al., 2001; Mumane et al., 
1994) compared to telomerase positive human cancers, which are homogenous and 
have shorter lengths (de Lange, 1995; Park et al., 1998). Approximately 85% of 
human turnours have telomerase activity (Shay and Bacchetti, 1997). Though it is not 
possible to suggest that the remaining 15% have ALT activated. 
ALT has been detected in a number of turnours including osteosarcoma, soft tissue 
sarcoma, glioblastoma and carcinomas of the lung, kidney, adrenal and breast (Bryan 
et al., 1997; Mehle et al., 1996; Scheel et al., 2001). There is evidence to suggest that 
some tumours have both ALT and telomerase activity (Bryan et al., 1997; Strahl and 
Blackbum, 1996). 
1.8.3 Telomere length independent survival function of telomerase 
There is evidence to suggest that telomerase acts as a survival factor and plays a role 
in resistance of cancers to chemotherapeutic drugs (Ludwig et al., 2001; Zhang et al., 
2003; Sharma et al., 2003; Shin et al., 2004). This has been supported by other 
investigations for example the upregulation of telomerase activity has been detected 
after DNA damaging drug treatments (Moriarty et al., 2002; Mapper et al., 2003; 
Sato et al., 2000). Telomerase could promote survival either by compensating for 
telomeric damage or by some telomere independent mechanism. However, there are 
arguments in favour of a telomere independent mechanism: 
1) Overexpression of telomerase has been shown to induce the expression of a 
number of DNA damage responses and repair genes (Sharma et al., 2003; Shin et al., 
2004). 
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2) Telomerase interacts with proteins involved in survival and apoptosis (Cao et al., 
2002; Haendeler et al., 2003; Zhang et al., 2003; Dudognon et al., 2004). 
3) If maintenance of telomere length and/ or structure by telomerase were important 
for the resistance of tumour cells to cytotoxins, one should expect that telomerase 
knockdown would result in compromised telomeres, followed by early induction of 
apoptosis or growth arrest. In fact, telomerase knock down induces apoptosis (Fu et 
al., 2000) in turnour cells and increased the sensitivity of cells to DNA darnaging 
drugs (Ludwig et al., 2001; Kondo et al., 1998). Though this occurs without any 
change in telornere length (Saretzki et al., 2001; Ludwig et al., 2001). 
4) Telomerase has been linked with various other pathways due to it being localised to 
different cellular compartments such as nucleolus, cytoplasm and mitochondria 
(Wong et al., 2002; Haendeler et al., 2003; Santos et al., 2004). 
1.8.4 Telomerase as a prognostic marker 
In some forms of cancer telomerase could be used as a prognostic marker for example 
in neuroblastoma. 94% of neuroblastomas (Hiyama et al., 1995) express telomerase 
suggesting an important role for telomerase in neuroblastoma development. 
Neuroblastoma (NB) arises from the embryonal neural crest and is the most common 
solid extracranial malignancy of infancy and childhood affecting I in 7000. They are 
turnours that are markedly heterogeneous in tenus of their biological, morphological 
and clinical characteristics (Maris and Matthay, 1999). It is an unpredictable cancer as 
some cases are highly aggressive and poorly responsive to current therapeutic 
schemes and others will spontaneously regress. Therefore leading to favourable and 
unfavourable prognosis even if multimodal therapy has occurred. 
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In order to predict the biological behaviour of an individual tumour there are several 
parameters to predict prognosis of neuroblastoma patients. These parameters include 
WCN gene amplification where loss of heterozygosity for lp32-36 and the 
subsequent increase in MYCN copy number predict poor outcome in all age and stage 
groups (Brodeur et aL, 1984; Ambros et aL, 1996; Caron et aL, 1996). 
A low Trk A expression is another powerful prognostic marker that identifies a 
favourable group of tumours (Nakagawara et al., 1993). Trk A is a proto-oncogene 
that is a transmembrane glycoprotein tyrosine kinase that is expressed selectively in 
the developing nervous system and whose product is a signal transducing receptor for 
nerve growth factor (Kaplan et aL, 1991). Trk is expressed in many primary 
neuroblastomas and is associated inversely with arnplification of the N-myc proto- 
oncogene. Ha-ras p2l expression (Tanaka et aL, 1991) and cellular DNA content are 
other markers. All these markers though do not give a complete accurate prognostic 
grouping (Bown et aL, 1999). 
Telomerase activity has been shown to be a powerful independent prognostic factor in 
neuroblastoma (Brinksmidt et al., 1998; Poremba et al., 1999; Poremba et al., 2000) 
or in association with another parameter for e. g. Trk A expression (Nozaki et al., 
2000). Neuroblastomas have been classed into groups of high and low telornerase 
activity and the expression profile assessed by microarray to determine any genes that 
could be used as a novel targets in aggressive neuroblastomas (Hiyama et al., 2003). 
Therefore since telornerase activity has prognostic significance in neuroblastoma it is 
particularly relevant that a study of telomeric damage caused by cisplatin and 
etoposide should focus on this disease. 
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1.9 Conventional Anticancer Therapeutics 
The best result from any cancer treatment is the complete eradication of all cells from 
the body giving a patient a normal life expectancy. The number of treatment choices 
depends on the type of cancer, the stage of the cancer, and other individual factors 
such as the age, health status of the patient. The four major types of treatment for 
cancer are surgery, radiation, chemotherapy, and biological therapies. Though there 
are hormone therapies (tamoxifen) and transplant options (bone marrow) available. If 
a tumour is amenable to surgery, then surgery is the most effective tool in the anti- 
cancer treatment. Anti-cancer agents are rarely used singly to treat cancer as only a 
few turnours are sensitive enough to be cured by single agents. Effective 
chemotherapy usually depends on the identification of suitable combinations to treat a 
specific type of turnour (Frei et aL, 1998), as combination treatments minimise drug 
resistance and the dose limiting toxicity to the patient. 
Conventional anti-cancer drugs have been designed with DNA as their target. Some 
target DNA synthesis though a problem lies in that tumour cells are not the only 
proliferating cells in the body i. e. cells that line the alimentary tract, bone marrow 
cells that generate red blood cells and cells to fight infection and epidennal cells 
including those that generate hair are all highly proliferative. New generation drugs 
have targets removed from the direct synthesis of DNA and now affect the signals that 
promote or regulate the cell cycle, growth factors and their receptors, signal 
transduction pathways and pathways affecting DNA repair and apoptosis. 
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1.10 Cisplatin 
1.10.1 History of cisplatin 
Cis-diamminedichloroplatinum (11) (cisplatin) is a neutral, inorganic compound that is 
widely used for the treatment of a variety of tumours. Cisplatin is a square planar 
complex that contains a single platinum atom with two ammonia and two chlonde 
groups that are bound in the cis configuration (Figure 1.10). 
H3N NH3 
Pt 
cl cl 
Figure 1.10 Structure of cisplatin. Two chloride and two ammonia groups attached 
to a single platinum atom. 
Cisplatin was first synthesized by M. Peyrone in 1844 and was called 'Peyrone's 
chloride'. Its structure was discovered by Alfred Werner in 1893 and then it was only 
serendipitously revealed to be an anti-cancer compound by Barnett Rosenburg in the 
1960's (Rosenburg et al., 1965). Rosenburg was interested in the resemblance 
between mitotic spindle of dividing cells and the lines of magnetic force as visualised 
by iron filings around a magnet. Initially he designed an experiment to measure the 
effect of an electric field on the growth of the bacteria Escherichia coli. He showed 
that the bacteria growth was inhibited by the electric current though there was an 
increase in their nonnal length. However this effect was due to an electrolysis product 
fori-ned by the interaction of dissolved platinum from the electrodes with ammonium 
in the culture medium. The product formed was identified as (NH4)2(PtCI6) and in 
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tum was converted by a photochemical reaction to CiS-(PtC14(NH3)2). As Rosenberg 
found that the platinum complexes were effective at inhibiting cell division 
(Rosenburg et al., 1967) he decided to test the platinum complexes against the mouse 
turnour, Sarcoma 180 (Rosenburg et al., 1969) and the compounds were also screened 
against the mouse leukaemia, L1210. The platinum complexes were found to be 
highly effective in eliminating tumours and were further tested in a number of animal 
models. In human trials, cisplatin was effective against a range of tumour types 
particularly testicular cancers (Higby et al., 1974) and ovarian cancer (Wiltshaw and 
Carr, 1974) though it was limited to some extent by toxic side effects. These side 
effects include renal toxicity, bone marrow suppression, hearing loss, neurotoxicty etc 
(Calvert et al., 1995), which have been made bearable by adjuvant therapies. For 
example, administration of continuous hypertonic saline along with diuretic drugs 
before and following cisplatin infusion has helped to reduce kidney damage (Hayes et 
al., 1977). Similarly, several effective antiernetic drugs protect the patient from the 
worst of nausea and vomiting (Kidgell et al., 1990). Today cisplatin is widely 
prescribed for a variety of turnours (germ-cell, advanced bladder carcinoma, adrenal 
cortex carcinoma, breast cancer, head and neck carcinoma, lung carcinoma, 
neuroblastoma). It is administered intravenously for one to 5 days in a row, followed 
by a rest period of 2-3 weeks. 
1.10.2 Biochemical mechanism of action of cisplatin 
Cisplatin's main intracellular target in mammalian cells is DNA, forming cisplatin- 
DNA adducts (Pinto and Lippard, 1985), though it can also react with RNA and 
protein. Cisplatin diffuses through the cell membrane and for the interaction to occur 
with DNA, the neutral cisplatin has to be activated through a series of aquation 
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reactions which involve the sequential replacement of the cis-chloro ligands of 
cisplatin with water molecules (Figure 1.11). A chloride ligand of the neutral cisplatin 
complex is displaced by a water ligand in the cytosol, to produce a monofunctionally 
active complex which can react with nucleophilic sites i. e. a single nitrogen on a DNA 
molecule. Displacement of the second chloride with water leads to the bifunctional 
active complex. The aquation process takes place in the cytosol as the presence of a 
high chloride ion concentration in extracellular fluid suppresses the aquation reaction. 
Cisplatin forms both monofanctional and bifunctional inter and intra-strand cross- 
links on DNA and the amounts of platinum bound to DNA have also been deten-nined 
(Jamieson and Lippard, 1999). The nature and proportions of these adducts are shown 
in Figure 1.12. The major adduct formed is the bifunctional intra-strand cross-link 
between adjacent guanines (1,2d(GpG)) 60-65%. Other adducts fon-ned are 1,2 intra- 
strand d(ApG) 20-25%, 1,3 intra-strand GpG 2%, monofunctional adducts 2% and 1,2 
G, G inter-strand cross-links - 2% (Fichtinger-Schepman et al., 1985). 
1.10.3 Cisplatin cytotoxicty 
Cisplatin is a potent inducer of apoptosis (Onnerod et al., 1996; Henkels and Turci, 
1997). It is unclear how the cisplatin-DNA adducts induces cytotoxicty, though it is 
widely thought that the cross-links fonned are the cause of the drugs cytotoxicty and 
there is linear correlation between gross levels of platinum bound to DNA and the 
extent of cytotoxicty (Fraval and Roberts, 1979). Reports exist that indicate that inter- 
strand cross-links are the most cytotoxic lesion (Knox et al., 1986). Though other 
evidence favours, intra-strand adducts as lesions largely responsible 
for the cytotoxic 
action (Pinto and Lippard, 1985) which is consistent with the 
knowledge that the 
intra-strand adducts account for 85- 90% of total lesions (Kelland, 1993). 
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H3N NH3 
Pt 
cl cl 
Aquation 
+ H20 
cl 
H3N NH3 
Pt 
cl (H20)+ 
H20 
H3N NH3 
Pt 
(H20)+ (H20)+ 
Neutral complex 
Active complex 
Active complex 
Figure 1.11 Formation of reactive cisplatin complexes in vivo. For cisplatin to be 
able to react with DNA the neutral complex is activated through a series of aquation 
reactions, whereby the cis-chloro ligands of cisplatin are replaced with water 
molecules. 
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Figure 1.12 Spectrum of cisplatin- DNA adducts. Cisplatin binds to DNA to form 
the following cross-links; (A) 1,2-(GpG)- intra-strand, (B) 1,2-d (GpG)- intra-strand, 
(C) 1,3-d (GpXpG)- intra-strand, (D) cisplatin bound mono functional Iy to guanine, 
(E) inter-strand cross-link. The percentage of the specific type of adduct formation is 
denoted below each diagram. 
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Additionally, the inactive trans isomer of cisplatin, trans-diamminedichloroplatinum 
(11), is sterically unable to form the major d(GpG) and d(ApG) intra-strand adducts. 
Instead a high proportion of DNA mono-adducts are fonned (Eastman and Barry, 
1987). A small number rearrange themselves to form bifunctional 1,3 or 1,4 guanine- 
guanine intra-strand cross-links or DNA inter-strand cross-links (Eastman and Barry, 
1987). 
DNA cross-links are considered to be cytotoxic to the cell due to the alteration of the 
DNA structure when cisplatin is bound to it and apoptosis is induced at any phase of 
the cell cycle. This alteration in DNA is believed to prevent replication and activate 
cellular repair mechanisms. The sequence of events that leads to apoptosis is believed 
to begin by the recognition of DNA damage by proteins which bind to the physical 
distortions of DNA induced by the cisplatin- DNA adducts (Bellon et al., 1991). 
These proteins which include the hMSH2 component of mismatch repair (Fink et al., 
1998) transcription factor 'TATA binding protein' (TBP) (Chaney and Vaisman, 1999) 
likely transduce DNA damage signals to downstream effectors but may have other 
implications in promoting cytoxicty by preventing their participation in transcription 
(Jordan and Canno-Fonseca, 2000). 
The cisplatin- DNA adducts are removed by the nucleotide excision repair (NER) 
pathway (Beck et al., 1973; Hansson and Wood, 1989). Only when repair is 
incomplete, when damage is severe, cells undergo apoptosis. Repair, checkpoint 
activation and apoptosis are associated with the turnour suppressor protein p53 
(Morgan and Kastan, 1997; Bullock and Fersht, 2001). Additionally, patients with a 
deficiency in NER, Xeroderma Pigmentosum (XP) were hypersensitive to cisplatin 
(Dijt ef al., 1988). Futhermore the transcribed strand has shown to be repaired more 
efficiently than the untranscribed strand due to the transcription coupled repair system 
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(Mellon and Hanavalt, 1989) and it has been shown that the major intra-strand d(GpG) 
adduct induced by cisplatin is poorly repaired compared to d(GpXpG) and 
monofunctional adducts (Page et al., 1990; Szymkowski et al., 1992). 
1.10.4 Cisplatin drug resistance 
Drug resistance is a major limitation in cisplatin cancer chemotherapy. Resistance can 
be either intrinsic (present at the onset of treatment) or acquired (occurring during 
treatment). Colorectal and non small cell lung tumours are examples of those 
exhibiting intrinsic resistance to cisplatin while ovarian and small cell lung cancers 
often develop acquired resistance (Kelland, 2000). Cisplatin resistance can be 
multifactoral, and the several mechanisms that can contribute to this property include 
changes in reduced intracellular drug accumulation (Kelland, 1993), increased 
inactivation by thiol containing molecules (Wolf et al., 1987) and an increase in DNA 
repair (Lai et al., 1988). Other possibly important mechanisms inhibit propagation of 
the DNA damage signal to the apoptotic machinery including loss of damage 
recognition, overexpression of HER-2/neu, activation of the P13-KJAkt (also known 
as P13-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, 
and interference in caspase activation (Siddick, 2003). 
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1.11 Etoposide 
1.11.1 Topoisomerase 11 poisons 
Topoisomerases are enzymes located in the nucleus of cells and induce topological 
changes in DNA during essential processes such as DNA replication, transcription, 
recombination and repair. Topoisomerase I (Wang, 1971) breaks single strand DNA, 
whilst topoisomerase 11 (Gellert et al., 1976) cleaves double strands of DNA and can 
untangle inter-twined double strands of DNA (Wang, 1996). For example 
topoisomerase II has shown to be essential for the segregation of daughter 
chromosomes in mitosis in S. cerevisiae (Dubrana et al., 2001). 
Toposiomerase 11 enzymes are multi subunit proteins, which require ATP for overall 
catalytic activity and modulate DNA topology by passing an intact helix through a 
transient double strand backbone break (Li and Chen, 1994; Froelich-Ammon and 
Oshesoff, 1995). Topoisomerase 11 poisons stabilise the cleavable complex, 
preventing the removal of covalently bound enzyme and religation of the DNA. The 
topoisomerase 11 poisons appear to be particularly toxic during S phase when 
replication forks and transcription complexes are both present as compared to other 
phases when only transcription complexes are present (Estey et al., 1987; D'Arpa et 
al., 1990). Intact p53 is required for G, arrest by topoisomerase inhibitors etoposide 
and doxorubicin (Fan et al., 1994). In normal human cells DNA topoisomerase 
inhibitors are efficient and reversible inducers of premature senescence (Michishita et 
al., 1998). 
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1.11.2 History of etoposide 
Etoposide (Figure 1.13) was the first agent recognised as a topoisomerase 11 inhibiting 
anti-cancer drug and is one of the most active anti-tumour agents against solid 
tumours. 
H3C 
OH 
Figure 1.13 Structure of etoposide. Etoposide, a topoisomerase 11 inhibitor, is a 
derivative of podophyllotoxin. 
Etoposide is the first drug choice for testicular cancer and small lung cancer though it 
is also used in treatments of lymphomas, Ewings sarcoma, Kaposi's sarcoma and 
ovarian cancer (Hande, 1998a). Etoposide is a derivative of the plant derived natural 
product, podophyllotoxin and was put into clinical trials in the 1970's. 
1.11.3 Biochemical mechanism of action and cytotoxicty of etoposide 
Etoposide is a typical topoisomerase 11 poison that stabilises the cleavable complex 
forination with DNA topoisomerase 11 without an intercalating action. Etoposide and 
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other topoisomerase Il posions do not kill cells by blocking topoisomerase catalytic 
function. Rather they poison these enzymes by increasing the steady state 
concentration of their covalent DNA cleavable complexes. This action converts 
topoisomerase into physiological toxins that introduce high levels of transient protein 
associated breaks in the genome of treated cells (Kaufinann, 1998). Etoposide is 
known to cause DNA strand breaks and to induce apoptosis in diverse cell types 
(Okamoto-Kubo et al., 1994; Bonelli et al., 1996; Hande, 1998b; Michishita et al., 
1998). Etoposide has been reported to have topoisomerase 11 independent functions, 
as it contains a phenolic group which when oxidised yields reactive metabolites 
(quinones) capable of irreversible binding to macromolecular targets like DNA 
(Stoyanovsky et al., 1993). Though it is not known if these play a significant role to 
etoposides pharmacological effects. 
1.11.4 Etoposide drug resistance 
Etoposide shows high affinity for P-glycoprotein and multidrug resistant cells show 
cross resistance to etoposide. Tumour cells resistant to topoisomerase 11 inhibitors 
often have low topoisomerase 11 levels whereas turnour cells with high levels of 
expression of topoisomerase 11 are sensitive to topoisomerase II inhibitors (Davies et 
aL, 1988). Overexpression of topoisomerase 11 in tumour samples has been reported 
in several types of turnours including lung cancer, ovarian cancer and lymphoma 
(Koomagi et al., 1996). 
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1.12 Telomerase Inhibition as a Potential Therapeutic 
Telomerase is active in early embryogenesis (Ulaner et al., 1998) but is down 
regulated during differentiation. It is expressed in adult reproductive cells, at very low 
levels in somatic cells (except proliferative cells of renewal tissues) and is expressed 
in 85% of human cancers (Shay and Bacchetti, 1997). There has been much attention 
given to the development of telomerase inhibitors as potential anti-cancer agents 
because of the strong potential advantages of broad versatility (nearly all known 
cancers express telomerase) and comparatively high tumour specificity (as the few 
human somatic cells that have telomerase seem to be less reliant on it than tumour 
cells). Additionally inhibiting telomerase activity will allow telomere shortening to 
occur which is a major mechanism to induce telomere uncapping and thus to signal 
growth arrest and/ or apoptosis. Unfortunately, the disadvantage with telomerase 
inhibition, is the requirement to maintain the inhibition over a long time in order to 
allow telomere erosion and eventually cell death (Kipling, 1995), as telomeres only 
erode at a rate of 50 to 100 bases per population doubling (Harley et al., 1990). This is 
especially relevant to turnours with long telomeres and provides circumstances highly 
favourable for the development of drug resistance. Alternatively, telomerase has been 
shown to have a telomere independent survival function (See Section 1.8.3) which 
may play a role in resistance of cancers to chemotherapeutic drugs and identifying the 
mechanisms involved could potentially be useful in future therapeutics. 
It may be possible to overcome this serious problem of telomerase inhibition by 
exploiting synergistic interactions that are predicted to arise from the correct 
combination of telomerase inhibitors with certain established and novel anti-cancer 
drugs. It has been shown that inhibition of telomerase activity by expression of a 
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ribozyme targeted against hTERT increases the sensitivity of breast cancer cells to 
doxorubicin, a topoisomerase inhibitor (Ludwig et al., 2001). 
As telomerase is controlled on a number of levels, various strategies have been 
investigated as targets for telomerase inhibition using either a direct or an indirect 
action by i) chemoprevention, ii) targeting telomerase components and their 
regulatory mechanisms, iii) targeting the telomere and iv) synergistic approaches 
(Reviewed: Keith et al., 2002; Saretzki., 2003). Inhibition of telomerase by different 
methods has lead not only to progressive telomere shortening and ensuing cell death 
(Herbert et al., 1999) but also to telornere length independent apoptosis induction 
(Saretzki et al., 2001). 
Tumours using the ALT mechanism will be resistant to telomerase inhibitors. 
Repression of ALT in ALT+ immortalised cell lines results in senescence and cell 
death (Nakabayashi et al., 1997; Perrem et al., 2001) which may also be an attractive 
target and help prevent drug resistance. Bechter and colleagues inhibited telomerase 
activity in a human cancer cell line with a mismatch repair defect and observed an 
ALT like telornere elongation (telomerase independent) which showed a novel 
mechanism of resistance to anti-telomerase therapy (Bechter et al., 2004). 
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1.13 Aims and Objectives 
The aim of this study was to establish the significance of the telomere/ telornerase 
complex for the action of the conventional cytotoxic anti-cancer drugs cisplatin and 
etoposide. This aim was approached by using cells with either long or short telomeres 
and by assessing a number of parameters to detect evidence for significant levels of 
drug-induced effects on telomeres. An important aspect of the experiments was to 
distinguish between effects that resulted from apoptosis as opposed to effects that 
could have induced apoptosis. Thus, the investigation examined whether induction of 
apoptosis was preceded or accompanied by telomere shortening or other observable 
changes in the telomere/ telomerase complex after drug treatments. 
The cell line used to investigate short telomeres was a neuroblastoma cell line, 
SHSY5Y with telomere lengths of -4 kbp and for the long telomeres an acute 
lymphoblastic T cell line 1301 with telornere lengths of -80 kbp was used. Both cell 
lines positively express telomerase. The study assessed two treatment regimes namely 
a short and a continuous exposure to both drugs. The short exposure drug treatment 
was 2 hours for cisplatin and 4 hours for etoposide and studies took place up to 48 
hours after exposure. For the continuous drug exposure, studies took place at daily 
intervals up to 72 hours after initial drug exposure. 
The main hypothesis to be tested was that drug induced DNA damage targets the 
telomere/ telomerase complex to a significant extent such that apoptosis and or 
growth arrest might largely be triggered from telomeres. If confirmed, this model 
would have important implications for the design of potentially effective anti-cancer 
therapies based on the combination of DNA damaging cytotoxic agents with 
telomerase inhibitors. 
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This work involved: 
0 Investigation of cytotoxicty of cisplatin and etoposide treatment on the 
SHSY5Y and 1301 cells 
0 Analysis of the cellular response to drug exposures by examining levels of 
apoptosis and kinetics of cell cycle 
0 Confirmation of DNA damage induction and response after cisplatin and 
etoposide exposure 
0 Examination of telomere restriction fragment length, length and integrity of 
single stranded G overhangs and telomeric single strand breaks after cisplatin 
and etoposide treatment 
0 Evaluation of telomerase activity after cisplatin and etoposide exposure 
0 Adaptation of an immunoFISH procedure to assess the co-localisation of 
telomeric DNA and DNA damage response foci 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Chemicals and Reagents 
Unless otherwise stated, the chemicals used in these studies were obtained from 
Sigma-Aldrich Company Ltd (Poole, Dorset, UK) or VWR International (Poole, 
Dorset, UK). 
2.2 Buffers and Solutions 
Alkaline buffer 50 mM NaOH, I mM EDTA 
B&W buffer 10 mM Tris-HCI pH 7.5,1 mM EDTA, 2M 
NaCl 
Buffer Cl 1.28 M sucrose, 40 mM Tris-Cl pH 7.5,20 mM 
M9CI2,4% Triton X- 100 
Buffer G2 800 mM guanidine HCI, 300 mM Tris-Cl pH 8, 
30 mM EDTA pH 8,5% Tween-20,0.5% 
Triton X- 100 
Buffer QBT 750 mM NaCl, 50 mM MOPS pH 7,15% 
isopropanol, 0.15 % Triton X- 100 
Buffer QC IM NaCl, 50 mM MOPS pH 7,15% 
isopropanol 
Buffer QF 1.25 M NaCl, 50 mM Tris-Cl pH 8.5,15% 
isopropanol 
Cell suspension buffer 10 mM Tris pH 7.2,20 mM NaCI, 50 mM 
EDTA 
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Culture medium Medium containing 10% (v/v) heat inactivated 
foetal calf serum, 1% (w/v) penicillin/ 
streptomycin, I% (w/v) L- glutamine 
Denaturation buffer 0.5 M NaOH, 1.5 M NaCl 
Depurination buffer 0.25 M HCI 
Diethanolamine solution 100 mM diethanolamine, I MM M9CI2pH 10 
ED TA b uffe r 10 mM EDTA pH 8.2,9 5% fonnamide 
FAD U alkali solution 200 mM NaOH, 40% FADU denaturation buffer 
FAD U denaturation buffer 9M urea, 10 mM NaOH, 25 mM CDTA, 0.1% 
SDS 
FAD U lysis buffer 0.25 M meso-inositol, IM M9CI25 10 MM 
Na2P04/ NaH2PO4, pH 7.2 
H buffer 50 mM Tris-Cl, 10 MM M9CI2,100 mM NaCl, 
I mM dithioerythritol pH 7.5 
Neutralisation buffer 0.5 M Tris-HCI, 1.5 M NaCl, pH 8 
13 D 
InG 0.2% cold water fish gelatine, 0.5% BSA in PBS 
Phosphate Buffered Saline (PBS) 10 mM Na/ KH2PO4,140 mM NaCI, 2.7 mM 
KCI, pH 7.4 
Plug wash buffer 20 mM Tris, 50 mM EDTA pH 8 
Protein reaction buffer 100 mM EDTA pH 8,0.2% sodium 
deoxycholate, 1% sodium laurylsarcosine 
Sen 6 gal staining solution 150 mM NaCI. 
2MM M902,40 mM citric acid, 
12 mM sodium phosphate pH 6, water, X-Gal, 
potassium ferrocynaide 
Sodium acetate buffer 80 mM NaOAc. 95% fon-namide 
Sulphorhodamine B (SRB) solution 0.4% (w/v) SRB dissolved in I% (v/v) acetic 
acid 
TBS buffer pH 7 0.14 M NaCl, 50 mM Tris, 2.7 mM KCI, pH 7 
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TBS buffer pH 8.5 
TE b uffe r 
Ix SSC 
Ix SSCI I% Triton X-1 00 
0. ]x SSCI 1% Triton X-] 00 
0.2x SSCI 0.1 % SDS 
0.5 x TBE 
2.3 Cell Culture 
2.3.1 Tissue culture supplies 
0.14 M NaC1,50 mM Tris, 2.7 mM KCI, pH 8.5 
10 mM Tris-Cl pH 8,1 mM EDTA pH 8 
0.0 15 M sodium chloride, 0.15 M sodium citrate 
0.015 M sodium chloride, 0.15 M sodium 
citrate/ I% Triton X- 100 
0.0015 M sodium chloride, 0.015 M sodium 
citrate, I% Triton X- 100 
0.03 M sodium chloride, 0.003 M sodium 
citrate, 0.1% sodium lauryl sulphate (SDS) 
45 mM Tris, 45 mM boric acid, 2 mM EDTA 
Tissue culture flasks (25 cm 25 75 CM2 and 150 cm 2) were supplied from Coming 
Incorporated, USA. All other plasticware used were obtained from VWR International, 
UK. All reagents were acquired from Sigma-Aldrich, UK unless otherwise stated. 
2.3.2 Equipment 
All tissue culture procedures were carried out in a Trimat 2 class II microbiological 
safety cabinet (Medical Air Technology, UK) and cell flasks were incubated in a C02 
tissue culture incubator (Binder GmbH, Germany). Cells were centrifuged in either a 
centrifuge equipped with a swing out rotor (Biofage Primo R, Heraeus, Kendro 
Laboratory Products, UK) or microcentrifuge (Eppendorf 5415R, Gennany). Culture 
media was pre-warmed in a 37'C waterbath (Grant Instruments, Jencons PLS, UK). 
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2.3.3 Cell lines/ strain 
Cell lines/ strain used in this study are listed in Table 2.1. 
Table 2.1 Characteristics of cell lines/ strain 
Cell Lines/ Strain Characteristics Reference Acq ui red 
SHSY5Y Human neuroblastoma Ross et al., 1983 ATCC, USA 
1301 Human T cell lymphoblast Hultdin et al., 1998 Dako, Denmark 
MRC5 Human lung fibroblasts Holliday et al., 1972 ECACC, UK 
2.3.4 Maintenance of cell lines/ strain 
SHSY5Y and MRC5 cells are adherent whilst the 1301 are suspension cells. 
SHSY5Y and 1301 cell lines were maintained in RPMI 1640 medium, MRC5 in 
Dulbecco's Modified Eagle's Medium (DMEM). All medium contained 10% (v/v) 
heat inactivated foetal calf serum (S0275551800/500, Biowest, UK), 1% (w/v) L- 
glutamine (200 mM) and I% (w/v) penicillin/ streptomycin. Cells were grown as 
asynchronous cultures at 37'C in a humidified atmosphere under air containing 5% 
C02- Mycoplasma testing was performed regularly using Mycoplasma Plus TM PCR 
Primer Set (Stratagene, USA). Cells tested negative throughout. 
2.3.5 Cryogenic storage 
Exponentially growing adherent cells were trypsinised (unnecessary for suspension 
cells) and both adherent and suspension cells were centrifuged at 800 g for 5 minutes 
at room temperature. The supernatant was removed, cells were washed in Dulbecco's 
phosphate buffered saline (PBS), recentrifuged and the cells resuspended in foetal calf 
serum (FCS) containing 5% (v/v) dimethyl sulfoxide (DMSO) at a density of IxIO 
6 
cells/ ml. DMSO is a cryoprotectant that reduces damage to cell structure by altering 
the nature of ice formation. 2 ml aliquots of cell suspension were immediately 
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transferred to cryo-vials and placed in a Nalgene 
TM Cryo PC freezing container filled 
with isopropanol. They were kept for 24 hours in a -80'C freezer to allow them to 
freeze slowly, before being stored in liquid nitrogen. 
2.3.6 Resuscitation of frozen cells 
Cryo-vials were removed from the liquid nitrogen bank and quickly thawed by being 
placed in a 37'C water bath for I to 2 minutes. The thawed cell suspension was then 
immediately seeded into a 75 cm 2 flask with 30 ml prewarmed medium. After 6 hours 
for adherent cells the medium was replaced to remove DMSO, cell debris etc. The 
medium was also replaced for the suspension cells after 6 hours, by centrifugation at 
800 g for 5 minutes at room temperature. 
2.3.7 Routine cell culture 
Adherent cells were always sub-cultured before reaching confluence, unless otherwise 
indicated. Adherent cells were harvested using trypsin/ EDTA. Initially the culture 
medium was removed, cells were washed in PBS and 5 ml of trypsin/ EDTA was 
added which covered the surface of the flask. Cells were exposed to trypsin for 5 
minutes or until they had detached from the flask, at 370C in the tissue culture 
incubator. Inactivation of the trypsin/ EDTA was achieved by adding an equal volume 
of culture medium. Cells were counted (Section 2.3.8) and were either reseeded into 
tissue culture flasks or collected by centrifugation at 800 g for 5 minutes. 
Suspension cells were sub-cultured when they were visibly at a high density. Cells 
were collected and centrifuged at 800 g for 5 minutes, the supernatant removed and 
cells were resuspended in fresh culture medium. Cells were counted (Section 2.3.8) 
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and were either reseeded into tissue culture flasks or collected by centrifugation at 
800 g for 5 minutes. 
2.3.8 Calculation of cell density 
Cells were counted using a Fuchs Rosenthal haemocytometer (VWR International, 
UK) and a standard microscope (DMIL, Leica Microsystems, UK). 20 ýtl of cell 
suspension was added to a haemocytometer to which the coverslip had been attached. 
Three lots of eight squares were counted and averaged. In order to avoid counting a 
cell twice, the cells touching the upper and right hand perimeter lines were ignored 
whereas those touching the lower and left hand lines were counted. With the coverslip 
in place the depth of the chamber is 0.2 mm, hence the volume of eight squares is 
calculated as followed: 
Eight squares= 1 mm x 0.5 mm x 0.2 mm = 0.1 =3 = (). 1 ýLI 
The total number of cells per ml can be calculated from the following equation: 
Total number of cells per ml = average of three cell counts x 10 4 
2.3.9 Calculation of population doubling 
For the MRC5 mortal cell strain, each time the cells were sub-cultured the population 
doubling (PD) level was calculated by comparing the amount of cells seeded with the 
number of cells obtained, using the following equation: 
PD= In (n2/ n I) 
In2 
where nI was the number of cells seeded and n2 was the number of cells harvested. 
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2.4 Drug Preparation 
2.4.1 Safety procedures 
Cisplatin and etoposide were the drugs used throughout the investigations. Both are 
known human carcinogens and were handled according to the local rules for use of 
potent carcinogens. All handling of powder or solutions of these drugs were 
performed in a Trimat 2 class 11 microbiological safety cabinet (Medical Air 
Technology, UK). 
2.4.2 Cisplatin 
Cisplatin was obtained from Sigma-Aldrich Company Ltd, UK. Cisplatin was 
weighed into -5 mg aliquots and dissolved in DMSO to give a 100 mM solution. The 
DMSO solution was immediately diluted in culture medium to give a concentration of 
I mM. This was then further diluted to achieve the concentrations required for use. 
For drug treatments the final concentration of DMSO was always less than I% (v/v). 
2.4.3 Etoposide 
Etoposide was obtained from Sigma-Aldrich Company Ltd, UK. Etoposide was 
dissolved in methanol to give a final concentration of 17 mM and placed in a 
Wheaton glass vial (Sigma-Aldrich Company Ltd, UK) which was covered in 
parafilm and stored at -20'C. Immediately prior to use etoposide stock solution was 
diluted in medium to the required concentration. 
66 
Chgpter 2 
2.5 Sulphorhodamine B (SRB) Growth Inhibition Assay 
2.5.1 Introduction 
The Sulphorhodamine B (SRB) assay measures cellular protein content of wells of a 
96 well cell culture plate (Skenhan et al., 1990). Cells were inoculated into 96 well 
plates, allowed to attach and then exposed to drugs for the appropriate length of time. 
The drug was removed and the cells are left to grow for a further 6 days. After 
fixation the number of cells adhering to each well was measured by staining with the 
SRB dye. SRB is a bright pink aminoxanthene dye, which contains two sulfonic 
groups that can bind electrostatically to basic amino acid residues under mildly acidic 
conditions. Excess dye is removed by washing and bound dye was solublised in order 
to make reliable measurement of the optical density, which is directly proportional to 
the number of cells. The drug concentration causing 50% reduction in number of cells 
present at the end of the growth period was detennined 
GC50). For the SRB growth 
inhibition assay it was important that the cells in the control wells remained in active 
growth throughout the period of culture. Therefore initially, experiments were carried 
out to determine optimum inoculum densities. 
2.5.2 SRB staining procedure 
2.5.2.1 Trichloroacetic acid (TCA) fixation 
Plates were removed from incubation and fixed by adding 50 ýtl of ice cold 50% (w/v) 
trichloroacetic acid (TCA) to each well and incubating for I hour at 4'C. Plates were 
immersed in water five times for washing, to remove TCA and air dried. Plates were 
stored at 4'C until ready to stain. 
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2.5.2.2 SRB staining 
Plates were removed from 40C and allowed to come to room temperature. Fixed cells 
were staine with 100 ýtl of SRB solution for 30 minutes at room temperature. 
Following staining, SRB was removed and any unbound dye on the plate was washed 
of with I% acetic acid using a plate washer (Dynex Technologies/The Microtiter 
Company MRWAM60). Any residual solution was removed by flicking the plates 
over the sink and air drying. The SRB was solublised by adding 100 gl of 10 mM Tris 
(pH 10.5) per well and gently shaking on a plate shaker (Heidolph Titramax 100) for 
10 minutes. Optical density (OD) was measured at 570 run on a spectrophotometric 
plate reader (Dynex Technologies Plate Reader MRX Version 2.02). 
2.5.3 Establishment of optimal inoculum conditions 
Initially cell densities and growth curves are determined for specific cell lines, so that 
control cells can grow actively for several population doublings after the drug 
exposure has ended. Cells were inoculated into ten 96 well plates (NLJNC, Life 
Technologies Ltd, Denmark) with a range of the following cell numbers per well in 
200 gl of medium: 2000,1000,500,250,125,62.5,31.2,15.6,7.8 and 3.8, where 
there were 6 wells per inoculated density on each plate. To minimise any edge effects 
the outermost wells of the 96 well plates were not used (Row A and H, columns I and 
12), though 200 ptl of medium was added to test the background levels of the medium. 
The 96 well plates were incubated at 37'C in the tissue culture incubator. Daily, 
plates were fixed (Section 2.5.2.1) and stored at VC. Once all plates were fixed the 96 
well plates were SRB stained and the opticall densities measured (Section 2.5.2.2). 
Growth curves were plotted. 
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2.5.4 DeterminationOf IC50values 
For growth inhibition studies an optimum inoculum density was chosen from the 
growth curve results, whereby cells maintained active growth for at least 5 days. The 
IC50is defined as the concentration of drug required to inhibit cell growth by 50% 
after the chosen post treatment incubation period. For these experiments a post 
incubation period of 6 days was used. The IC50 concentrations for a2 hour drug 
exposure to cisplatin and a4 hour drug exposure to etoposide were calculated. In six 
replicate 96 well plates, SHSY5Y cells were plated at a density of 125 cells in 200 ýd 
of medium per well. The outermost wells of the 96 well plates were not used (Row A 
and H, columns I and 12) though 200 ýtl of medium was added to each. A day later 
cells were treated with a range of drug concentrations for either 2 hours (cisplatin) or 
4 hours (etoposide). Control cells were treated with medium containing 1% DMSO. 
Following exposure to the drugs, the medium was removed and wells were washed 
three times with fresh medium to remove the drug. After final addition of 200 ýtl of 
medium to each well, the plates were incubated for 6 days. After 6 days the cells were 
fixed and stained (Section 2.5.2). The mean absorbance of the wells, for each drug 
concentration was then expressed as a percentage of the mean absorbance from the 
control (untreated cells). 
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2.6 DNA Extraction 
2.6.1 Materials 
DNA was extracted from cells using "Blood and Cell Culture DNA Midi Kits" 
(Qiagen, UK), with reagent solutions supplied with the kits (Section 2.2). This 
procedure yielded high molecular weight DNA of a high purity. 
2.6.2 Method 
Up to 2xI 07 cells were centrifuged at 800 g for 5 minutes, washed in PBS and 
resuspended in PBS to a final concentration of 107 cells per ml. 2 ml of ice cold 
Buffer CI (lysis buffer that stabilises and preserves the nuclei) and 6 ml of ice cold 
distilled water was added to the cell suspension. The tube was mixed by inverting and 
was incubated for 10 minutes on ice. The lysed cells were centrifuged at 4'C for 15 
minutes at 1300 9 and the supernatant discarded. I ml of ice cold Buffer CI was 
added with 3 ml of ice cold distilled water and the pelleted nuclei were resuspended 
by vortexing. The nuclei were centrifuged again at 4'C for 15 minutes at 1300 g and 
the supernatant discarded. 5 ml of Buffer G2 (digestion buffer) was added and the 
nuclei resuspended by vortexing for 30 seconds at maximum speed. 95 ýtl of 
proteinase K was added and cells were incubated for I hour at 50'C. A Qiagen 
genomic tip 100/g was equilibrated with 4 ml of Buffer QBT (equilibration buffer). 
After digestion, samples were vortexed and applied to the genomic tip, where it 
passed through by gravity flow (Figure 2.1). 
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Figure 2.1 DNA extraction using Qiagen columns. Pure genomic DNA is isolated 
from cell pellets. 
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The genomic tip was washed three times with 7.5 ml of Buffer QC (wash buffer) and 
the DNA was eluted with 5 ml of Buffer QF (elution buffer) into a fresh tube. The 
DNA was precipitated by adding 3.5 ml of isopropanol, centrifuged at >5000 g for at 
least 15 minutes at 4'C, washed in 70% ice cold ethanol, vortexed briefly and 
centrifuged at >5000 g for 10 minutes at 4'C. DNA was dissolved in an appropriate 
volume of TE buffer. 
2.6.3 Concentration of DNA 
The concentration and the purity of the DNA were detennined by the absorbance of 
UV light in a spectrophotometer (Unicam UVNIS, Spectronic Analytical Instruments, 
UK). DNA was diluted in sterile water. Both protein and DNA absorb UV light but 
they have different absorbance spectra. The peak of light absorption is at 260 nm for 
DNA and at 280 nm for protein. The optical density was measured at both 
wavelengths. The concentration of the DNA was calculated from the absorbance at 
260 nm (an absorbance of I OD at 260 nm in a 10 mm path length cuvette 
corresponds to 50 [tg/ ml of DNA). The purity of the DNA was checked by 
deten-nining the ratio OD260/OD280. The ratio of pure DNA should be > 1.8 and this 
value was typically observed for the isolated DNA. 
2.7 Telomeric DNA Isolation 
2.7.1 Introduction 
Telomeres are composed of repeat sequences in which the strand with its 3' end at the 
tenninus is G rich and fonns a single stranded G-rich overhang. Wright and 
colleagues developed a technique for purifying human telomeres (Wright et al., 1997). 
This procedure to purify human telomeres was based on the ability of biotinylated 
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oligonucleotides complementary to the G-rich telomeric repeat to anneal to the G rich 
overhang in otherwise double stranded DNA (Shay et al., 1994). 
Following annealing, DNA/ oligonucleotide complexes were bound to streptavidin 
coated magnetic beads and washed (Figure 2.2). Purified telomeres were eluted and 
analysed on pulsed field agarose gels. 
2.7.2 Hinfl restriction digestion of genomic DNA 
Extracted double stranded genomic DNA (Section 2.6) was restriction digested to 
completion for 6 hours in 150 gl of Hinfl (20- 40 units; Roche), H buffer (Boehringer) 
and water at 3 TC in a block thennostat (BI 100, Kleinfield, Labortechnik, Germany). 
Hinfl recognizes the sequence G/ANTC and generates fragments with 5' cohesive 
tennini. DNA samples were then ethanol precipitated by the addition of 1/ 10 sodium 
acetate (3 M) and three times the volume of 100% ethanol. This ethanol precipitation 
solution was placed in -20'C freezer for 2 hours. 
2.7.3 Mixing of biotinylated oligonucleotides and DNA 
The precipitated DNA was pelleted by centrifugation and dissolved in Ix SSC/ 1% 
Triton X-100. The dissolved DNA was mixed with 5' biotinylated oligonucleotide 
(MWG) with the sequence (CCCTAA)6 and annealed for 15 minutes each at 65'C, 
55'Cl 45'Cl 35'C and 20'C. It was then combined with streptavidin coated magnetic 
beads (Dynal Inc, Norway) that had been preincubated for at least I hour in 5x 
Denhardts solution. The DNA bead suspension was rotated end over end at 4'C 
ovemight. 
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Figure 2.2 Isolation of telomeric DNA. This procedure uses a magnetic bead 
approach to purify telomeric DNA from the rest of the genomic DNA. 
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2.7.4 Elution of telomeres 
The magnetic beads were drawn to the sides of a tube using a magnet (Systems 1000) 
and the supernatant removed and saved. The beads were resuspended and washed 
twice with Ix SSC/ 1% Triton X-100. The bound telomeres were eluted from the 
beads by melting the oligonucleotide/ telomere interaction at 65'C for 10 minutes in 
0.1 x SSC/ I% Triton X- 100. 
2.7.5 Pulsed field gel electrophoresis (PFGE) 
The isolated telomeres and supernatant were size separated by PFGE (CHEF-DRIII, 
BioRad) for 17 hours at 3.5 V in a 1% pulsed field agarose gel with 0.5x TBE as 
running buffer. The gel was stained for 30 minutes in 0.5 ýtg ethidium bromide/ ml in 
a Class I Cabinet (Clean Air Limited, UK) and photographed using a UV 
Alphaimager (Alpha Innotech Corporation, UK). 
2.7.6 Southern blotting 
Following staining with ethidium bromide, the gel DNA was partially depurinated in 
depurination buffer for 30 minutes, denatured in denaturation buffer for I hour and 
neutralised for 60 minutes in neutralisation buffer. The DNA was then transferred 
from the gel onto a Hybond N+ membrane by vacuum blotting for 90 minutes at 200 
mbar (Vacum. blotter Model 785, BioRad) in I Ox SSC transfer buffer. The membrane 
was then rinsed in lx SSC and the DNA was cross-linked to the membrane by 
exposing it to UV light on a transilluminator for 5 minutes. 
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2.7.7 Membrane hybridisation 
2.7.7.1 Using an alkaline phosphatase labelled probe 
The amino modified oligonucleotide (TTAGGG)4 was conjugated to alkaline 
phosphatase using the LIGHSMITH Luminescence Engineering System for 
Oligonucleotides (Promega, UK). Briefly the amino modified oligonucleotide was 
activated and purified using a G-50 column. The activated oligonucleotide was then 
conjugated to alkaline phosphatase and purified with a S-100 column. The AP 
telorneric probe was stored in 50% glycerol at -20'C. 
The hybridisation steps took place in glass tubes in a hybridisation oven (Hybridize 
HB-1000, Camlab, UK). The membrane was preincubated in Quantum Yield 
Blocking Solution (Promega, UK) for I hour at 50'C then removed. The (TTAGGG)4 
probe conjugated to alkaline phosphatase was diluted 1: 1000 in low stringency 
hybridisation solution and hybridised for I hour at 50'C. The membrane was then 
washed 2x 10 minutes in Ix SSC/ 0.1% SDS at 50'C and this was repeated at 20' C. 
The SDS was removed by an additional wash in Ix SSC. The membrane was next 
incubated for 5 minutes in 200 ýd diethanolamine solution and the chemiluminescent 
substrate (CSPD) (Tropix Inc, Massachusetts, USA) was diluted 1: 100 in fresh 
diethanolainine solution and added to start the chemiluminescence reaction. The 
membrane was covered with clear film and exposed to Hyperfilm ECL (Amersham/ 
Phan-nacia) at 37'C for 90 minutes. Alternatively the membrane was on occasion 
scanned using a Fuji Film Luminiscent Image Analyzer LAS 1000- Pro (Raytek, UK). 
2.7.7.2 Using a digoxigenin labelled probe 
Digoxygenin is a ligand that can be incorporated into DNA and detected after 
hybridisation with an anti- digoxgenin antibody enzyme conjugate. This procedure 
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used the "TeloTAGGG Telomere Length Assay" kit (Roche, UK) and hybndisation 
took place according to the manual. All reagents were provided in the kit. Briefly the 
membrane was prehybridised for 30 minutes at 42'C in Easy-Hyb solution in the 
hybridising oven (Hybridize HB- 1000, Camlab, UK). Following this the dig labelled 
probe was diluted 1: 1000 in fresh Easy-Hyb solution and left for I hour at 42'C. The 
membrane was removed and washed as follows: 
2x5 minutes in 2x SSC/ 0.1% SDS at 20'C 
2x 15 minutes in 0.2 x SSC/ 0.1% SDS at 50'C 
Ix5 minutes in washing buffer at 20'C 
The membrane was then placed in blocking solution for 30 minutes at 20'C. This 
was poured off and the anti- digoxigenin antibody diluted 1: 1000 in fresh blocking 
solution was added for 30 minutes at 20'C. The membrane was next washed four 
times for 10 minutes in washing buffer at 20'C and soaked in detection buffer for 5 
minutes. The CSPD was diluted 1: 100 in detection buffer and placed onto the 
membrane for 5 minutes without shaking. Excess liquid was drained and sandwiched 
between clear film and exposed at 37'C for 90 minutes on a Hyperfilm ECL. 
2.8 Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) 
2.8.1 Equipment 
ICP-MS Perkin Elmer Sciex Elan 6000 (Figure 2.3) 
Department of Earth Sciences, Durham University 
2.8.2 Introduction 
Inductively coupled plasma- mass spectrometry was used to detect platinum (Pt) 
bound to DNA and phosphorus (P) levels as an indicator of DNA concentration, with 
high sensitivity. The inductively coupled plasma is an argon plasma maintained by the 
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interaction of a radio frequency (RF) power supply (generally 1150 W) and ionised 
argon gas. Power is transferred into the plasma gas by inductive heating. The argon 
gas passes continuously through the plasma torch which is located in a2 or 3 turn 
induction coil carrying a very high frequency alternating current. Samples are 
nebulised and injected into the plasma. Singly charged ions are fon-ned from the 
elemental species within a sample and are directed towards the quadropole mass 
spectrometer. The mass spectrometer separates the ions introduced from the ICP 
according to their mass to charge ratio (Thompson and Walsh, 1983). Ions of selected 
mass/ charge ratio are then directed to a detector which quantifies the number of ions 
present. Pt is naturally present as four main isotopes 194 Pt (32.97% abundance), 195 
Pt (33.83% abundance), 196 Pt (25.24% abundance) and 198 Pt (7.18% abundance). 
2.8.3 Preparation of DNA samples 
DNA was extracted as in Section 2.6 with the following modifications. After cell 
resuspension in buffer G2, cells were sonicated for 2 minutes using a VibracelITM 
ultrasonic processor equipped with a cup-hom (Roth Scientific, UK). 10 ýfl of RNase 
A (Qiagen, UK) was then added and left to stand at room temperature for 15 minutes 
before 95 ýd of proteinase K addition and incubation for I hour at 50'C. Telomeric 
DNA was isolated as in Section 2.7. 
2.8.4 Method 
The Perkin Elmer Sciex Elan 6000 ICP-MS uses a standard cross flow nebuliser and 
Scott type double pass spray chamber. Nebuliser gas flow rates varied between 0.8 to 
1.0 1/ minute and were optimised to keep the production of CeO+ less than or equal to 
3% of the total Ce+ signal. All test samples were diluted into I ml of 3.5% (w/v) nitric 
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acid and incubated overnight (70'C) to hydrolyse the DNA so that the precipitated 
DNA is dissolved. Phosphorus levels and the four isotopes of platinum (Pt) were 
monitored (194,195,196 and 198) to evaluate possible isobaric interferences. 
Standard solutions of 50,100,200ý 500 and 1000 parts per billion (PPB) of 
phosphorus and standard solutions of 0,100,500,1000 and 2000 parts per trillion 
(PPT) of Pt were run at the beginning of the analytical session, during and at the end 
to check for instrumental drift. Platinum standard solutions were made from Johnson 
Matthey 1000 parts per million (PPM) stock solutions. Test samples were introduced 
manually into the ICP-MS and were ideally meant to give signals within the 
calibration range of the standard solutions. 
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Figure 2.3 Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). A 
schematic diagram of the quadropole Perkin Elmer Sciex Elan 6000 ICP-MS 
(Montaser, 1998). 
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2.9 Telomere Restriction Fragment Lengths 
2.9.1 Production of agarose plugs 
Cells were counted and washed in PBS. Depending on the amount, cells were re- 
suspended in cell suspension buffer prewan-ned at 50'C and the appropriate amount of 
2% agarose (Biorad 170-3594 Clean-cut). The suspension was then carefully pipetted 
into the moulds, at a density of 107 cells/ ml (Biorad 170-3713), which were placed at 
4'C for at least 10 minutes to set. The plugs were transferred into tubes containing 5 
ml of proteinase K reaction buffer and 250 ýtl 20 mg/ ml proteinase K. The tubes were 
placed at 37'C whilst shaking for at least 48 hours in an orbital incubator (S150, 
Bibby Sterlin Ltd, UK). After digestion the plugs were washed four times for I hour 
with plug wash buffer. They were then stored at 4'C in 50 ml of sterile 10- fold 
diluted plug wash buffer. 
2.9.2 Hinfl digestion 
One quarter to one half of a plug (2.5- 5.0 x10 5 cells) was restriction digested to 
completion for 6 hours in 150 ýd of Hinfl. (60 U per plug; Roche), H buffer 
(Boehringer) and water at 37'C. 
2.9.3 Pulsed field gel electrophoresis 
Restricted plugs were analysed in a 1% agarose gel (Ultrapure DNA grade agarose, 
Biorad) with marker, by pulsed field gel electrophoresis (CHEF-DRIII, Biorad) at 3.0 
V/cm for SHSY5Y cells and 5.5 V/cm for 1301 cells for 17 hours with a switching 
time of 2 to 10 in 0.5x TBE. For the SHSY5Y cells the Hind III bacteriophage 
Lambda marker was used. The bacteriophage Lambda DNA is fragmented in a 
restriction digestion with Hind III endonuclease. The digestion reaction results in 8 
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double stranded DNA fragments at 23.1,9.4,6.6,4.4,2.3,2.0,0.6 and 0.1 kbp. Only 
7 bands are visible on the gel due to small size of the 0.1 kbp fragment. For the 13 01 
cells the 0.1 - 200 kbp pulse marker (Sigma Aldrich, UK) was used. This marker 
contains a mixture of 12 fragments consisting of Lambda DNA Hind III fragments 
plus uncut Lambda DNA and Lambda DNA concatemers. Its fragment sizes are 194, 
145.5 5 97,48.5 5 23.1,9.4,6.6,4.4,2.3,2.0,0.6 and 0.1 kbp. 
2.9.4 Hybridisation 
2.9.4.1 Preparation of 32P-y-ATP labeHed oligonucleotide probes 
The following mix was prepared: 
33 gI water 
5 gl 10 x polynucleotide kinase (PNK) buffer (New England Labs Inc, USA) 
I gl oligonucleotide 
I gl T4 PNK 
Total: 40 ýtl 
10 ýtl (= 100 ýtCi/ 3.7 MBq) of 32P (-185TBq/ mmol; -6000 Ci/ mmol) (Amersharn 
Bioscience) was added and incubated for I hour at 37'C, then for a further 15 minutes 
at 70'C to inactivate the kinase. Eppendorfs were briefly centrifuged and a Microspin 
G column (Amersham Bioscience) was prepared by I minute centrifugation at 0.8 g. 
The probe preparation was passed through the column by 2 minutes centrifugation at 
0.8 g and the elute added to 10 ml Rapid Hyb buffer (Amersham Bioscience). 
2.9.4.2 Hybridisation of dried gels 
Gels were dried at room temperature for 2 hours (Model 583 gel drier, Biorad), 
stained with ethidium bromide (0.5 ýtg/ ml) for 30 minutes in a Class I Cabinet (Clean 
Air Limited, UK) and photographed using a UV Alphaimager (Alpha Innotech 
Corporation, UK). Gels were denatured (denaturation buffer) for 30 minutes, 
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neutralised. (neutralisation buffer) for 30 minutes and in-gel hybridised with 32P-y- 
ATP(CCCTAA)4 at 43'C for 16 hours. Gels were washed four times in 0.2x SSC at 
43'C for 30 minutes each and then exposed to a phosphoimager screen overnight. 
Signals were visualised using a phosphoirnager (Storm 820, Molecular Dynamics, 
Amersham). 
2.9.4.3 Hybridisation of membranes 
Gels were southern blotted to Hybond-N+ membranes by vacuum blotting at 200 
mbar (Vacum blotter Model 785, BioRad) in I Ox SSC transfer buffer. The membrane 
was then rinsed in Ix SSC and the DNA was cross-linked to the membrane by 
exposing it to UV light on a transilluminator for 5 minutes. The membrane was 
hybridised with 32P-y-ATP (CCCTAA)4 at 43'C for 16 hours. Blots were washed 
four times in 0.2x SSC/ 0.1% SDS at 43'C for 30 minutes each and then exposed to a 
phosphoimager screen overnight. Signals were visualised using a phosphoimager 
(Storm 820, Molecular Dynamics, Amersham). 
2.9.5 Evaluation of telomere length by fragment size determination 
The images after hybridisation and the UV gel pictures with the molecular weight 
markers on them were cropped and adjusted to the same size using Photoshop, Adobe 
software. The marker lanes were overlayed onto the telomere restriction fragment 
length image. The merged image could then be used to evaluate fragment size with 
AIDA densitometry software (Raytek, Sheffield, UK). The AIDA program was used 
in the ID evaluation mode. Lanes were defined starting with the marker lanes. The 
peaks of all marker lanes were assigned to the Lambda phage Hind III DNA marker. 
For each telomere fragment profile a baseline and a peak position by centre was 
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determined enabling the program to calculate the average fragment length per lane as 
weighted mean of the optical density. 
2.9.6 MinisateHite probing 
To test for non-specific degradation of DNA, gels or membranes were rehybridised 
with the minisatellite probe (CAC)8. The probe was made as in section 2.9.4.1 with 
the only modification in using the (CAC)8 oligonucleotide instead of the telorneric 
sequence. To strip the gels of radioactivity dried gels were denatured (denaturation 
buffer) for 30 minutes, neutralised (neutralisation buffer) for 30 minutes. To strip the 
membranes of radioactivity I ml of 20% SDS was boiled in 100 ml of water and 
poured onto the membrane and left for 10 minutes. The SDS was removed from the 
blot by washing three times in Ix SSC. Dried gels or membranes were hybridised 
with 32P-y-ATP (CAC)8 at 43'C for 16 hours and washed and screened as in sections 
2.9.4.2 and 2.9.4.3 respectively. 
2.10 Telomeric Single Stranded Overhangs 
The length of single-stranded terminal overhangs in telomeres was measured by in-gel 
hybridisation of telomeric probes onto non-denatured DNA. As in Section 2.9, treated 
cells were embedded in 0.65% low melting agarose plugs at a density of 10 7 cells/ ml 
before treatment with proteinase K. DNA was completely digested by Hinfl (60 U per 
plug; Roche) at 37'C (Section 2.9.2). Plugs were analysed in a 1% agarose gel by 
pulsed field gel electrophoresis (Biorad) at 3 V/ cm for 17 hours with a switching time 
of 2 to 10 in 0.5 x TBE. In-gel hybridisation with 32P-7-ATP (CCCTAA)4 was 
performed on non denatured gels at 370C for 16 hours. Gels were washed four times 
in 0.2 x SSC at 37'C for 30 minutes each and then exposed to a phosphoirnager 
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screen overnight. Signals were visualised using a phosphoimager (Stonn 820, 
Molecular Dynamics, Amersham). Under these conditions, only single-stranded G- 
rich DNA is available as target for hybridisation. The gel is then denatured 
(denaturation buffer) for 30 minutes, neutralised (neutralisation buffer) for a further 
30 minutes and in-gel hybridised with 32P-y-ATP (CCCTAA)4 at 43'C to allow 
detection of the total telomeric signal. To assess overhang length, the ratio of the 
relative hybridisation signal intensity of overhangs alone/ whole telomeres were 
evaluated using AIDA densitometry software (Raytek, Sheffield, UK). 
2.11 G Rich Strand Telomeric DNA Damage 
Agarose plugs DNA were digested overnight at 37'C with Hinfl as described in 2.9.2. 
Digested DNA was pre-incubated for 2 hours in alkaline buffer and then 
electrophoresed. at 26 V for 20 hours for SHSY5Y cells and 40 V for 24 hours for 
1301 cells in 0.7% agarose in alkaline buffer. Gels were then neutralised 
(neutralisation buffer) for I hour and dried at room temperature. Gels were hybridised 
(Section 2.9.4.1) with 32P-y-ATP (CCCTAA)4at 43'C for 16 hours and washed four 
times in 0.2 x SSC at 43'C for 30 minutes each. They were then exposed to a 
phosphoimager screen overnight. Signals were visualised using a phosphoimager 
(Stonn 820, Molecular Dynamics, Amersharn). 
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2.12 Telomerase Activity 
2.12.1 Introduction 
Telomerase activity was detennined by the TeloTAGGG Telomerase PCR Elisa 
(TRAP assay, Roche Applied Science, Germany) kit which uses an extension of the 
original method described by Kim and colleagues (Kim et al., 1994). All reagents 
were supplied with the kit and composition of reagents was not specified. The assay 
works (Figure 2.4) by initially telomerase adding telomeric repeats (TTAGGG) to the 
3' end of the biotinylated primer (P I- TS primer). Then the extended products were 
amplified by PCR using the PI -TS and reverse primers generating PCR products with 
the telornerase specific 6 nucleotide additions. An aliquot of the PCR product was 
denatured and hybridised to a digoxigenin telorneric specific repeat probe. The 
resulting product was immobilised via the biotin labelled primer to a streptavidin 
coated microtiter plate. The immobilised PCR product was then detected with an 
antibody against digoxigenin that was conjugated to peroxidase. Finally the probe was 
quantified by determination of peroxidase activity using a chromogenic substrate. 
2.12.2 Lysis 
Cells were harvested, counted and 1 million cells pelleted and lysed with 200 ýfl of 
lysis buffer. The cells were left on ice for 30 minutes and centrifuged at 14000 rpm 
for 30 minutes at 4'C. The supernatant was aliquoted into fresh tubes and frozen at 
-80'C until required. 
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Figure 2.4 TeIoTAGGG Telomerase PCR Elisa. Step 1: telomerase adds telomeric 
repeats to the PI-TS primer. Step 2: the elongation products are amplified by PCR. 
Step 3: the PCR product is denatured and hybridised to telomere repeat detection 
probe. Step 4: a coloured reaction product is formed. 
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2.12.3 Determination of protein concentration by Bradford assay 
A standard curve between 0 and 14 ýtg/ ml protein stock concentrations were prepared 
in duplicate. 5 ýtl of sample lysate was dissolved in 800 ýtl of water and 200 [d of 
Bradford reagent (BioRad, UK) was added. Samples were vortexed and left to stand 
for 10 minutes. The absorbance of the protein samples were measured at 595 nm 
(Unicam UVNIS Spectrometer, Spectronic Analytical Instruments, UK). 
2.12.4 Telomeric repeat amplification protocol (TRAP) 
Lysates were defrosted on ice and the following for each sample was placed into PCR 
microcentrifuge tubes: 23 ýtl PCR water, 
25 [d Reaction mix, 
2 ýtl Sample lysate 
Total Mix = 50 ýtl 
For a positive and negative control a positive turnour cell line and water was added 
instead of the sample lysate respectively. 
Samples were subjected to a combined primer elongation/ amplification reaction by 
the following protocol in Table 2.2. 
Table 2.2 Telomeric repeat amplification PCR procedure 
Step Time Temperature StepstCycles 
1. Primer Elongation 10-30 min 25"C Step 1 
2. Telomerase Inactivatior 5 min 94'C Step 2 
3. Amplification 
denaturation 
annealing 
polymerisation 
30s 
30s 
90S 
10 min 
94"C 
50'C 
72C 
720C 
Cycles 1-30 
Step 3 
4. Hold I 4'C Step 4 
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2.12.5 Hybridisation & ELISA 
5 gI of the amplification product was added to 20 gl of denaturation reagent and 
incubated for 10 minutes at room temperature. 225 ýfl of hybridisation buffer was 
added to each sample and mixed by vortexing briefly. 100 ýtl of the mixture was 
added to a well of a 96 well plate that had been precoated with streptavidin (supplied 
with the kit). Wells were covered with self adhesive foil to prevent evaporation and 
the plate incubated on an orbital shaker (Janke & Kunkel Gmbh & Co, Germany) at 
300 rpm for 2 hours. The hybridisation solution was removed completely and wells 
were washed three times with 250 ýtl of washing buffer for a minimum of 30 seconds 
each. 100 ýd of a solution of peroxidase conjugated anti- digoxigenin antibody (a 
polyclonal antibody from sheep) was added per well. The plate was covered and 
incubated at room temperature for 30 minutes, shaking at 300 rpm. The solution was 
removed and washed five times for a minimum of 30 seconds each with washing 
buffer. 100 gl of TMB substrate (solution containing the peroxidase substrate 
3,3', 5,5' tetramethyl benzidine) was added to each well and incubated for colour 
development at room temperature for 10- 20 minutes whilst shaking at 300 rpm. 100 
ýtl of stop reagent was added to the reacted substrate to stop colour development (blue 
to yellow) and absorbance of the samples were measured at 450 nm (reference 
wavelength of 690 nm) on a microtiter plate reader (Thermo Labsystems Multiscan 
EX, Model 355, UK) within 30 minutes of the addition of the stop reagent. 
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2.13 Flow Cytometry 
2.13.1 Equipment 
Partec Pas flow cytometer (Partec GmbH,, Munster, Germany) (Figure 2.5) 
Data handling was perfon-ned using FlowMax instrument software (Partec GmbH, 
Munster, Gennany) 
waste 
fluorescence 
side scatter 
diode la 
sample 
ard 
Iter 
Figure 2.5 Principle of the Partec Particle Analysing System (PAS). A schematic 
diagram of the Partec Pas flow cytometer (Partec Pas web page). 
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2.13.2 Introduction 
Flow cytometry detects for individual cells, light that has been scattered or emitted via 
fluorescence activation. The method can be used in numerous applications such as 
identifying cells labelled with fluorescent antibodies or size through light scatter. 
There are key components of all flow cytometers; 
1. A light or excitation source e. g. laser that emits light at a particular wavelength 
2. A liquid flow that moves the suspended cells through the instrument, past the laser 
3. A detector for detecting the brief flashes of light coming from the particles as they 
pass through the light beam 
Samples are injected into the flow cytometer in small test tubes that form a tight seal 
around an 0 ring. The cells are pushed up and in the flow chamber join the sheath 
fluid, where cells are directed through the laser beam through pressure. There are 
many things that can affect the way in which the samples will be analysed, for 
example the amount of pressure driving the sample through the system, sample size 
and flow rate. All the parameters must be optimised and manually controlled by the 
operator to achieve the precise alignment of cells one at a time in the laser beam. The 
cells leave the flow chamber (hydrodynamic focusing) and the light is focused 
through a lens into a light beam as it approaches a liquid stream. The stream and the 
light beam intersect (analysis point) and the light can be reflected, absorbed, 
diffracted and/ or refracted to give the signal (Givan et al., 2001). Photodetectors that 
vary in position, colour filters etc convert the light signal into an electrical impulse. 
Fluorescence based detection depends on the absorption of light by the cell and the 
reemission of this light at different frequencies. Filters block the original light source 
from reaching the detector, while the fluorescence emission is allowed through for 
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detection (Ormerod, 2000). Cells can be labelled with a fluorescent marker, which 
fluoresce only when light of the appropriate wavelength hits them. There are different 
spectral regions available to detect multicolour fluorescence in parallel, for example 
FL- I is green, FL-2 is orange and FL-3 and red. 
2.13.3 Setting up the flow cytometer 
The precision and balance was checked using Partec 3 ýM calibration beads (Partec 
Cat Code-05-4007) checking FSC/ SSC dotplots and FL-1, FL-2, FL-3 histograms r: ) 
and/ or dotplots for a narrow range signal (Figure 2.6). If the signal was wider than 
desired, the 3D position of the cuvette relative to the laser was adjusted using 
micro scewdrivers. For cleaning and stabilising 2 ml of I% Triton X 100 (dissolved in 
water), followed by 2 ml of PBS and 2 ml of water was passed through. Ix PBS was 
used as sheath fluid for the Partec Pas. 
640 
512 
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256 
128 
0 
0.1 1 10 100 100 
FL2 
Fioure 2.6 Calibration pasbeads. FL-2 histogram of the calibration beads showing a t5 Z-n 
narrow signal range. 
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2.13.4 Measuring Apoptosis 
2.13.4.1 Introduction 
The pattern of light scattered is dependent on cell size (Forward Scatter; FSC), shape 
and internal structure (Light Scattered Sideways; SSC) giving relative measures of 
these cellular characteristics as cells flow through the beam. Apoptosis was assessed 
as the fraction of small, granular apoptotic cells that are distinguishable from viable 
cells by their lower forward and higher sideward light scatter (Sgonc and Gruber, 
1998). 
2.13.4.2 Method 
After appropriate treatment non adherent and adherent cells were collected in RPMI 
plus 10% FCS, counted using a haemocytometer (Section 2.3.8) and stained with 10 
ýtg/ ml propidium iodide for 15 minutes at 4'C to determine the number of cells with 
intact plasma membrane. Propidiurn iodide binds to double stranded DNA, but can 
only cross the plasma membrane of non viable cells, therefore cells that have lost 
membrane integrity show red propidiurn iodide staining throughout the nuclei. The 
cells were immediately used for apoptosis analysis in a flow cytometer. For apoptosis 
cells were analysed on FL4- SSC (log 3 scale) and FSC (log 4 scale) and propidium 
iodide staining was monitored in the FL2 channel. 
2.13.5 Cell Cycle Analysis 
2.13.5.1 Introduction 
Using flow cytornetry we are able to identify what stages of the cell cycle the cells are 
in after drug treatments by analysing the DNA content. This is due to the fact that the 
amount of DNA in the nucleus of a cell changes through the cell cycle from one copy 
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(n) to two (2n) during DNA replication. Cells in Go are not cycling at all and G, have 
just divided and/ or in preparation for further entry to the cell cycle. S phase cells are 
in the process of DNA synthesis and so have intermediary DNA content i. e. cells in 
late stage S phase will have double (diploid) whilst cells in early S phase will have 
one copy. G2 cells have double the amount of DNA. Cells in mitosis are undercyoinc, Z-: ) r:, 
chromosome condensation. By staining the cells with DAPI or propidium idodide a 
DNA flow cytometry histogram (Figure 2.7) can be produced determining the cells :D 
position in the cell cycle based on its DNA content during DNA replication. 
2.13.5.2 Method 
Non adherent and adherent cells were collected, washed in PBS and fixed in 70% ice 
cold ethanol for I hour. Cells were washed in PBS,, resuspended in DAPI stain/ PBS 
and analysed in the flow cytometer using UV excitation. Cells were analysed on FL4- 
SSC (linear scale) and FSC (log 4 scale). 
320 
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Figure 2.7 DNA cell cycle histogram. Peaks for each stazc-De of the cell cycle can 
clearly be identified and from this, percentages of cells can be calculated. 11ý 
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2.13.6 BrdU Incorporation 
2.13.6.1 Introduction 
BrdU is a thymidine analogue and when added to culture medium it becomes 
incorporated into cellular DNA during replication, in the place of thymidine. 
Antibodies with specificity for BrdU are available. Thus after a short treatment with 
BrdU, the DNA can be partially denatured exposing the BrdU so that it can be stained 
with anti-BrdU antibody. As the cells have been fixed, the DNA can be stained with 
propidium iodide at the same time to see the total DNA content. BrdU incorporation 
allows us to distinguish cells that are proliferating from cells that may be blocked in S 
phase. 
2.13.6.2 Method 
Cells were incubated in medium supplemented with 20 ýM 2-bromo-5-deoxuridine 
(BrdU) for I hour and harvested. Cells were centrifuged at 300 g for 5 minutes, 
resuspended in PBS and re-centrifuged for 5 minutes. The supernatant was aspirated 
and the pellet was loosened by tapping the tube. Cells were then fixed in 70% ice cold 
ethanol, to a final concentration of 107 cells/ ml and allowed to warm to room 
temperature for 20 minutes. Cells were washed in PBS plus 0.5% bovine serum 
albumin (BSA), re-centrifuged at 300 g for 5 minutes and denatured in 2M HCI in 
PBS plus 0.5% BSA at room temperature for 20 minutes at a concentration of 150 ýtl/ 
106 cells. Cells were resuspended in I ml PBS plus 0.5% BSA and centrifuged at 300 
g for 5 minutes. After neutralisation for 2 minutes in 0.1 M sodium borate pH 8.5,1 
ml PBS plus 0.5% BSA was added and the cell suspension was divided into tubes for 
test and control. Cells were stained with FITC-AntiBrdU (Phanningen Cat#33284X) 
or FITC-IgG control (Phanningen Cat# 35404X) diluted in PBS plus 0.5% Tween-20 
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and 0.5% BSA at a concentration of 50 vtl/ 106 cells and incubated in the dark at room 
temperature for 30 minutes. Cells were stained with the FITC-IgG control to detect 
any unspecific binding of the BrdU. Cellular DNA was stained with 10 ýtg/ ml 
propidium iodide for 30 minutes in the dark. Samples were diluted in PBS and then 
were analysed by flow cytometry. Data was displayed as a dotplot of FL- I (log4 scale, 
detects BrdU) against FL-3 (linear scale, detects PI). Propidium iodide fluoresces red 
in FL-3, FITC-fluoresces green in FL-1. 
2.14 Fluorescence Detected Alkaline DNA Unwinding Assay (FADU) 
2.14.1 Introduction 
The fluorescence detected alkaline DNA unwinding assay (FADU) is a procedure 
used to detect DNA damage, which is or can be converted to strand breaks (Bimboim 
and Jevcak, 1981). The assay is based upon the observation that DNA strand breaks 
accelerate DNA strand separation in alkaline conditions. DNA unwinding starts from 
strand breaks, which after alkaline denaturation, destabilises short duplex regions. The 
remaining double strand regions are selectively bound by a fluorescent intercalating 
dye. Therefore the fluorescence intensity of a sample is inversely correlated to the 
number of DNA strand breaks present. 
Levels of single and double DNA strand breaks were assessed using a semi- 
automated FADU assay (Braebeck et al., 2003). Briefly lysed cells were transferred 
onto 96 well plates and denatured in detergent/ urea buffer. An alkaline solution was 
added under controlled conditions to allow partial unwinding of the DNA starting 
from DNA strand interruptions. The fraction of DNA that remained double stranded 
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bound the DNA intercalating dye SYBR Green and the fluorescence intensity was 
measured. 
2.14.2 Determination of DNA strand damage 
Cells were treated with DNA damaging drugs, washed in PBS and lysed in FADU 
lysis buffer. The lysed cells were transferred onto a 96-well plate (replicates of 8-10) 
where at 4'C the FADU denaturation buffer was added, followed by the FADU alkali 
solution at 37'C for 90 minutes. DNA was stained with the intercalating dye SYBR 
Green (diluted 1: 25,000 in 13 mM NaOH) and fluorescence was measured in a 
fluorescence reader Spectrafluor Plus (Tecan, Crailsheim, Gennany) at kex 492 mn 
and kern 520 mu. The fluorescence intensity was inversely correlated to the number 
of DNA strand breaks present at the time of lysis. DNA damage percentage was 
calculated as I 00x (Po - Px)/Po, with Po: fluorescence intensity of an untreated control 
sample and P,,: fluorescence intensity of the treated cell sample. 
2.14.3 Deterntination of repair 
To measure the amount of DNA which was being repaired after exposure to the drugs, 
cells were treated as in Section 2.14.2 with the following modifications. Cells were 
treated with a drug, after treatment was complete the medium was removed, cells 
were washed in PBS and placed at 37'C for a further 4 hours in serum free medium to 
minimise proliferation. The cells were then lysed and analysed as in Section 2.14.2. 
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2.15 Senescence Associated -p galactosidase (SA- P gal) 
2.15.1 Introduction 
Normal beta galactosidase histochernical procedures identify the lysosomal form of 
the enzyme. Such assays are performed at pH 4 and use the substrate 5-bromo- 
4chloro-3indolyl P-D-galactopyranoside (X-Gal). Whilst senescence associated beta 
galactosidase (SA- P gal) activity is optimal at pH 6 and is observed in the cytoplasm 
in the non lysosomal regions (Dimri et al., 1995) of senescent cells. It is commonly 
used as a marker for senescence. A hallmark of senescence is a permanent arrest of 
cell cycle as senescent cells arrest at the GI/ S transition with a G, content of DNA 
(Goldstein, 1990). Dirnri and colleagues showed that staining for beta galactosidase 
was poor in young, non proliferating quiescent or terminally differentiated cells but 
stained more intensely once senescent. Additionally they tested human skin samples 
from a range of age donors and found an age related increase in the marker in den-nal 
fibroblasts and epidennal keratinocytes (Dinui et al., 1995). 
2.15.2 Method 
Cells were seeded onto petri dishes and allowed to grow until near confluence. Cells 
were washed twice with PB S and fixed with I% fon-naldehyde/ PB S for 5 minutes at 
room temperature. Cells were washed twice with PBS, the Sen P gal staining solution 
(Section 2.2) was added and cells were incubated at 37'C for several hours. As a 
positive control MRC5 senescent fibroblasts underwent the same procedure. Images 
were obtained using a DMIL microscope (Leica Microsystems, UK). 
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2.16 Histone H2A. X Phosphorylation (y-H2A. X) 
2.16.1 Introduction 
The DNA damage response was examined by staining with an antibody recognising 
the phosphorylated form of histone H2A-X (7-H2A. X). 7-H2A. X accumulates in 
response to DNA damage, at discrete foci within nuclei. A number of other proteins 
accumulate at these foci which function as signal transducers between DNA strand 
breaks and the cellular repair, growth arrest and apoptosis machinery (d'Adda di 
Fagagna et al., 2003). One of the first cellular responses to the introduction of double 
strand breaks is the phosphorylation of H2A. X. Serine 139 in the unique carboxy 
terminal tail of H2A. X is phosphorylated rapidly after damage and the number of 
H2A. X molecules phosphorylated increases with the severity of the damage. The 
phosphorylation is mediated by ATM (Rogakou et al., 1999), ATR (Furuta et al., 
2003) and/ or DNA dependent protein kinase (DNA-PK) (Park et al., 2003). 
Checkpoint and DNA repair proteins such as Rad50, Rad5l and Brcal colocalise with 
y-H2A. X (Paull et al., 2000). 
2.16.2 Method 
Ethanol sterilised 16 mm circular coverslips were placed in a 12 well plate. I ml of 
cell suspension was added to each well and incubated for 24 hours at 37'C. The 
medium was aspirated from the wells and cells were washed twice for 5 minutes in 
PBS. Cells were fixed by incubating for 10 minutes at room temperature with I ml of 
2% parafon-naldehyde/ PBS. Cells were washed twice with PBS and permeabilised by 
adding I ml of PBG with 0.5% Triton X-100 for 45 minutes at room temperature 
whilst shaking slightly. The solution was removed and cells were incubated with anti- 
99 
Chapter 2 
phospho histone H2A. X (Ser 139) clone JBW103 mouse monoclonal IgGI (Upstate, 
CAT#05-636) in PBG with 0.5% Triton X-100 (400 gl) for 1 hour at room 
temperature, shaking slightly. Cells were washed twice with PBG plus 0.5% Triton 
for 5 minutes and incubated with a dilution of Alexafluor 594 goat anti-mouse IgG 
(H+L) (Molecular probes, Cat# Al 1005) in PBG plus 0.5% Triton for 45 minutes up 
to I hour at room temperature as a secondary antibody. Cells were washed three times 
with PBS for 5 minutes and 400 ýd of DAPI staining solution was added for 10 
minutes at room temperature. DAPI (4'-6-Diamidino-2-phenylindole) is known to 
form fluorescent complexes with natural double-stranded DNA and is used as a 
specific nuclei counterstain. When DAPI binds to DNA, its fluorescence is strongly 
enhanced as it binds to the minor groove of the DNA helix around A-T clusters. Cells 
were further washed three times with PBS for 5 minutes, aspirated and sealed onto a 
glass slide containing a drop of anti-fade mounting medium (Vecta Shield). Slides 
were examined using a Zeiss epifluorescence microscope. The DAPI and Alexafluor 
594 fluoresce at separate wavelengths of 372 mn (blue excitation) and 594 mn (red 
excitation) respectively. These images are then merged using the LeicaQfluro 
Imaging Capture Program. 
2.17 ImmunoFISH 
2.17.1 Introduction 
To determine whether any sites of DNA damage localised to the telomeres, a protocol 
was devised that combines the immunological detection of y-H2A. X foci with 
fluorescence in situ hybridisation (FISH) detection of telorneres using a telornere 
specific peptide nucleic (PNA) probe. This procedure enables detection of the damage 
and telomeres at different wavelengths through a fluorescence microscope. 
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To see both the telorneric DNA and the y-H2A. X DNA damage foci simultaneously, 
initially a variety of procedures were attempted from published data and through 
personal communication. For the detection of DNA damage foci through 
immunohistochernistry and telorneric DNA using FISH, cells have to be in a fixed 
state. Originally it was endeavoured to use the same fixation method for both the 
immunohistochernistry and the FISH techniques and the individual procedures were 
primarily examined separately using the following reagents; parafon-naldehyde, 
acetone and methanol/ acetic acid. Once it was determined which of the fixing 
reagents gave positive signals for both the DNA dwnage foci and telomeres 
individually, the procedures were combined for immunoFISH, with the telomeres 
being probed before the DNA damage foci. The results obtained using the various 
fixing reagents for the immunoFISH, either gave a signal for DNA damage foci but 
not the telomeres and vice versa. Therefore the procedure was modified whereby cells 
were fixed individually for each procedure using different fixation reagents, with the 
telomeres targeted before the damage response staining. Through further modification, 
the immunoFISH procedure was finalised by firstly staining for the DNA damage 
response, then probing for the telomeres and reapplying the secondary antibody to 
detect 7-H2A. X DNA damage foci. 
2.17.2 Method 
Cells on coverslips were fixed by incubating for 10 minutes at room temperature with 
I ml of 2% paraformaldehyde/ PBS. Cells were washed twice with PBS and 
pen-neabilised by adding I ml of PBG with 0.5% Triton X- 100 for 45 minutes at room 
temperature whilst shaking slightly. The solution was removed and cells were 
incubated with anti-phospho histone H2A. X (Ser 139) clone JBW103 mouse 
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monoclonal (Upstate, CAT#05-636) in PBG with 0.5% Triton X-100 (400 ýtl) for I 
hour at room temperature, shaking slightlY. Cells were washed twice with PBG Plus 
0.5% Triton for 5 minutes and incubated with a dilution of Alexafluor 594 goat anti- 
mouse IgG (H+L) (Molecular probes, Cat# Al 1005) in PBG plus 0.5% Triton for 45 
minutes up to I hour at room temperature as a secondary antibody. Cells were washed 
three times with PBS for 5 minutes and I ml of fixative (methanol: acetic acid 3: 1) 
was added for 15 minutes, washed in PBS and a further 1.3 ml of fixative was added 
for a further 15 minutes. Cells were then washed in PBS, washed in I ml fixative and 
baked at 60'C for I hour. Cells were rehydrated in 2x SSC at 37'C for 2 minutes and 
dehydrated in a series of 70%, 80%, 95% ethanol for 2 minutes each and air dried. 
Cells were treated with 20 ýtl of Cy-3 labelled telornere specific (C3TA2)3peptide 
nucleic acid (PNA) probe (4ng/ gl) (Applied Biosysterns) containing 70% formamide/ 
2x SSC. Both probe and cellular DNA were codenatured at 75'C for 10 minutes in a 
moist chamber containing Ix SSC and hybridised for 2 hours in a moist chamber at 
37'C in Ix SSC, washed with 2x SSC/ 0.05% tween for 10 minutes shaking at room 
temperature. Cells were further incubated with a dilution of the fluorescein conjugated 
secondary antibody in PBG plus 0.5% Triton for 45 minutes at room temperature and 
washed three times for 5 minutes in PBS. Coverslips were mounted in Vectashield 
mounting solution containing DAPI as a DNA counterstain and examined using a 
Zeiss epifluorescence microscope. The DAPI, Alexafluor 594 and Cy-3 fluoresce at 
separate wavelengths of 372 nm (blue excitation), 594 mn (red excitation) and 494 nm 
(green excitation) respectively. The images are merged using the LeicaQfluro 
Imaging Capture Program. 
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CHAPTER 3 
NEUROBLASTOMA APOPTOSIS INDUCTION AFTER 
CISPLATIN TREATMENT IS NOT 
TELOMERF DEPENDENT 
3.1 Introduction 
Cisplatin is a chemotherapeutic agent for the treatment of neuroblastoma, a common 
solid extracranial malignancy of childhood and infancy. Cisplatin binds to DNA to 
cause a biological effect by fonning cisplatin- DNA adducts and is a potent inducer of 
apoptosis (Ormerod et al., 1996; Henkels and Turchi, 1997). The major DNA adduct 
formed is the bifunctional intra-strand cross-links between adjacent guanines. It is 
unclear how the cisplatin- DNA adducts induce cytotoxicty, though this is widely 
attributed to the formation of various types of cross-links. There is a linear correlation 
between gross levels of platinum bound to DNA and the extent of cytotoxicty (Fraval 
and Roberts, 1979). Reports exist that strongly favour intra-strand adducts as lesions 
largely responsible for the cytotoxic action (Pinto and Lippard, 1985), which is 
consistent with the knowledge that the intra-strand adducts account for 85- 90% of 
total lesions (Kelland, 1993). Though other reports indicate that inter-strand cross- 
links are the most cytotoxic lesion (Knox et al., 1986). 
Telomeres, the DNA-protein structures that form the ends of chromosomes, play a 
number of important roles in the function and organisation of the genome. Their 
shortening with each round of DNA replication is caused by different mechanisms, 
one of these being their sensitivity to DNA damage. Thus, telomere shortening can be 
greatly accelerated or decelerated by controlling oxidative stress within the cells (von 
Zglinicki, 2002). Cisplatin has been shown to bind preferentially to runs of two or 
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more consecutive guanines (Grimaldi et al., 1994). Human telomeric DNA is partially 
composed of guanines as its repeat sequence is TTAGGG. Therefore, cisplatin may 
preferentially target telomeric DNA. Telomeres end in single stranded overhangs of 
the G-rich strand, which appear to be essential for telomeric higher order structure 
(Griffith et al., 1999) and for the generation of DNA damage signals from telomeres 
(Saretzki et al., 1999; von Zglinicki, 2001; Stewart et al., 2003). Telomerase, a 
reverse transcriptase that uses an RNA template to add telomeric repeats onto the ends 
of chromosomes (Greider and Blackburn, 1987; 1989) is expressed in 94% of 
neuroblastomas (Hiyama et al., 1995) and has been shown to be a powerful 
independent prognostic factor (Brinksmidt et aL, 1998). Thus a specific role of the 
telomere/ telornerase complex in mediating cisplatin induced neuroblastorna cell 
death may be expected. 
In fact, cisplatin induced cell killing of turnour cells was associated with a decline in 
detectable telornerase activity (Burger et al., 1997; Kunifuji et al., 2002; Zhang et al., 
2002) and a continuous cisplatin treatment induced loss of telomeres in HeLa cells 
(Ishibashi and Lippard, 1998). However, in testicular teratorna and haematopoietic 
cell lines the decline in telomerase activity following cisplatin treatment was shown to 
be a consequence of, rather than a cause for, apoptosis (Akiyama et al., 1999; Cressey 
et al, 2002). Telomerase inhibition by different methods has been shown to lead not 
only to progressive telomere shortening and cell death (Herbert et al., 1999) but also 
to telornere length independent apoptosis induction (Saretzki et al., 2001), while 
activation of telomerase was related to increased resistance to apoptosis (Holt et al., 
1999; Ludwig et al., 2001). Telomerase inhibition was found to increase the 
sensitivity of various cell lines to cisplatin induced apoptosis, for example 
glioblastornas (Kondo et al., 1998; Kondo et al., 2001) and HEC- I cells (Murakami et 
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al., 1999). However this was not detected in human breast tumour cells and 
overexpression of hTERT, the catalytic subunit of telomerase in human fibroblasts did 
not increase their cisplatin resistance (Ludwig et al., 2001). Given these contradictory 
results, the aim of the work described in this chapter was to test the hypothesis that 
there is a role for the telomere/ telomerase complex in cisplatin induced 
neuroblastoma cell apoptosis. No indications for a causal involvement were found. 
3.2 Methods 
All methods used in this study are described in Chapter 2. 
3.3 Results 
3.3.1 Growth inhibitory effect of cisplatin on SHSY5Y cells 
Initially it was very important to establish the relationship between cisplatin treatment 
and growth inhibitory effects as a basis for experiments on mechanism of action. Cell 
growth was assessed by cell counting and by the SRB assay after cisplatin treatment. 
The latter is widely used to assess the effect of cytotoxic drugs. 
Growth curve data for the SHSY5Y cells (Figure 3.1 A) were used to determine the 
optimal inoculum density for the SRB assay. The cytotoxicty levels of cisplatin on the 
SHSY5Y cells were then examined by exposing cells to a short (2 hour) exposure 
drug treatment and incubating for a further 6 days before fixing and staining with the 
SRB reagents (Section 2.5). The control cells (untreated) optical density (OD) was set 
at 100%. The OD of the treated cells were converted into percentages of the control 
OD, plotted against cisplatin concentration (Figure 3.1 B) and the IC50 value 
calculated from this giving anIC50value of 13.3 ýM. 
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Figure 3.1 Determination of IC50 of SHSY5Y cells after cisplatin treatment. (A) 
Growth curves of SHSY5Y cells. Cells were grown at various densities in ten 96 well 
plates and each day plates were fixed and stained with sulphorhodamine B to give the 
optical densities. The OD was directly proportional to the number of cells and these 
values can be used to determine the optimum inoculum density to be used in further 
experiments. (B) SHSY5Y cells were exposed to a2 hour drug treatment and 
incubated for 6 days before fixing and staining with sulphorhodamine B. Treated cells C) zn 
were converted into % of the control OD which was used to estimate the IC50 value. 
A-1 
1 
Time (Days) 
106 
0.1 10 lc, ýo 100 
Chanter 3 
In a separate set of experiments, effects of cisplatin on growth of cclis was dclhied by 
counting cell numbers at various times after drug exposure. Cell numbers were 
counted for the SHSY5Y cells after a short (Figure 3.2 A) and continuous (Figure 3.2 
B) exposure to cisplatin. The IC50 values deten-nined by cell counting I'M both a short 
(48 hours after treatment) and continuous (72 hours after treatment) cxposurc resulted 
in IC50 values of 23 ýM for the short exposure and 0.7 [tM Im the continuous 
exposure. After a short exposure to cisplatin, an increase in cell number was dctcctcd 
for treatments :! ý 15 [tM, though no net growth was observed for ý! 100 ýM (Figure 3.2 
A). The SHSY5Y cells decreased in cell number after ý! 2 [jM continuous cxposurc to 
cisplatin, though some net growth was established after 0.5 ýM treatment (Figure 3.2 
B). The inhibition of net growth after both cisplatin treatment regimens confirined the 
IC5o values. In conclusion the relationships between cisplatin concentratimi md 
growth inhibition have been defined for short and continuous cxposures. 
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Figure 3.2 Cell numbers of SHSY5Y cells after a short and continuous exposure 
to cisplatin. SHSY5Y cells were exposed to cisplatin for 2 hours (A) or continuously 
(B) and cell numbers per flask were counted up to at least 48 hours after. Data are 
mean ± SEM from triplicate experiments. 
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3.3.2 Cisplatin induces apoptosis and S phase arrest in SHSY5Y cells 
Cells exposed to cytotoxic drugs, under many circumstances undergo apoptosis. It 
was relevant to determine the proportion of cells with apoptotic features induced by 
cisplatin exposure and also how soon after treatment apoptotic cells appeared. There 
are many methods available for detection of apoptotic cells. The method used here 
was based on flow cytometry in which apoptotic cells were detected on the basis of 
their size and granularity. This method of estimation of apoptotic cells has been 
shown to be comparable to TUNEL- positive cells and sub-GI cells in tumour cells 
(Saretzki et al., 2001). In order to understand the effect of cisplatin on the cells, it was 
also important to compare other cellular drug responses to the drug exposures. 
Therefore it was essential to investigate the effect of cisplatin on cell cycle 
progression. 
Examples of typical dot plots of flow cytometry apoptotic data for SHSY5Y cells 
exposed to a short exposure and continuous exposure treatment are shown in panels A 
of Figure 3.3 and 3.4 respectively. Panels B of Figure 3.3 and 3.4 show averaged data 
from 3 separate experiments for percentage of apoptotic cells. 
SHSY5Y cells exposed to a short exposure cisplatin treatment exhibited a time and 
concentration dependent induction of apoptosis, with a large increase in apoptotic 
cells at ý! 100 ýM after 24 hours (Figure 3.3). SHSY5Y cells exposed to a continuous 
treatment of cisplatin also displayed a time and concentration dependent induction of 
apoptosis (Figure 3.4). Though the SHSY5Y cells not exposed to cisplatin (untreated) 
exhibited an increased frequency of apoptotic cells, this is thought to be due to 
adverse growth conditions i. e. confluency. 
Measurement of the cellular DNA content in SHSY5Y cells after a short exposure 
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cisplatin treatment revealed significant increases of the fraction of cells with aS phase 
DNA content after high dose drug treatment i. e. 100 [tM (Figure 3.5- 3.6). Figure 3.5 
illustrates typical examples of the cell cycle DNA histograms which were obtained 
after a2 hour treatment. The percentage of SHSY5Y cells in each stage of the cell 
cycle after short exposure (Figure 3-6) indicated an increase of cells with aS phase 
DNA content with increasing concentration, with the highest amount of cells with aS 
phase DNA content after a 100 ýM treatment. 
Cell cycle analysis of the SHSY5Y cells after a continuous exposure to cisplatin 
additionally displayed an increase of the fraction of cells with aS phase DNA content 
after high dose drug treatment i. e. 5 ýM (Figure 3.7- 3.8). Figure 3.7 illustrates typical 
examples of the cell cycle DNA histograms which were obtained after a continuous 
treatment. The percentage of SHSY5Y cells in each stage of the cell cycle after 
continuous exposure (Figure 3.8) indicated an increase of cells with aS phase DNA 
content with an increase in concentration of treatment. 
As the SHSY5Y cells after high dose treatments for both regimens appeared to have a 
high proportion of cells with aS phase DNA content compared to the untreated 
control, BrdU incorporation was examined to identify whether the cells in S phase 
were proliferating or growth arrested (Figure 3.9). For the BrdU incorporation, 
treatment with cisplatin consisted of a 500 ýM short exposure treatment with a further 
incubation of 48 hours and a5 gM continuous exposure to cisplatin for 48 hours. 
BrdU was added for I hour after treatment was complete. Figure 3.9 A illustrates the 
DNA content of the cells after the treatments, whilst Figure 3.9 B displays the FITC 
labelled anti- BrdU fluorescence. BrdU is incorporated in the untreated cells 
(compared to 0 [M IgG) as expected. Though 48 hours after high dose treatments 
BrdU was not incorporated suggesting that the cells were arrested in S phase. 
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Figure 3.6 Stages of SHSY5Y cells in the cell cycle after a short exposure to 
cisplatin. Percentage of cells in GI (blue), S (purple) and G2(yellow) phase 24 hours Z: ) 
(A) and 48 hours (B) after a short exposure cisplatin treatment at the indicated 
concentrations, assessed by flow cytometry. Data are mean ± SEM from triplicate 
experiments with three replicates in each experiment. 
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Figure 3.7 Cell cycle analysis of SHSY5Y cells exposed to cisplatin continuously. 
% ratios of cell cycle stages were measured in DNA histograms from DAPI stained 
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Figure 3.8 Stages of SHSY5Y cells in the cell cycle after a continuous exposure to 6 
cisplatin. Percentage of cells in Gi (blue), S (purple) and G, ) (yellow) phase 24 hours 
(A), 48 hours (B) and 72 hours (C) after a continuous cisplatin treatment at the 
indicated concentrations assessed by flow cytometry. Data are mean ± SEM from 
triplicate experiments with three replicates in each experiment. 
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3.3.3 Cisplatin induces DNA strand breaks as a result of attempted repair 
As discussed in Chapter I, cisplatin in its cis conformation favours the formation of 
highly toxic types of DNA adducts due to the steric restriction on the way that the 
drug reacts with the DNA. Results described in Section 3.3.2 indicate that exposure of 
cells to a wide range of concentrations of cisplatin induced apoptosis. In order to 
detect strand breaks after cisplatin treatment, DNA strand breaks and the DNA 
damage response was investigated by the fluorescence detected alkaline DNA 
unwinding (FADU) assay and an antibody recognising the phosphorylated form of 
histone H2A. X (y-H2AX) respectively. It was of importance to determine if cisplatin 
exposure of SHSY5Y cells resulted in strand breaks because strand breakage in 
telorneric DNA could be detected by available techniques. 
The presence of DNA strand breaks were measured after exposure for 2 hours to 
cisplatin at 7,100 and 500 ýM. Samples were analysed immediately after the 
exposure period and following further incubation for 14 and 24 hours (Figure 3.10). 
Strand breaks were detectable at 14 and 24 hours after a short exposure treatment, 
though not immediately after treatment. This increase in strand breaks after an 
incubation period was statistically significant (ANOVA) compared to breaks 
measured immediately after treatment. 
The level of DNA breaks was higher after 24 hours than 14 hours. Strand breaks 
present after treatment increased with cisplatin concentration up to 100 ýM. The 
apparent decrease in strand breaks at 500 ýM is attributed to the fact that many of the 
cells were in apoptosis (Figure 3.3). 
The DNA damage response of SHSY5Y following exposure to cisplatin was 
examined by y-H2A. X staining, immediately after a 100 ýM and 500 ýM, 2 hour 
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treatment (Figure 3.11 A) and after a further 24 hours (Figure 3.11 B). Immediately 
after the 2 hour exposure the cells did not show the presence of DNA damage foci. 
After 24 hours further incubation the majority of the cells stained positive for 
H2A. X. 
As cisplatin- DNA adducts primarily do not induce strand breaks, the delayed 
detection of H2A. X phosphorylation and DNA strand breaks in cisplatin treated cells 
is probably associated with DNA repair activities. As described in Chapter 1, NER is 
known to be involved in repair of cisplatin DNA intra-strand cross-links and this 
process involves strand incision. However, induction of H2A. X phosphorylation is 
generally associated with double strand breaks which are likely to fonn during repair 
of stalled replication forks or during repair of inter-strand cross-links. 
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Figure 3.10 DNA strand breaks in cisplatin treated SHSY5Y cells. DNA strand 
breaks were measured immediately after a2 hour exposure (pink), 14 hours later (blue) 
and 24 hours (purple) after 2 hour exposure by fluorescence detected alkaline DNA 
unwinding (FADU) assay. Data are mean +/- SEM from at least three experiments. 
Statistically significant differences towards the 0 hours after exposure treatment are 
marked by an asterisk (p < 0.05, ANOVA). 
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Figure 3.11 DNA damage response in cisplatin treated SHSY5Y cells. Cells were 
fixed after a 100 ýM and 500 ýM cisplatin treatment, immediately after a2 hour 
exposure (A) and 24 hours after a2 hour exposure (B) and stained with an antibody 
against the phosphorylated fonn of H2A-X (7-H2A. X) and DAPI nuclear stain. 
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3.3.4 Cisplatin does not shorten telomeres in SHSY5Y ceUs 
The main hypothesis being tested in this chapter was that cisplatin induces growth 
arrest/ apoptosis via the telomere/ telomerase complex. The aim of the following 
experiments was to detennine telomere lengths using an in-gel hybridisation 
technique at various times after exposure of SHSY5Y cells to cisplatin and to find out 
whether cisplatin induced growth arrest/ apoptosis was preceded or accompanied by 
telomere shortening. In addition, non-specific degradation of DNA and the presence 
or absence of single strand breaks on the G rich telomeric strand was assessed. The 
SHSY5Y cells are a neuroblastorna cell line with telornere lengths of -4 kbp. This 
cell line was chosen for this investigation as cisplatin is a conventionally used 
chemotherapeutic drug in the treatment of neuroblastoma. 
SHSY5Y cells were exposed to cisplatin for either 2 hours (0,7,15,100,350 and 500 
ýM) or continuously (0,0.5,2,5 gM). At 6,24 and 48 hours after short exposure and 
24ý 48 and 72 hours after continuous exposure telomere restriction fragment lengths 
were assessed. 
Figure 3.12 shows an example of typical data. Panel A illustrates images of ethidium 
bromide fluorescence from electrophoresis gels to indicate distribution of total 
cellular DNA and MW markers. The intensity signal was proportional to the amount 
of DNA loaded, which was kept constant throughout. Panel B demonstrates the 
telomere restriction fragment length gel. The calculated average telomere lengths are 
superimposed as white bars. Panel C shows the average of at least 3 separate 
determinations of mean telomere length plotted against time after exposure to a range 
of cisplatin concentrations. SHSY5Y cells exposed to cisplatin for 2 hours show no 
significant change in telomere length at any concentrations. 
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To assess the integrity of the total nuclear DNA, the telomere restriction fragment 
length gels were rehybridised with an interstitial minisatellite probe (CAC)8 (Figure 
3.13 A) and the average relative intensities of a high (LI) and a low (L2) molecular 
weight band, for at least three experiments were calculated (Figure 3.13 B). 
Degradation of DNA was not detected using this minisatellite marker. 
Typical results for the presence of single strand breaks on the G rich telomeric strand 
after exposure to cisplatin for 2 hours are shown in Figure 3.14. There was no 
evidence of single stranded DNA breaks on the G rich telomeric strand for as long as 
48 hours after treatment. 
Similarly, after a continuous cisplatin treatment no telomere shortening was detected 
in the SHSY5Y cells (Figure 3.15), with no evidence of single stranded DNA damage 
on the telomeric G rich strand (Figure 3.16 A). The single stranded DNA telomeric G 
rich strand when reprobed with the interstitial minisatellite probe (CAC)8 displayed 
no degradation of DNA (Figure 3.16 B). 
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Figure 3.12 Telomere restriction fragment lengths after short exposure cisplatin 
treatment on SHSY5Y cells. (A) Ethidium. bromide fluorescence of genomic DNA. 
(B) Telomere gel. Cisplatin concentrations (in ýLM) and times after onset of treatment 
(in h) are indicated on top of the figure. White bars indicate average telomere length. Z--ý :Z 
The positions of the size markers (2.33.1,4.36,2-32,2.03 kbp) are shown by black bars. 
(C) Average telomere length. Gels were normalised to a standard and average 
fragment lengths of at least 4 experiments were calculated. Data are ± SEM. Cý 
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Figure 3.13 Determination of unspecific DNA degradation. Gels were rehybridised 1-13 
with (CAQ8 minisatellite marker to test for unspecific DNA degradation (A). The 
positions of the size markers (23.1,4.36,2.32,2.03 kbp) are shown by black bars. The 
intensity ratios between high (LI) and low molecular weight (L2) bands were C) Z: ) 
compared over time and cisplatin concentration (B). Data are mean ± SEM from 
triplicate experiments. 
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Figure 3.14 Denaturing gel to detect G rich telomeric strand breaks after short 
exposure cisplatin treatment. Examples of denaturing gel on SHSY5Y cells. 
Cisplatin concentrations (in ýM) and times after onset of treatment (in h) are indicated 
on top of the figures. 
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Figure 3.15 Telomere restriction fragment lengths after continuous exposure 
cisplatin treatment on SHSY5Y cells. (A) Ethidiurn bromide fluorescence of 
genomic DNA. (B) Telomere gel. Cisplatin concentrations (in ýM) and times after 
onset of treatment (in h) are indicated on top of the figure. White bars indicate 
average telomere length. The positions of the size markers (23.1,4.36,2.32,2.03 kbp) 
are shown by black bars. 
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Figure 3.16 DNA degradation after continuous cisplatin treatment. (A) 
Denaturing gel to detect G rich telomeric strand breaks. (B) Gels were rehybridised 
with (CAQ8 minisatellite marker to test for unspecific DNA degradation. Cisplatin 
concentrations (in ýtM) and times after onset of treatment (in h) are indicated on top of 
the figures. 
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3.3.5 Effects of cisplatin on telomeric overhangs 
Telomeric single stranded G rich overhangs have been implicated in telomere 
structural maintenance (Griffith et al., 1999) and generation of a DNA damage/ 
growth arrest response (Stewart et al., 2003; Saretzki et al., 1999; von Zg1inicki et al., 
2001). In order to test whether cisplatin treatment might interfere with the integrity of 
the overhangs, the effect of exposure to cisplatin on the overhangs was examined by 
an in-gel hybridisation technique and a telomere isolation procedure. 
3.3.5.1 In-gel hybridisation 
Figure 3.17 shows typical data of overhang length measurements by in-gel 
hybridisation. Panel A illustrates probed non denatured (overhang) and denatured 
(telomere) gels. Panel B shows the average graph of 3 independent experiments of the 
ratio of the intensity signals of the overhang/ telomeres after a2 hour cisplatin 
treatment. The ratio of non denatured/ denatured hybridisation signals was the same 
for the untreated compared to cells exposed to 500 ýM cisplatin for 2 hours. This 
indicates that, at least under these conditions, SHSY5Y cells showed no significant 
change in overhang lengths. 
3.3.5.2 Telomere isolation 
In an alternative approach to investigating the effects of cisplatin on telomeric 
overhangs, isolated telomeres were extracted from restriction digested genomic DNA 
(supernatant) by a streptavidin coated magnetic bead approach with biotinylated 
oligonucleotides complimentary to the G-rich telomeric strand. 
To purify telomeric DNA, isolated telomeres were extracted from restriction digested 
genomic DNA (supernatant) and were detected by being run on a pulsed field gel, 
then hybridised using a telomere specific probe (Figure 3.18 A). The procedure 
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Figure 3.17 Telomeric G rich overhangs in SHSY5Y cells after short exposure 
cisplatin treatment. 2 hours after treatment with either 0 or 500 ýM cisplatin a 
(CCCTAA)6probe was hybridised to a non denatured gel to detect G rich overhangs 
(left) and again to the same gel after DNA denaturation (right) to detect whole 
telomeres (A). The intensity ratios of non denatured/ denatured signals are compared 
after treatment to control (B). 
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requires the presence of single stranded overhangs at the telomeres in solution. Using 
this procedure, approximately 50% of the telomeric restriction fragments were 
extracted from the supernatant (Compare lanes 2 and 3, Figure 3.18 A). To determine 
if it would be possible to isolate the remaining telomeric DNA from the supernatant, 
fresh reagents were added and the whole procedure repeated a number of times in 
cycles (Figure 3.18 B). Repeating the procedure resulted in further isolation of a small 
amount of additional telorneric DNA. 
The purification procedure was modified by using different amounts of starting 
material and up scaling reagents and cells accordingly to give an increase in yield of 
isolated telomeres (Figure 3.19 A). This scaling up would enable the isolated 
telomeres to be used in further investigations described in Section 3.3.6. To test the 
purity of the isolated telomeres the blots were rehybridised with a minisatellite probe 
with the sequence (CAC)8, which should not be present in the purified telorneres 
(Figure 3.19 B). As expected, the minisatellite sequence was not detected in the 
purified telomeres but was present in the supernatant DNA. 
The telomeric isolation procedure (Chapter 2) was used to detennine if cisplatin 
treatment led to any reduction in recovery of telomeric DNA isolated by the 
hybridisation procedure (Figure 3.20). Any such reduction could indicate a drug- 
induced loss of single strand overhangs. SHSY5Y cells were treated with a short 
exposure treatment to either 100 ýM or 500 ýM cisplatin, the DNA was isolated and 
the telomeric DNA purified (Figure 3.20 A). The ratio of intensities of hybridisation 
signals for telomeres remaining in the supernatant (S) to telomeres isolated (T) was 
similar in drug treated and control cells (Figure 3.20 B). In conclusion, cisplatin 
treatment even at high concentrations does not induce degradation of the single 
stranded G rich telomeric overhang. 
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Figure 3.18 Telomeric DNA isolation. Telomeres were captured by solution 
hybridisation of single stranded G rich overhangs to magnetic bead coupled 
oligonucleotides and eluted from the magnetic beads. Samples were analysed by 
pulsed field gel electrophoresis, blotted, denatured and then hybridised with a 
telomere specific probe (A). Purification of the remaining telomeres in the supernatant 
using ftirther cycles of the isolation procedure (B). 
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Figure 3.19 Modification of telomeric DNA isolation. The procedure was modified 
to increase the quantities of telomeric DNA (A). Confirmation of purity of the isolated 
telomeres by rehybridising blots with (CAQ8 minisatellite marker (B). 
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Figure 3.20 Telomeric DNA isolation after treatment with short exposure to 
cisplatin. (A) 2 hours after a short exposure cisplatin treatment with the indicated 
concentrations, telomeres were captured by solution hybridisation of single stranded 
G rich overhangs to magnetic bead-coupled oligonucleotides. (B) The ratio of isolated 
telomeres (T) to those remaining in the supernatant (S). 
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3.3.6 Attempt to determine whether cisplatin preferentially targets the telomeres 
by direct measurement of platinum-DNA adducts 
The aim of this section was to determine if telomeres were preferential targets for the 
binding of cisplatin compared to the rest of the genomic DNA directly, by 
measurement of the levels of platinum that became bound to isolated telomeric DNA 
and to total DNA. As telomeric DNA constitutes around 0.01% of all genomic DNA, 
only a very small yield of this material was anticipated. 
Furthermore, the levels of Pt that become bound to the total DNA following relevant 
exposures to cisplatin are very small. Therefore, measurement of adducts on the 
telomeric fragments would require quantification of extremely low levels of platinum. 
An appropriate high sensitivity of detection of platinum was available via the ICP-MS 
(Section 2.8) facility in the Geology Department at Durham University. In these 
experiments, telomeres from cisplatin treated SHSY5Y cells were purified using the 
telomeric DNA isolation procedure (Section 2.7). The supernatant DNA (the 
restriction digested genomic DNA that the telomeres have been extracted from) was 
used as the comparison DNA (i. e. rest of the genome). 
The following calculation indicates the amount of telorneric DNA that was anticipated 
to have been obtained from I mg of total genomic DNA (10 8 cells). 
Mean telomere repeat length = 5000 bp 
As there are 92 telorneres per cell= 4.6 x 105 bp per genome 
Genome size= 3x 109 bp 
Thus proportion of genome in telomere fragments= 4.6 x 10 5/3x 109 = 1.53 x 10-4 
Therefore I mg of DNA contains: 
IX 10-3 gX1.53 x 10 -4 = 153 ng of telomeric fragment 
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For the telomere isolation procedure, a maximum of 300 ýtg of total genomic DNA 
was used as starting material and it was anticipated from this that at least 30% of all 
telorneres were expected to be isolated. 
Therefore 1 mg DNA =- 153 ng telomeric fragment 
300 ýtg DNA =- 45 ng telomeric fragment 
30% yield =- 13.5 ng telomeric fragment 
The following calculation indicates the expected level of Pt in 13.5 ng of telomeric 
DNA (the anticipated yield from 300 ýtg of total genomic DNA). 
If adduct level were 500 nmoles Pt/g DNA then assuming that adduct levels 
on telomeric DNA are similar to overall genome: 
13.5 ng telomeric DNA would carry 13.5 x 10-9 x 500 x 10-9 = 6.75 x 10-15 moles Pt 
At mass of Pt = 195 
Therefore 6.75 x 10-15 moles Pt = 6.75 x 10-15 x 195 = 1.3 x 10-12 g Pt 
If dissolved in 0.1 ml water the concentration of Pt would be: 
1.3 X 10-12 g Pt in 0.1 g= 13 X 10-12 g per g= 13 PPT 
It is essential to accurately quantify the concentration of DNA as well as Pt because 
adduct levels must be calculated as the ratio of the two values. It was not possible to 
measure the concentration of the purified telomeres by UV spectrophotometry due to 
low sensitivity of this method for small amounts of DNA. Additionally, the use of 
fluorescent intercalating dyes would have utilised DNA for estimation of 
concentration. The dye-DNA mixtures could not be re-utilised for Pt measurement 
because of the risk of the introduction of Pt contamination. Consequently, phosphorus 
was measured in the samples simultaneously with platinum as a method to accurately 
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calculate DNA concentration. In the past, chemical measurement of phosphorus has 
been used to provide definitive measurements of concentration of large quantities of 
DNA. However, for determination of low concentrations of DNA by ICP-MS, the 
presence of background levels of P exists as a serious problem since P is present in 
many commonly used solutions. 
The telomeric DNA isolation procedure requires a buffer in which to dissolve the 
genomic DNA and a buffer to elute the telomeres from the magnetic beads (Section 
2.7). These buffers are composed of Ix SSC/ 1% Triton X-100 and O. Ix SSC/ 1% 
Triton X- 100 respectively. When extracting telomeric DNA for ICP-MS, these buffers 
or components in them may cause interference and high background levels of 
phosphorus or platinum. Therefore a variety of alternative buffers (Table 3.1) were 
examined for use in the telomere, isolation procedure. The isolated supernatant 
and telorneric DNA were initially analysed by hybridisation to see whether or not the 
yield of telomeres purified varied from the possible buffer combinations (Section 2.7). 
The altemative buffers gave similar levels of isolated telomeres compared to the 
initial buffers used. Samples to be analysed for the ICP-MS were prepared in triplicate 
in a series of dilutions in 3.5% nitric acid and incubated overnight at 70'C (Section 
2.84). 
The variety of buffer and buffer components were measured by ICP-MS in two 
independent experiments to see if any of them contained high levels of P (in the 
n, k absence of DNA) which would subsequently give inaccurate calculations for the 
concentration of DNA (Table 3.2). High purity water from Durham University that 
was known to be suitable for ICP-MS was used throughout for the DNA extraction 
and isolation of telomenc DNA procedures to avoid the risk of contamination. 
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Table 3.1 Combination of buffers tested in the telomere isolation procedure 
Buffers 
Supernatant Dissolved In Telomeres Eluted In 
1 1x SSC/ 1 %Triton X-1 00 0.1 x SSC/ 1% Triton X-1 00 
2 TE buffer TE buffer 
3 TE buffer B&W buffer 
4 1x TBS pH= 8.5 1x TBS pH= 8.5 
5 EDTA buffer EDTA buffer 
6 1x TBS pH= 8.5 EDTA buffer 
7 Sodium acetate buffer Sodium acetate buffer 
8 1x TBS pH= 8.5 Sodium acetate buffer 
9 B&W buffer EDTA buffer 
10 B&W buffer Sodium acetate buffer 
Samples were also diluted in a very pure nitric acid which was again obtained from 
the ICP-MS facility at Durham University. High levels of P were detected in samples 
of reagents and the levels of P measured in samples varied between experiments 
(Table 3.2). This suggested that contamination of P had occurred, presumably related 
to the widespread use of phosphate buffers and detergents in biological laboratories. 
Furthermore, P suffers from many spectral and isobaric interferences in ICP-MS 
measurements and these can severely impair the detection limit. 
From the results from Table 3.2, the buffers and solutions that induced high levels of 
P were eliminated from the telomere isolation procedure and the risk of contamination 
was kept at a minimum in the preparation steps. 
Purified telomeres were isolated from cisplatin treated and untreated DNA and the 
samples measured using the ICP-MS for both Pt and P levels. The procedure for 
isolation of telomeres began with 300,90 or 30 ýtg of genomic DNA. Telomeric DNA 
and remaining genomic DNA were isolated from these quantities and assessed by 
ICP-MS (Table 3.3). 
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Table 3.2 Measurement of phosphorus levels in buffers used in telomeric DNA 
isolation procedure using ICP-MS 
Experiment I Experiment 2 
Sample Dilution Phosphorus Phosphorus 
Factor Levels/ ppb Levels/ ppb 
Special water from Durham 10 12.63 32.61 
Special water from Durham 20 9.56 32.5 
Special water from Durham 100 12.37 29.11 
_ Nitric Acid from Durham 0 28.38 31.34 
100% Triton 10 107.84 821.34 
100% Triton 20 1196.47 517.71 
100% Triton 100 486.49 216.15 
1% Triton/ 1x SSC 10 19.09 57.21 
1% Triton/ 1x SSC 20 10.73 48.06 
1% Triton/ 1x SSC 100 8.23 34.33 
1% Triton/ 0.1 x SSC 10 18.24 66.07 
1% Triton/ 0.1 x SSC 20 13.04 53.27 
1% Triton/ 0.1 x SSC 100 6.83 32.91 
1 XSSC 10 9.47 38.45 
1 XSSC 20 11.38 32.37 
1x SSC 100 13.45 35.21 
1x TBS pH=7 10 8.13 34.24 
1x TBS pH=7 20 9.19 32.56 
1x TBS pH=7 100 18.9 35.81 
1x TBS pH=8.5 10 13.04 21.34 
1x TBS pH=8.5 20 16.1 26.43 
1x TBS pH=8.5 100 11.45 34.93 
B& W Buffer 10 4.13 156.78 
B& W Buffer 20 8.32 95.83 
B& W Buffer 100 8.41 60.32 
EDTA buffer 10 66.19 33.77 
EDTA buffer 20 45.64 30.69 
EDTA buffer 100 23.46 32.25 
10mM EDTA 10 9.54 114.78 
10mM EDTA 20 17.14 32.8 
10mM EDTA 100 12.62 58.68 
Sodium acetate buffer 10 64.87 36.23 
Sodium acetate buffer 20 31.13 36.33 
Sodium acetate buffer 100 20.85 33.3 
_ 80mM NaOAc 10 8.1 124.13 
80mM NaOAc 20 9.63 110.29 
80m M NaOAc 100 8.69 53.76 
100% Formamide 10 113.25 25.5 
100% Formamide 20 34.27 32.74 
100% Formamide 1 100 32.58 1 11.59 
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Telomeric DNA and remaining genomic DNA were prepared from control cells 
(untreated) using a variety of buffers to estimate the range of background levels of Pt 
and to assess use of P for quantifying DNA (Table 3.3). 
Telomeric DNA and remaining genomic DNA that were extracted from cells that had 
been incubated for 2 hours with high concentrations of cisplatin were analysed on the 
ICP-MS. This was undertaken using the combination of buffers (supernatant dissolved 
in B&W buffer and telomeres eluted in EDTA buffer) which gave a similar yield to 
the initial buffers used in the isolation procedure (! ý 50%) when assessed on a 
southern blot (Section 2.7) and low background levels of Pt and P (Table 3.3). 
Table 3.3 shows that Pt and P levels for the treated telorneric DNA were very low 
even when the initial starting amount of DNA was 300 ýtg and would not be 
distinguishable from background levels using the ICP-MS. For that reason a high 
resolution instrument, Plasma Ionisation Multicollector Mass Spectrometer (PIMMS) 
was used which had a higher sensitivity to lower levels of Pt and P. 
The calculations outlined above indicated that Pt levels in solutions of isolated 
telorneric DNA could be up to about 13 PPT. Using PIMMS, these levels of Pt on the 
telomeric DNA after cisplatin treatment would have been easily detectable (See Table 
3.3). 
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Table 3.3 Total Pt concentration determined from measurement of Pt 195 and P 
concentration on cisplatin treated and untreated telomeres/ supernatant using a 
combination of buffers 
Pt 195 P 
Dilution Conc/ Conc/ 
Factor Ppt ppb 
DNA samples from untreated (control cells) 
B& W Supernatat-300pg DNA 3.85 2.07 1205.62 
EDTA+95% Form Telomeres-300pg DNA 3.33 2.21 302.58 
B& W Supernatat-30pg DNA 100 4.72 97.1 
EDTA+95% Form Telomeres-30pg 100 5.83 22.48 
B& W Supernatant -30pg DNA 100 5.02 66.72 
NaOAc Telomere-30pg 100 5.02 17.7 
B& W Supernatant -90pg DNA 20 4.06 284.26 
NaOAc Telomere-90pg 20 5.68 17 
TBS Supernatant-300pg DNA 3.33 6.79 152.64 
EDTA+95% Form Telomeres-300pg 3.33 1.26 169.16 
DNA samples after a2 hour cisplatin treatment 
100pM cisplatin- B&W Sup-300pg DNA 3.33 567.19 1177.62 
100pM cisplatin- EDTA+95% Form Telo-300pg DNA 3.33 6.27 263.39 
100pM cisplatin- B&W Sup-30pg DNA 66.67 59.28 83.24 
100pM cisplatin- EDTA+95% Form Telo-30pg DNA 66.67 5.39 17.49 
500pM cisplatin- B&W Sup-30pg DNA 66.67 1100.67 317.53 
500pM cisplatin- EDTA+95% Form Telo-30pg DNA 66.67 6.2 14.16 
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The telomeric preparations were expected to contain only about 14 PPB of P as shown 
by the following estimation: 
13.5 ng telomeric DNA = (13.5 x 10-9/ 300) = 4.5 x 10-11 moles of nt (or P) 
At. mass of P= 32 
Thus the yield of P=4.5 x 10-11 x 32 = 1.44 x 10-9 gP 
If this were dissolved in 0.1 ml water. Wt of water = 0.1 g 
8 Conc P=1.44 x 10- * 0.1 = 14.4 x 10- g per g water = 14 PPB 
Thus the P concentrations of the expected levels of telomeric DNA were similar to the 
lowest concentrations of the background levels in the best of the buffers tested. 
Furthennore there was a high degree of variation in the background levels of P and 
even the water and nitric acid samples gave high background levels of P. This, as 
previously mentioned, is presumably related to the widespread use of phosphate 
buffers and detergents in the biological laboratory where the DNA extraction and 
isolation procedure was carried out. In general, the P levels detennined in the various 
DNA samples did not agree with the expected values. However, since the background 
P levels were too high, attempts were not made to resolve this aspect. Therefore, since 
an accurate measure of DNA concentration was essential as well as an accurate 
measure of Pt concentration, the attempt to directly measure Pt in telomeric DNA was 
ceased. 
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3.3.7 Cisplatin decreases telomerase activity in SHSY5Y ceUs 
Telomerase activity is activated in tumour cells and thus plays an important role in 
maintaining their telomeres at a stable length. Conventionally used anti- cancer drugs 
may induce their cytotoxic effects via the telomere/ telomerase complex and much 
contradictory data exists on the effect of cisplatin treatment on telomerase activity in a 
variety of cell lines. Therefore, telomerase activity was measured by the semi- 
quantitative TRAP PCR ELISA in SHSY5Y cells after a short exposure cisplatin 
treatment after further incubation for 6,24 and 48 hours, at the concentration ranges 
0- 500 ýM as for all previous experiments (Chapter 2). The relative telomerase 
activity was calculated and for each experiment, activities measured in untreated 
control samples were set as 100%. 
A decrease in relative telomerase activity was detected after cisplatin treatment 
(Figure 3.21). This decrease occurred after treatment with the highest cisplatin 
concentrations (i. e. ý! 100 gM) and became significant after 24 hours with a 500 gM 
treatment where > 80% of the cells were apoptotic (See Section 3.2.2) and after 48 
hours for ý! 100 ýtM treatments (Figure 3.21). The statistically significant differences 
towards untreated controls were confinned by one way analysis of variance 
(ANOVA). Treatments with concentrations :! ý 100 ýM displayed a decrease in activity 
levels, though not to a significant degree compared to the untreated controls. 
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Figure 3.21 Telomerase activity in SHSY5Y cells after short exposure to cisplatin. 
Relative telomerase activity was measured using a telomerase PCR ELISA or PCR 
ELISAP"". Data are mean ± SEM from at least four independent experiments. For 
each experiment, activities measured in untreated control samples were set as 100%. 
Statistically significant differences towards untreated controls are marked by an 
asterisk (p<0.05, ANOVA). 
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3.3.8 Response of 1301 cells to cisplatin treatment 
SHSY5Y cells have relatively short telomeres with mean lengths of -4 kbp. As 
sensitivity to cisplatin induced damage could have been proportional to telomere 
length, SHSY5Y telomeres might be rather insensitive to the drug treatments used. 
Moreover, very small changes in average telomere length would have been hard to 
detect. Therefore, to test more rigorously the hypothesis that there was a role for 
telomeres in cisplatin induced growth arrest/ cell death, the tetraploid acute 
lymphoblastic T cell line 1301 was used. 1301 cells have telornere lengths of -80 kbp 
and were exposed to the same conditions of cisplatin treatment as were used for the 
SHSY5Y cells. Initially, the IC50values were calculated for the 1301 cells after 
cisplatin treatment by cell counting for both a short (Figure 3.22 A) and continuous 
exposure (Figure 3.22 B) and resulted in IC50 values of 2 ýM for the short exposure 
and 0.6 ýtM for the continuous exposure. Net growth was detected only for the 
untreated cells after a short exposure treatment, whilst cell growth was observed for 
0.5 ýM after a continuous exposure. 
The kinetics of apoptosis was measured in the 1301 cells, similar to the SHSY5Y cells, 
after a short (Figure 3.23) and continuous (Figure 3.24) exposure to cisplatin. 
Examples of typical dot plots of flow cytometry apoptotic data for 1301 cells exposed 
to cisplatin treatment are shown in panels A. Panels B of the figures show averaged 
data from three separate experiments for percentage of apoptotic cells. 
1301 cells exposed to a short exposure cisplatin treatment exhibited a time and 
concentration dependent induction of apoptosis, with a large increase in apoptotic 
cells at ý! 100 ýM after 24 hours (Figure 3.23). 1301 cells exposed to a continuous 
treatment of cisplatin also displayed a time and concentration dependent induction of 
apoptosis, at concentrations ý: 2 ýM (Figure 3.24). 
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Figure 3.22 Cell numbers of 1301 cells after cisplatin treatment. Cell numbers per 
flask were counted after a short (A) and a continuous (B) exposure to cisplatin for at 
least 48 hours after treatment. Data are mean ± SEM from triplicate experiments. 
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Figure 3.23 Levels of apoptosis after short exposure cisplatin treatment on 1301 
cells. Apoptotic cells were measured by flow cytometry according to their size 
(forward scatter; FSC) and granularity (light scattered sideways; SSQ. (A) Examples Zn 
of gated apoptotic cells R2, to non apoptotic cells RI after cisplatin treatment. Time 
after treatment and concentration of cisplatin indicated. % of apoptotic cells are 
shown in red. (B) % of apoptotic cells after cisplatin treatment average graph. Data 
are mean ± SEM from triplicate experiments with three replicates in each experiment. 
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Figure 3.24 Levels of apoptosis after continuous exposure cisplatin treatment on 
1301 cells. Apoptotic cells were measured by flow cytometry according to their size 
(forward scatter; FSQ and granularity (light scattered sideways; SSQ. (A) Examples 
of gated apoptotic cells R2, to non apoptotic cells RI after cisplatin treatment. Time 
after treatment and concentration of cisplatin indicated. % of apoptotic cells are 
shown in red. (B) % of apoptotic cells after cisplatin treatment average graph. Data 
are mean ± SEM from triplicate experiments with three replicates in each experiment. 
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The 1301 cells in comparison to the SHSY5Y cells showed a slightly higher 
sensitivity after a short exposure treatment to cisplatin (compare to Figures 3.2 and 
3.3), while the effects of a continuous exposure were quantitatively very similar in 
SHSY5Y and 1301 cells (compare to Figures 3.2 and 3.4). 
After short exposures to a range of cisplatin concentrations, the 1301 telomere 
restriction fragment lengths (Figure 3.25 A) showed no visible shortening, despite 
these cells having long telomeres. The average telomere lengths from at least four gels 
(Figure 3.25 B) showed no significant change after any of the cisplatin treatments 
applied. 
Similar to the short exposure treatment, telomere degradation was not apparent after a 
continuous exposure (Figure 3.26) even after induction of apoptosis. 
Denaturing gel electrophoresis exhibited no specific degradation of the G rich 
telomeric strand after either a short (Figure 3.27 A) or continuous (Figure 3.27 B) 
exposure to cisplatin. 
The telomeric single strand G rich overhangs were measured after cisplatin treatment 
for the 1301 cells. Figures 3.28 and 3.29 show typical data of overhang length 
measurements by in-gel hybridisation. Panel A illustrates probed non denatured 
(overhang) and denatured (telomere) gels. Panel B shows the average of three 
independent experiments of the ratio of the intensity signals of the overhang/ 
telomeres after cisplatin treatment. The 1301 cells after short (Figure 3.28) or 
continuous (Figure 3.29) exposure to cisplatin displayed no significant change in 
overhang lengths. 
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Figure 3.25 Telomere restriction fragment lengths after short exposure cisplatin 
treatment on 1301 cells. (A) Telomere gel. Cisplatin concentrations (in ýM) and 
times after onset of treatment (in h) are indicated on top of the figure. White bars tý 
indicate average telomere length. The positions of the size markers (194,97,48.5, 
23.1 kbp) are shown by black bars. (B) Average telomere length. Gels were 
normalised to a standard and average fragment lengths of at least four experiments 4: ) tý 
were calculated. Data are ± SEM. 
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Figure 3.26 Telomere restriction fragment lengths after continuous exposure 
cisplatin treatment on 1301 cells. (A) Telornere gel. Cisplatin concentrations (in ýtM) 
and times after onset of treatment (in h) are indicated on top of the figure. White bars t) 
indicate average telomere length. The positions of the size markers (194,97,48.5, 
23.1 kbp) are shown by black bars. (B) Average telomere length. Gels were 4D 
normalised to a standard and average fragment lencyths of at least four experiments 
were calculated. Data are ± SEM. 
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Figure 3.27 Denaturing gels to detect G rich telomeric strand breaks after 
cisplatin treatment on 1301 cells. Examples of denaturing gel after short (A) and 
continuous (B) cisplatin treatment. Cisplatin concentrations (in ýM) and times after 
onset of treatment (in h) are indicated on top of the figures. 
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Figure 3.28 Telomeric G- rich overhangs in 1301 cells after short exposure 
cisplatin treatment. The overhang length is measured as the ratio of hybridisation 
intensities to the overhang alone vs whole telomere. (A) Example of an overhang and Cý 
telomere gel. The position of the size markers (194,97,48.5,23.1 kbp) are shown by 
black bars. M= markers. White bar indicates average telomere length. (B) Graph 
showing ratios. Data are mean ± SEM from at least three experiments. 
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Figure 3.29 Telomeric G- rich overhangs in 1301 cells after continuous exposure 
cisplatin treatment. The overhang length is measured as the ratio of hybridisation 
intensities to the overhancy alone vs whole telomere. (A) Example of an overhang and Cý t:, 
telomere gel. The position of the size markers (194,97,48.5,2-3). 1 kbp) are indicated. 
M= markers. White bar indicates average telomere length. (B) Graph showing ratios. Z: ) 
Data are mean ± SEM from at least three experiments. 
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3.3.9 DNA damage foci are not localised at the telomeres after cisplatin 
treatment 
Cisplatin treatment induces delayed strand breakage and a DNA damage response in 
the fonn of histone H2A. X phosphorylation as confirmed in Section 3.2.3. In order to 
determine whether foci of histone H2A. X phosphorylation induced in response to 
cisplatin occurs preferentially on telomeres, an immunoFISH procedure was 
developed and applied to drug treated 1301 cells. This procedure assesses y- H2A. X 
DNA damage foci by immunohistochernistry and telorneric DNA by FISH in the 
same individual cells. As the FISH procedure requires a PNA probe to bind to the 
telomeric DNA, the 1301 cells with telomere lengths of greater than 80 kbp it seemed 
likely that they would have be an easier target and more clearly visible compared to 
the SHY5Y cells which have telornere lengths of less than 5 kbp. Therefore the 1301 
cells were used to detect whether the DNA strand breaks induced by cisplatin localise 
at telomeric DNA. 
14 hours after a7 gM short exposure cisplatin treatment (Figure 3.30), 1301 cells 
were fixed and stained with y- H2A. X, telomere PNA probe and DAPI nuclear stain. 
DNA damage foci were clearly present after cisplatin treatment and telomeric DNA 
was also detectable. Merged images display that the majority of DNA damage foci do 
not colocalise to the telomeric DNA (ý! 7 cells out of 10 in triplicate fields in three 
independent experiments). 
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y-H2A. X MERGED 
Figure 3.30 DNA damage foci do not colocalise with telomeres after a short 
exposure cisplatin treatment. 130 1 cells were fixed 14 hours after a4 hour treatment 
with 7 ýM cisplatin and stained as specified. The merged images show lack of 
colocalisation between DNA damage foci and telomeres. x 100 objective 
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3.4 Discussion 
As discussed in Chapter 1, there is much evidence to suggest a link between the 
interaction of DNA damaging drugs and telomeres. More specifically, there are 
indications to suggest a relationship between cisplatin and telomeres (Grimaldi et aL, 
1994). A DNA repair yeast mutant exhibited a gradual shortening of the telomere in 
the presence of cisplatin (Ishii et al., 2000). In human hepatoma cells (Zhang et al., 
2002) and HeLa cells (Ishibashi and Lippard, 1998) telomeres shortened after 
cisplatin treatment. Though long term cultivation of colorectal cancer cells with 
cisplatin led to telomere elongation at the same time as the cultures became drug 
resistant (Kuranaga et al., 2001). Additionally, cisplatin treatment led to a reduction in 
telomerase activity in some cell lines like human testicular tumour cells (Burger et al., 
1997). Other studies established that this decline in telomerase activity was a 
consequence of apoptosis (Akiyama et al., 1999; Cressey et al., 2002). Therefore the 
aim of the study described here was to investigate the effects of cisplatin on the 
telomere/ telomerase complex and determine whether telomeres have a role in 
cisplatin mediated cell death. 
As expected (see Chapter 1), cisplatin did not induce DNA strand breakage 
immediately after drug exposure but strand breaks and DNA damage foci were 
detected 14 hours after treatment. The H2A. X phosphorylation and strand breaks 
detected in cisplatin treated cells over time was probably associated with DNA repair. 
This has been suggested by Huang and colleagues who have reported H2A. X 
phosphorylation after cisplatin exposure (Huang et al., 2004). Evidently, cisplatin- 
induced cross-links do not induce DNA damage foci formation by itself However, 
strand breaks and y-H2A. X foci are found later, indicating that they are the result of 
processing of the original lesions. 
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The experiments described in this chapter included an assessment of the effect of 
cisplatin exposure on total telomere length and also on the length of the single- 
stranded telomeric overhangs. A wide range of drug concentrations, decided by the 
IC50 values were employed for both short and continuous drug exposures. For samples 
taken at various times after this wide range of conditions, no evidence was found for 
an effect of cisplatin on telomere length or integrity. This contrasts with the 
publication by Ishibashi and colleague (Ishibashi and Lippard, 1998) who reported 
telomere length reduction in cells exposed to cisplatin and attributed the reduction of 
length to replication blocking. Another study showed a decrease of telomeres in BEL- 
7404 human hepatoma cells, whereby the telomere shortening in cisplatin treated cells 
was independent of time or dose and did not correlate with the induction of apoptosis 
(Zhang et al., 2002). The discrepancy in the results could be due to the difference in 
cell lines examined and/ or experimental protocols and any changes may be dependent 
on initial telomere length. A particularly relevant difference between the cell lines was 
their telomere lengths which averaged 20 kbp for the HeLa cells used by Ishibashi and 
Lippard (1998) and -4.2 kbp for the BEL-7404 cells used by Zhang et al (2002). The 
SHSY5Y cells used here showed an average telomere fragment length of -4 kbp. 
Therefore, we examined further an acute lymphoblastic T cell line, 1301, with 
telomere lengths of -80 kbp to discriminate between any discrepancies in cells with 
either long or short telomeres. Again, like the SHSY5Y cells, the 1301 cells showed 
that apoptosis induction by cisplatin treatment was not telomere dependent. 
There are conflicting data on the relationship between effects of cisplatin and changes 
in telornerase activity. Telornerase inhibition has been shown in testicular turnour 
cells after cisplatin treatment, whereby cisplatin effected gene transcription by 
decreasing the hTR expression (Burger et al., 1997). Akeshima and colleagues 
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demonstrated that hTERT expression did not change with time after cisplatin 
treatment in ovarian cancer cells (Akeshima et al., 2001). Whilst another study found 
an inhibition of telomerase activity after cisplatin treatment in BEL-7404 human 
hepatoma (Zhang et al., 2002). This occurred with no changes in expression level of 
hTR or hTERT mRNA but with a change in cell growth (Zhang et al., 2002), in 
accordance with others (Faraoni et al., 1997). However, in testicular teratoma and 
haernatopoietic cell lines the decline in telornerase activity following cisplatin 
treatment was shown to be a consequence of, rather than a cause for, apoptosis 
(Akiyama et al., 1999; Cressey et al., 2002). Though others did not see an inhibition 
of telomerase activity after cisplatin treatment in human nasopharyngeal cells (Ku et 
aL, 1997) and there has been a report of an increase in hTERT mRNA and protein 
during cisplatin treatment (Lin et al., 2001). Therefore, telomerase activity was 
examined after a short exposure cisplatin treatment. In the SHSY5Y cells the 
telomerase activity levels decreased significantly only where the highest 
concentrations of cisplatin were used. Comparison of data on apoptosis induction 
(Figure 3.3) with data on telomerase activity (Figure 3.21) shows that loss of 
telomerase activity only occurred after the majority of cells were in apoptosis, in 
accordance with others (Akiyama et al., 1999; Cressey et al., 2002). These findings 
indicate that down regulation of telomerase activity appears to be a consequence and 
not a possible cause of cisplatin induced apoptosis or growth arrest. 
Dysfunctional telomeres trigger growth arrest and/ or apoptosis via telomere-specific 
induction of DNA damage foci, also termed senescence-associated DNA damage foci 
(d'Adda di Fagagna et al., 2003). Therefore, DNA damage foci were assessed after 
cisplatin treatment on the telomeric DNA. DNA damage foci did not colocalise to 
telomeric DNA in the 1301 cells after a short exposure treatment. 
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3.5 Conclusions 
In conclusion, the data presented here show the characterisation of the response to a 
short exposure and continuous cisplatin treatment as a combination of S phase arrest 
and apoptosis in high concentration cisplatin treated cells and no indication for a 
specific role of telomeric damage in the execution of this response. Therefore we find 
no indication that telomeres and/ or telomeric damage play any preferential role as 
signal transducers. This is in disagreement with another study which has led to the 
proposal that telomeric damage plays a particularly important role in the cytotoxic 
effects of cisplatin (Ishibashi and Lippard, 1998). The study described here reveals 
that the telomere/ telornerase complex is not involved in cisplatin induced apoptosis. 
Rather, our data suggest that DNA strand breaks elsewhere in the genome, occurring 
as a result of attempted repair induce DNA damage foci formation leading to 
apoptosis and/ or cell cycle arrest. 
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CHAPTER FOUR 
THE ROLE OF TELOMERES IN ETOPOSIDE INDUCED 
TUMOUR CELL DEATH 
4.1 Introduction 
Topoisomerase 11 enzymes (Gellert, 1976) break double strands of DNA and induce 
topological changes in DNA (Wang et al., 1996). Etoposide, a topoisomerase 11 
poison, stabilises the cleavable complexes formed by topoisomerases, converting 
them into physiological toxins that take the fonn of protein associated breaks in the 
genome of treated cells (Kaufinann et al., 1998). This effect is reversible and 
etoposide has a short elimination half life (Hsiang and Liu, 1989). Levels of 
topoisomerase 11 are generally elevated in cells that are undergoing rapid proliferation 
and due to the mechanism of drug action, the higher the physiological concentration 
of topoisomerase 11, the more lethal the poison becomes. 
Human telomeres, the specialised DNA-protein structures on the end region of 
chromosomes, are composed of the repeat sequence TTAGGG. Evidence indicates 
that their shortening with each round of DNA replication is caused by several 
mechanisms, one of these being their sensitivity to DNA damage. Thus, telomere 
shortening can greatly be accelerated or decelerated by controlling oxidative stress 
within the cells (von Zglinicki et al., 2002). Telomeres end in single stranded 
overhangs of the G-rich strand, which appear to be essential for telomeric higher order 
structure (Griffith et al., 1999) and possibly for the generation of DNA damage 
signals from telomeres (Stewart et al., 2003; Saretzki et al., 1999; von Zglinicki, 
2000). In the vast majority of cancer cells, telomere shortening is counteracted by 
telomerase (Greider et al., 1987; 1989). Inhibition of telomerase by different methods 
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has been shown to lead not only to progressive telomere shortening and ensuing cell 
death (Herbert et al., 1999) but also to telomere length independent apoptosIs 
induction (Saretzki et al., 2001). 
Etoposide has been shown to generate topoisomerase-DNA cleavable sites in 
telomeres in vitro and in vivo (Yoon et al., 1998). Contradictory data exists on the 
interaction between etoposide and telornerase. Upregulation of telomerase activity 
was observed in the human leukemic cell line HL60 (Moriarty et al., 2002; Klapper et 
al., 2003) and a number of pancreatic tumour cell lines after etoposide treatment (Sato 
et al., 2000). However a decrease in telomerase activity was observed in 
hepatocarcinomas and other leukemic cell lines (Li et al., 2002) and no change in 
levels of telornerase in haernatopoietic (Akiyarna et al., 1999) and nasopharyngeal 
carcinoma cells (Ku et al., 1997). Though the decline in telomerase activity following 
DNA damaging drug treatments was shown to be a consequence of, rather than a 
cause for, apoptosis (Akiyama et al., 1999; Cressey et al., 2002). There is evidence 
that inhibition of telornerase sensitises cells to topoisomerase II poisons including 
etoposide (Ludwig et al., 2001; Misawa et al., 2002) and that overexpression of the 
catalytic subunit of telornerase (hTERT) in cells that also expressed the telomerase 
template RNA (M) led to an increased resistance against etoposide (Ludwig et al., 
2001; Zhang et al., 2003). Conversely, others could not confinn a telomerase 
dependency of the sensitivity of various tumour cells to etoposide (Chen et al., 2003; 
Folini et al., 2000). 
Given these inconsistent results, the aim of the work presented in this chapter was to 
test the hypothesis that a role exists for the telomere/ telomerase complex in etoposide 
induced cell death. Neither telomere length, telomere strand break frequency, or 
length of G-rich telomeric single-stranded overhangs changed in etoposide treated 
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cells before onset of apoptosis. Overall the results indicate that telomeres are not 
directly involved in the signalling pathway to etoposide induced turnour cell growth 
arrest or apoptosis. 
4.2 Methods 
All methods used in this study are described in Chapter 2. 
4.3 Results 
4.3.1 Growth inhibition effect of etoposide 
It was important to establish the relationship between etoposide exposure and growth 
inhibitory effects as a basis for experiments on mechanism of action. The cytotoxicty 
levels of etoposide on the SHSY5Y and 1301 cells were unknown, therefore initially 
cells were exposed to a broad range of drug concentrations and the IC5o values were 
measured by the SRB assay and/ or cell counting after etoposide treatment. 
Growth curve data for the SHSY5Y cells were used to determine the optimal 
inoculum density for the SRB assay (see Figure 3.1 A). The cytotoxicty levels of 
etoposide on the SHSY5Y cells were then examined by exposing cells to a short (4 
hour) exposure treatment and incubating for a further 6 days before fixing and 
staining with the SRB reagents (Section 2.5). The control cells (untreated) optical 
density (OD) was set at 100%. The OD of the treated cells were converted into 
percentages of the control and plotted against etoposide concentration (see Figure 3.1 
B for example of a typical graph after a drug treatment), producing an IC50value of 
7.1 gM. 
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In independent cell count experinlents the IC50 values were detennined by cell 
counting for both a short (48 hours after treatment) and continuous (72 hours after 
treatment) exposure for both the SHSY5Y and 1301 cells. The mean results from 3 
separate cell count experiments are shown in Table 4.1. The IC50 values suggest the 
1301 cells are more sensitive to etoposide exposure for both a short and continuous 
treatment compared to the SHSY5Y cells. 
For all subsequent etoposide experiments, cells were exposed to either a short 
treatment, which lasted for 4 hours then further incubation for up to 48 hours or a 
continuous treatment for up to 72 hours. These two regimens used the concentration 
ranges 0,3,7,15,100 and 350 ýM for the short treatment and 0,0.25,0.5ý 11 2 and 5 
ýLM for the continuous treatment. 
Table 4.1 Growth inhibitory concentrations (IC50) after etoposide treatment 
assessed by cell counting 
IC50 Values Expos re/ pM 
Cell Lines Short Continuous 
SHSY5Y 56.1 1.4 
1301 16.4 0.6 
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Changes in cell number with time after exposure to various etoposide concentrations 
are shown in Figure 4.1 (short exposure) and Figure 4.2 (continuous exposure). For 
the SHSY5Y cells (Figure 4.1 A), cell growth occurred for treatments :! ý 15 ýM over 
the 48 hour time course similar to the untreated cells in a time and concentration 
dependent manner. Whereas concentrations ý: 100 ýM displayed no increase in cell 
number after exposure for the whole 48 hour period. The 1301 cells (Figure 4.1 B) 
exhibited a similar relationship after short exposure etoposide treatment, with net 
growth for treatments of :!! ý 15 ýM and arrest with concentrations ý! 100 ýM. 
Cell numbers after a continuous exposure for both cell lines (Figure 4.2) showed a 
similar time and concentration dependent pattern. For the SHSY5Y cells (Figure 4.2 
A) an increase in cell growth arose at concentrations :! ý 0.5 ýM, though for the 1301 
cells (Figure 4.2 B) an increase in growth occurred only at a 0.25 gM exposure. 
In conclusion, the relationships between etoposide concentration and growth 
inhibition have been defined for short and continuous exposure treatments. 
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Figure 4.1 Cell numbers of SHSY5Y and 1301 cells after a short exposure 
etoposide treatment. SHSY5Y (A) and 1301 (B) cells were exposed to etoposide for 
4 hours and cell numbers per flask were counted 4- 48 hours after. Data are mean + 
SEM from triplicate experiments. 
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Figure 4.2 Cell numbers of SHSY5Y and 1301 cells after a continuous exposure 
'01 (B) cells were exposed to etoposide etoposide treatment. SHSY5Y (A) and 1-1 
continuously and cell numbers per flask were counted 24- 72 hours after. Data are 
mean ± SEM from triplicate experiments. 
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4.3.2 Etoposide induces apoptosis 
Cells exposed to cytotoxic drugs, under many circumstances undergo apoptosis. It 
was relevant to detennine the proportion of cells with apoptotic features induced by 
etoposide exposure and also how soon after treatment apoptotic cells appeared. As 
discussed in Section 3.2.2 apoptosis was detected by flow cytometry in which 
apoptotic cells were detected on the basis of their size and granularity. , K- 
Examples of dot plots of flow cytometry data for SHSY5Y and 1301 cells exposed to 
a short exposure etoposide treatment are shown in panels A of Figure 4.3 and 4.4. 
Panels B of Figure 4.3 and 4.4 show averaged data from 3 separate experiments for 
percentage of apoptotic cells. SHSY5Y cells not exposed to drug showed an increased 
frequency of apoptotic cells by 72 hours, thought to be due to confluency of the cells. 
Both SHSY5Y and 1301 cultures exposed to etoposide at 100 RM and 350 [tM 
showed clear increases in apoptotic cells by 24 hours, with further increases at later 
time points. Exposure of SHSY5Y cultures to concentrations of 15 ýtM or below 
caused not more than a slight increase in frequency of apoptotic cells above control 
and that only after a 48 hour incubation period (Figure 4.3). Following exposure to a 
concentration of drug of 15 gM or lower, no increase in apoptosis was seen in cultures 
of 1301 cells even at 48 hours (Figure 4.4). From both the scatter dot plots and the 
average graphs, it can be distinguished that 48 hours after a short exposure treatment, 
1301 cells had higher levels of apoptosis (74%) compared to the SHSY5Y cells (64%). 
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Figure 4.3 Levels of apoptosis after short exposure etoposide treatment on 
SHSY5Y cells. Apoptotic cells were measured by flow cytometry according to their 
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average graph. Data are mean ± SEM from triplicate experiments with three replicates 
in each experiment. 
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Data for cells exposed continuously to a lower range of etoposide concentrations are 
shown in Figures 4.5 and 4.6. Apoptosis was induced at concentrations above I ýM in 
SHSY5Y cells. The 1301 cells after a continuous exposure exhibited a different 
behaviour in tenns of the induction of apoptosis (Figure 4.6). The proportion of 
apoptotic cells only increased after the highest concentration (5 ýM) treatment despite 
a significant inhibition of net growth (Table 4.1). In fact the majority of non- 
apoptotic cells were growth arrested at 2 days after the onset of treatments. Again like 
the SHSY5Y cells, the highest levels of apoptosis were after a5 ýM 72 hour 
treatment though this time with a much lower level of apoptosis present. 
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Figure 4.5 Levels of apoptosis after continuous exposure etoposide treatment on 
SHSY5Y cells. Apoptotic cells were measured by flow cytometry according to their 
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apoptotic cells are shown in red. (B) % of apoptotic cells after etoposide treatment 
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4.3.3 Etoposide causes S phase arrest with features of senescence 
In order to understand the effect of etoposide on the cells it was important to compare 
cellular responses to the drug exposures. An important aspect of this is the effect of 
etoposide on cell cycle progression. Initially the kinetics of cell cycle were measured 
using flow cytometry. Measurement of the cellular DNA content in SHSY5Y cells 
after a short exposure treatment revealed significant increases of the fraction of cells 
with an S phase DNA content after 48 hours (Figure 4.7 A). Figure 4.7 A illustrates 
typical examples of the cell cycle DNA histograms which were obtained after a4 hour 
exposure. If the ratio of S/ G, phase cells are calculated from the percentages of cells 
in each stage of the cell cycle it can be clearly observed that after all concentrations of 
etoposide treatment compared to the untreated control there appears to be a high ratio 
of S/ G, phase cells after 48 hours (Figure 4.7 B). The percentage of SHSY5Y cells in 
each stage of the cell cycle (Figure 4.8) also indicated a slight increase of cells in S 
phase (Figure 4.8 B), with a minor decrease in G, phase (Figure 4.8 A) after short 
exposure etoposide treatment compared to untreated cells. 
Cell cycle analysis of the SHSY5Y cells after a continuous exposure (Figure 4.9) to 
etoposide did not show the same pattern of DNA content as the short exposure 
treatment. From the histograms and the graph examining the ratio of S/ G, phase cells 
after continuous treatment (Figure 4.9 B), no significant change can be detected from 
the treated cells compared to the untreated. This was visible if the percentage of 
SHSY5Y cells in each stage of the cell cycle are assessed individually (Figure 4.10). 
The fall in S/ G, ratio between 4- 24 hours after short exposure treatment (Figure 4.7 
B) could be a result of changing medium as this decrease was not detected after 
continuous exposure (Figure 4.9 B). 
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Figure 4.8 Stages of SHSY5Y cells in the cell cycle after a four hour exposure to 
etoposide. Percentage of cells in GI (blue), S (purple) and G2 (yellow) phase 4 hours 4: ) 
(A), 24 hours (B) and 48 hours (C) after a4 hour etoposide treatment at the indicated 
etoposide concentrations, assessed by flow cytometry. Data are mean ± SEM from 
triplicate experiments with three replicates in each experiment. 
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Figure 4.10 Stages of SHSY5Y cells in the cell cycle after a continuous exposure 
to etoposide. Percentage of cells in G, (blue), S (purple) and G2 (yellow) phase 24 
hours (A), 48 hours (B) and 72 hours (C) after continuous etoposide treatment at the 
indicated etoposide concentrations, assessed by flow cytometry. Data are mean + 
SEM from triplicate experiments with three replicates in each experiment. 
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As the cells after 48 hours after a short exposure etoposide treatment appeared to have 
a higher percentage of cells in S phase compared to the untreated control, BrdU 
incorporation was examined to identify whether the cells that were in S phase were 
proliferating or growth arrested (Figure 4.11). For the BrdU incorporation cells were 
treated with 0 [tM and 3 gM etoposide for 4 hours and then incubated for a further 48 
hours and BrdU was added for I hour after treatment was complete. Figure 4.11 A 
shows the FITC labelled anti- BrdU fluorescence whilst Figure 4.11 B identifies the 
DNA content of the cells after the treatments. BrdU is distinctly incorporated in the 
untreated cells (compare to 0 gM IgG) as expected. Though 48 hours after a3 gM 
exposure BrdU was not incorporated suggesting that cells were arrested in S phase. 
Cells which were treated with a short exposure etoposide treatment were assessed to 
see whether they had a senescence-like phenotype (See Section 1.7). Senescence is 
associated with the activity of beta galactosidase at pH 6. SHSY5Y cells were 
exposed to 3 ýM etoposide treatment for 4 hours and after a further 48 hours were 
stained for P galactosidase activity (Figure 4.12). MRC5 cells undergoing telomere- 
dependent senescence were used as a positive control. The results showed detectable 
stains in the control and drug treated SHSY5Y cells and therefore evidence of 
senescence. 
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Figure 4.11 BrdU incorporation of short exposure treated SHSY5Y cells. 
Scattergrams of cells treated for 4 hours with either 3 ýM etoposide or untreated (A) tn 
were assessed after 48 hours. FITC labelled anti- BrdU fluorescence is measured in 
FLI and DNA content is measured in FL-3). Cell cycle phase positions GI, S, G2/ M 
are indicated at the x- axis and in the corresponding, DAPI stained DNA content 
histograms (B). 
180 
50 100 150 200 250 
FL3 
50 100 150 200 250 
FL3 
Chapter 4 
MRC5 
senescent cells 
0 
SHSY5Y 
0 ILM 
SHSY5Y 
3 ILM 
ol 
" '. ýA . OW 
I 
i" »1/ 
i 
 
Figure 4.12 Senescence Associated -P galactosidase (SA- P gal) of SHSY5Y cells 
after a short exposure etoposide treatment. SHSY5Y cells were stained at 48 hours 
after a4 hour treatment with -3) ýM etoposide or untreated. 
Etoposide treated cells 
stained positive for SA- P gal. As a positive control MRC5 senescent fibroblasts were 
stained with P gal. 
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4.3.4 Etoposide triggers a DNA damage response 
Etoposide induces stabilisation of topoisomerase 11 cleavable complexes and their 
associated double and single DNA strand breaks. Results described in Section 4.3.2 
indicate that exposure of cells to a wide range of concentrations of etoposide resulted 
in apoptosis. In order to confinn that under the conditions in this work general 
damage to the overall genome is induced by etoposide, DNA strand breaks and the 
DNA damage response was investigated by the FADU assay and an antibody 
recognising the phosphorylated fonn of histone H2A. X (y-H2A. X) respectively. 
FADU measurements confirmed the expected concentration dependent rise of DNA 
strand breaks immediately after a4 hour treatment in both SHSY5Y cells (Figure 4.13 
A) and 1301 cells (Figure 4.13 B), which correlates well with the observed 
frequencies of apoptotic cells after short term treatment (Figures 4.3 and 4.4). 
The 1301 cells religated strand breaks more efficiently, resulting in significantly less 
breaks remaining after a further 4 hour incubation (compare Figure 4.13 A and 4.13 
B), which might be related to the ability of 1301 cells to redirect their response to low 
etoposide concentrations from apoptosis towards growth arrest. The significance of 
religation capacity was confinned by paired t-tests. The SHSY5Y cells show 
significant religation effects only after 350 gM short etoposide exposure, whilst the 
1301 cells show a significant religation effect at concentrations ý! 15 gM. 
After a 15 ýM short exposure to etoposide, cells were fixed 24 hours later and stained 
with a DAPI nuclear stain and an antibody against y-H2A. X (Figure 4.14) to examine 
the DNA damage response. DNA damage foci were clearly evident in the majority of 
the cells after 24 hours after a short treatment with as low as 15 ýtM etoposide. 
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Figure 4.13 Measurement of DNA strand breaks in etoposide treated cells. DNA 
strand breaks were measured by FADU after a4 hour etoposide treatment (blue bars) 
and after a further 4 hours recovery time allowing for religation of cleavable 
complexes (purple bars) in SHSY5Y (A) and 1301 (B) cells. Data are mean ± SEM 
from six parallel measurements. Significant repair effects are denoted by an asterisk 
(p < 0.05, paired t-test). 
1 
37 15 100 350 
Etoposide concentration (pM) 
Chapter 4 
DAPI 
y-H2A. X 
MERGED 
Figure 4.14 DNA damage response in etoposide treated SHSY5Y cells. Cells were 
fixed at 24 hours after a4 hour treatment with 15 ýLM etoposide and stained with an 
antibody against the phosphorylated form of H2A. X (7-H2A. X) and DAPI nuclear Z-: ) 
stain. x 40 objective 
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4.3.5 Etoposide does not influence telomere length 
The main hypothesis being tested in this chapter was that the cytotoxic effects of 
etoposide induce growth arrest/ apoptosis via the telomere/ telomerase complex. 
Topoisomerase 11 cleavable complexes in telomeres would cause DNA double strand 
breaks and hence directly lead to shortening of telorneres. 
The aim of the following experiments was to determine telomere lengths using an in- 
gel hybridisation technique at various times after exposure of cells to etoposide and to 
find out whether etoposide induced growth arrest/ apoptosis was preceded or 
accompanied by telomere shortening. 
The SHSY5Y cells have telornere lengths of -4 kbp while the 1301 cells have 
telomere lengths of -80 kbp. The cell lines were chosen for this investigation, due to 
the large difference in the telomere lengths, as any changes that may occur may not be 
detectable in SHSY5Y cells with the shorter telomeres, though more pronounced in 
the 1301 cells with longer telomeres. 
Cells were exposed to etoposide for either 4 hours (0,3,7,15,100 and 350 RM) or 
continuously (0,0.25,0.5,1,2,5 ýM). At 4,24 and 48 hours after short exposure and 
24,48 and 72 hours after continuous exposure mean telomere restriction fragment 
lengths were measured. 
Figures 4.14 to 4.18 show typical data. Panel A illustrates images of ethidium 
bromide fluorescence from electrophoresis gels to indicate distribution of total 
cellular DNA and MW markers. The intensity signal was proportional to the amount 
of DNA loaded, which was kept constant throughout. 
Panel B demonstrates the telomere restriction fragment length gel. The calculated 
average telomere lengths are superimposed as white bars. Panel C shows the average 
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of at least three separate determinations of mean telomere length plotted against time 
after exposure to a range of etoposide concentrations. 
SHSY5Y cells exposed to etoposide for 4 hours (Figure 4.15) or continuously (Figure 
4.17) show no significant change in telomere length at any concentrations or time 
points. 1301 cells exposed to etoposide for 4 hours (Figure 4.16) or continuously 
(Figure 4.18) also showed no changes to the length of telomeres following exposure 
to any of the drug concentrations used. Measurement of telomere length at times up to 
48 hours after exposure revealed no drug induced changes in telomeric restriction 
fragment lengths. This indicates that topoisomerase 11 cleavable complexes were not 
present in the telomere terminal repeat at a level sufficiently high to significantly 
reduce telomere length directly as a result of inherent double strand breaks. This is 
particularly relevant for the highest concentrations where the acute level of cleavable 
complexes is expected to be considerable. At the lower drug concentrations, telomere 
shortening might be expected as consequence of stalled DNA replication forks or 
other mechanisms. 
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Figure 4.15 Telomere restriction fragment lengths after short exposure etoposide 
treatment on SHSY5Y cells. (A) Ethidium bromide fluorescence of genomic DNA. 
(B) Telomere gel. Etoposide concentrations (in ýM) and times after onset of treatment C) 
(in h) are indicated on top of the figure. White bars indicate average telomere length. 
The positions of the size markers (2-3 3.1,4.3 3 6,2.32,2 - 0-3 ) 
kbp) are shown by black bars. 
(C) Average telomere lencyth. Gels were normalised to a standard and average 4: ) ýn 
fragment lengths of at least four experiments were calculated. Data are ± SEM. 
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Figure 4.16 Telomere restriction fragment lengths after short exposure etoposide 
treatment on 1301 cells. (A) Ethidium bromide fluorescence of genomic DNA. (B) 
Telomere gel. Etoposide concentrations (in gM) and times after onset of treatment (in 
h) are indicated on top of the figure. White bars indicate average telomere length. The 
positions of the size markers 194,97,48.5,23.1 kbp) are shown by black bars. (C) 
Average telomere length. Gels were normalised to a standard and average fragment 
lengths of at least four experiments were calculated. Data are ± SEM. 
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Figure 4.17 Telomere restriction fragment lengths after continuous exposure 
etoposide treatment on SHSY5Y cells. (A) Ethidium bromide fluorescence of 
genomic DNA. (B) Telomere gel. Etoposide concentrations (in ýM) and times after 
onset of treatment (in h) are indicated on top of the figure. White bars indicate 
average telomere length. The positions of the size markers (23.1,4.36,2.32,2.0-3) kbp) 
are specified. (C) Average telomere length. Gels were normalised to a standard and 
average fragment lengths of four experiments were calculated. Data are ± SEM. 4-: ) 4D Z: ) 
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Figure 4.18 Telomere restriction fragment lengths after continuous exposure 
etoposide treatment on 1301 cells. (A) Ethidium. bromide fluorescence of genomic 
DNA. (B) Telomere gel. Etoposide concentrations (in ýM) and times after onset of 4D 
treatment (in h) are indicated on top of the figure. White bars indicate average 
telomere length. The positions of the size markers (194,97,48.5,23.1 kbp) are 
specified. (C) Average telomere length. Gels were normalised to a standard and 
average fragment lengths of four experiments were calculated. Data are ± SEM. 
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4.3.6 Etoposide does not influence the length of telomeric single stranded 
G-rich overhangs 
Telomeric single stranded overhangs have been implicated in telomere structural 
maintenance (Griffith et al., 1999) and generation of a DNA damage/ growth arrest 
response (Stewart et al., 2003; Saretzki et al., 1999; von Zg1inicki et al., 2001). In 
order to test whether etoposide treatment might interfere with the integrity of the 
overhangs, the effect of exposure to etoposide on the length of the overhangs was 
examined by measuring the relative hybridisation signal intensity of overhangs alone 
against whole telorneres (Keys et al., 2004). 
Figures 4.19- 4.22 show typical data. Panel A illustrates probed non denatured 
(overhang) and denatured (telomere) gels. Panel B shows the average graph of three 
independent experiments of the ratio of the intensity signals of the overhang/ 
telomeres after etoposide treatment on each type of analysis. 
SHSY5Y and 1301 cells exposed to etoposide for 4 hours or continuously show no 
significant change in overhang lengths at any concentrations or time points. Even at 
high concentrations for as long as 48 hours after treatment no degradation of the 
single stranded G- rich telomeric overhang occurred. 
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Figure 4.19 Telomeric G-rich overhangs in SHSY5Y cells after short exposure to 
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Figure 4.20 Telomeric G-rich overhangs in 1301 cells after short exposure to 
etoposide. The overhang length is measured as the ratio of hybridisation intensities to 
the overhang alone vs whole telomere. (A) Example of an overhang and telomere gel. Z: ) 
The position of the size markers (194,97,48.5,23.1) kbp are shown by black bars. M 
=: markers. White bar indicates average telomere length. (B) Graph showing ratios. 
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Figure 4.21 Telomeric G-rich overhangs in SHSY5Y cells after continuous 
exposure to etoposide. The overhang length is measured as the ratio of hybridisation 
intensities to the overhang alone vs whole telomere. (A) Example of an overhang and 
telomere gel. The position of the size markers (23 ). 1,4.36,2.32,2.03 kbp) are shown 4n 
by black bars. M= markers. White bars indicate average telomere length. (B) Graph 
showing ratios. Data are mean ± SEM from four experiments. 
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4.3.7 Etoposide does not induce single strand breaks in the G rich 
telomeric strand 
The G rich telomeric strand has been suggested to be preferentially targeted by DNA 
damaging drugs due to its partial composition of guanine residues. For example it was 
determined that the topoisomerase 11 cleavage sites occurred in telomeric DNA 5" 
TTAGG*G 3' when etoposide was present (Yoon et al., 1998). Additionally, it has 
been suggested that not only telomere shortening, but also an abundance of DNA 
single strand breaks in telomeres could lead to opening of the t-loop and uncapping of 
telomeres (von Zglinicki, 2001). Therefore, the G rich telomeric strand was separately 
analysed for the presence of strand breaks using denaturing alkaline gel 
electrophoresis. 
Typical results for SHSY5Y and 1301 cells exposed to etoposide for 4 hours are 
shown in Figure 4.23. After a short exposure etoposide treatment on the SHSY5Y 
cells (Figure 4.23 A), there was no evidence of single stranded DNA breaks on the 
telomeric G rich strand. This was also the case for the 1301 cells after short exposure 
treatment (Figure 4.23 B). 
A continuous exposure of the SHSY5Y and 1301 cells to etoposide at all time points 
and concentrations again showed no detectable G rich strand breaks (Figure 4.24). 
Under a wide variety of drug exposures and incubation times, the mean length of G 
rich strand of terminal repeat fragments remained unchanged. The results indicate that 
even following very high concentrations of etoposide, no detectable single strand 
breaks were present in the G rich telomeric strand. 
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Figure 4.23 Denaturing gel to detect G rich telomeric strand breaks after short 
exposure etoposide treatment. Examples of gels, SHSY5Y (A) and 1301 (B) cells. 
Etoposide concentrations (in ýM) and times after onset of treatment (in h) are 
indicated on top of the figures. 
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Figure 4.24 Denaturing gel to detect G rich telomeric strand breaks after 
continuous exposure etoposide treatment. Examples of gels, SHSY5Y (A) and 
1301 (B) cells. Etoposide concentrations (in ýM) and times after onset of treatment 
(in h) are indicated on top of the figures. 
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4.3.8 Etoposide decreases telomerase activity only after onset of apoptosis 
Telomerase is activated in tumour cells and thus plays an important role in 
maintaining their telomeres at a stable length. Conventionally used anti-cancer drugs 
may induce their cytotoxic effects via the telomere/ telomerase complex and much 
contradictory data exists on the effect of etoposide treatment on telomerase activity in 
a variety of cell lines. Therefore telomerase activity was examined after a continuous 
exposure to etoposide on the SHSY5Y cells by the semi-quantitative TRAP PCR 
ELISA. 
An increase in telomerase activity was found in the SHSY5Y cells treated for 48 
hours with low concentrations of etoposide, which was significant for the treatment 
with 0.25 ýM (Figure 4.25). The statistically significant differences compared to 
untreated controls were confirmed by one way analysis of variance (ANOVA). At the 
same time, a significant decrease in telomerase activity became apparent 48 hours 
after treatment with 5 ýtM etoposide, the highest concentration tested. 72 hours after a 
continuous treatment with etoposide in concentrations at or above 2 gM telomerase 
activity significantly decreased as well (Figure 4.25). At these time points and 
concentrations more than 50% of the cells are in apoptosis (Figure 4.5). 
In conclusion telomerase activity was significantly upregulated 48 hours after a low 
dose continuous etoposide treatment on the SHSY5Y cells, at the same time a 
significant decrease was also detected at the highest concentrations. This significant 
increase could be a response to the cytotoxic treatment. The later decrease in 
telornerase activity could have been a consequence of etoposide induced apoptosis 
rather than a cause of cell death. 
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Figure 4.25 Telomerase activity in SHSY5Y cells after continuous etoposide 
treatment. Relative telomerase activity was measured using a telomerase PCR 
ELISA. Data are mean ± SEM from at least four independent experiments. For each 
experiment, activities measured in untreated control samples were set as 100%. 
Statistically significant differences towards untreated controls are marked by an 
asterisk (p < 0.05, ANOVA). 
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4.3.9 DNA damage foci do not colocalise to the telomeres after 
etoposide treatment 
Etoposide treatment induces general genomic DNA damage in the SHSY5Y and 1301 
cells as confinned in Section 4.3.4 by assessing the frequency of DNA strand breaks 
and the DNA damage response. In order to determine whether DNA damage induced 
by etoposide occurs specifically in the telomeric DNA, immunoFISH was undertaken 
as described in Section 3.3.9. 
14 hours after a3 gM short exposure etoposide treatment (Figure 4.26), 1301 cells 
were fixed and stained with y-H2A. X, telomere PNA probe and DAPI nuclear stain. 
DNA damage foci were clearly present after the etoposide treatment and telomeric 
DNA was also detectable. Merged images display that the ma ority of DNA damage i 
foci do not colocalise to the telomeric DNA (ý! 8 cells out of 10 in triplicate fields in 
three independent experiments). 
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Figure 4.26 DNA damage foci do not colocalise with telomeres after a short 
exposure etoposide treatment. 1301 cells were fixed 14 hours after a4 hour 
treatment with -3) ýtM etoposide and stained as 
indicated. The merged image, show 
lack of colocalisation between DNA damage foci and telomeres. x 100 objective 
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4.4 Discussion 
There are several lines of evidence to suggest that telomere/ telomerase complexes 
could be important signal transduction intermediates in drug induced cell growth 
arrest and apoptosis (see Chapter 1). The telomere/ telomerase complex has been 
shown to be sensitive to etoposide treatment. For example, etoposide treatment of 
tumour cells has been claimed to shorten telomeres (Yoon et al., 1998) and modify 
telomerase expression and/ or activity (Spiropoulou et al., 2004). Inhibition of 
telornerase sensitised mice cells (Lee et al., 2001) and human cells (Ludwig et al., 
2001; Misawa et al., 2002) towards cytotoxic drugs including etoposide. Accordingly, 
overexpression of the catalytic subunit of telomerase increased the resistance of cells 
against etoposide (Ludwig et al., 2001; Zhang et al., 2003). However, a number of 
published results are contradictory. Some data, both in mice (Lee et al., 2001) and in 
human cells (Chen et al., 2003) suggest that it is telomere length rather than 
telomerase activity that modifies the sensitivity of cells to anti-cancer drugs. In 
contrast to that, arguments for a telomere length independent protective action of 
telomerase per se were found in a number of different systems (Saretzki et al., 2001; 
Ludwig et al., 2001; Sharma et al., 2003). Other authors, however, did not detect any 
effect of telornerase inhibition on the sensitivity of turnour cells to etoposide (Chen et 
al., 2003; Folini et al., 2000). 
The FADU data in Figure 4.13 confinns that, in the cells used here, etoposide induced 
widespread DNA strand breaks. Also the formation of foci of phosphorylated histone 
H2A. X (Figure 4.14) confirmed the classical DNA damage response. This was 
followed by a combination of growth arrest and apoptosis in a concentration and cell 
strain dependent manner. 
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To establish the role of telomeres in this process, we measured not only telomere 
length, but also length of single stranded telorneric G rich overhangs and the 
frequency of single strand breaks in the G-rich strand of telomeres. Since the 
importance of a telomere-dependent signal transduction pathway, if it existed at all, 
might be different in cells with long and short telomeres, we examined one cell line 
with very short (SHSY5Y, average telomere length -4 kbp) and one with extremely 
long (1301, average telomere length -80 kbp) telomeres. None of the parameters 
mentioned above changed significantly in either cell line under the treatments despite 
induction of growth arrest and/ or apoptosis. This is not in accordance with Yoon et al 
who show a slight shortening of telomeres in HeLa cells with telomere lengths of - 20 
kbp after a30 minute 100 ýM treatment with etoposide (Yoon et al., 1998). Whether 
this discrepancy to our results might be cell line specific, is not clear. However, our 
data clearly establish that measurable telomeric damage, might it be shortening, 
accumulation of single strand breaks or deterioration of the G-rich overhang, is not 
necessary as a signal transduction intermediate in etoposide induced tumour cell 
growth arrest and apoptosis. Additionally, there was no co-localisation of y-H2A. X 
foci with telomeric DNA after etoposide treatment. 
We next examined telomerase activity levels in SHSY5Y cells after continuous 
exposure to etoposide. Previous studies on telomerase activity after etoposide 
treatment have been somewhat contradictory. An upregulation of telomerase activity 
after etoposide treatment was reported in a human leukemic cell line, HL60 (Moriaty 
et al., 2002 and Mapper et al., 2003) and pancreatic tumour cell lines (Sato et al., 
2000). While a decrease was detected in hepatocarcinomas (Li et al., 2002) there was 
no change in haernatopoietic (Akiyarna et al., 1999) and nasopharyngeal cancer cells 
(Ku et al., 1997). Under our conditions of continuous treatment, we found a transient 
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increase of telomerase activity after 48 hours, which was significant under the lowest 
etoposide concentration. Even high concentrations of etoposide did not induce any 
immediate change in telomerase activity. However, a decrease of telomerase activity 
was observed with increasing concentration of etoposide and with increasing time of 
treatment. Comparison of telomerase data (Figure 4.5) with the time course of 
induction of apoptosis (Figure 4.25) reveals that telomerase activity only became 
reduced after the appearance of a high frequency of apoptotic cells. This indicates that 
loss of telomerase did not trigger apoptosis but was probably a consequence of 
apoptotic changes in cells. These results are in accordance with others (Akiyama et al., 
1999). Thus, downregulation of telornerase is a consequence, not a possible cause of 
etoposide induced apoptosis or growth arrest. However, the possibility remains that 
telomerase is upregulated also in response to higher etoposide concentrations, but that 
this is masked by a parallel induction of apoptosis. Thus, upregulation of telomerase 
might be part of a compensatory response of tumour cells to cytotoxic treatments. 
Telomerase could promote survival by a telomere-independent mechanism (See 
Section 1.8.3). In fact, upregulation of telomerase has been demonstrated in response 
to etoposide in previous studies (Moriarty et al., 2002; Klapper et al., 2003; Sato et al., 
2000). This is consistent with the idea of telomerase acting as a "survival factor" 
(Saretzki et al., 2001; Zhang et al., 2003; Shanna et al., 2003). 
Telomerase working as a protective factor has also been observed in MRC5 human 
fibroblasts which had been stably transfected with hTERT. The response after 
etoposide treatment between parental MRC5 and MRC5-hTERT cells indicated that 
hTERT expressing fibroblasts were efficiently protected from apoptosis (Jeyapalan et 
al., 2004). A similar protective effect of hTERT overexpression against the 
cytotoxcity of etoposide, other topoisomerase 11 poisons and cisplatin has been shown 
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before in other human cell lines (Ludwig et al., 2001; Zhang et al., 2003; Biroccio et 
al., 2003). 
4.5 Conclusions 
In conclusion, our data suggest that DNA strand breaks elsewhere in the genome (not 
in the telomeric region) occurring as direct consequence of etoposide treatment induce 
DNA damage foci fon-nation leading to apoptosis and/ or cell cycle arrest. While a 
transient activation of telomerase is evident under some conditions, which might be 
part of an attempted survival response, we find no indication that telomeres and/ or 
telomeric damage play any preferential role as a signal transducer towards apoptosis 
and/ or growth arrest in etoposide treated tumour cells. 
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CHAPTER 5 
FINAL DISCUSSION 
5.1 Introduction 
Telomeres appear to be particularly sensitive to DNA damage demonstrated by a 
number of factors. Firstly, telomeres are sensitive to DNA damage induced by UV 
(Kruk et al., 1995), oxidative stress (von Zg1inicki et al., 1995; Stewart et al., 2003) 
and possibly, chemotherapeutic drugs (Yoon et al., 1998). Secondly, dysfunctional 
telomeres trigger growth arrest and/ or apoptosis via telomere- specific induction of 
DNA damage foci, also termed senescence-associated DNA damage foci (d'Adda di 
Fagagna et al., 2003). Thirdly, inhibition of telomerase sensitises mice cells (Lee et al., 
2001) and human cells (Ludwig et al., 2001; Misawa et al., 2002) towards cytotoxic 
drugs. Accordingly, overexpression of the catalytic subunit of telomerase increased 
the resistance of cells (Ludwig et al., 2001; Zhang et al., 2003). Fourthly, drug 
treatment of tumour cells has been claimed to shorten telomeres (Yoon et al., 1998) or 
to modify telomerase expression and/ or activity (Spiropoulou et al., 2004). Some 
data, both in mice (Lee et al., 2001) and in human cells (Chen et al., 2003) suggest 
that it is telomere length rather than telomerase activity that modifies the sensitivity of 
cells to anti-cancer drugs. 
There have been indications that at least two classes of established anti-cancer drugs 
act on telomeric DNA, namely cisplatin (Section 3.1) and etoposide (Section 4.1). 
Though there are many contradicting studies. Therefore, the relationship between 
conventionally used DNA damaging drugs and the telomere/ telomerase complex are 
not at all clear. 
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5.2 Aim 
The aim of the work described in this study was to establish to what extent the 
telomere/ telomerase complex plays a role in the cytotoxic effects of the widely used 
anti-cancer drugs, cisplatin and etoposide. This has be done using cells with either 
short or long telomeres. An important aspect of the work was to distinguish effects of 
apoptotic changes from the direct effects of the drugs on telomere biology. This was 
approached by detennining whether or not induction of growth arrest and apoptosis 
preceded effects on telomeres and telomerase after drug treatments. Secondly, the 
work involved the determination of the spatial relationship between telomeres and 
DNA damage foci after drug exposure by development of an immunoFISH technique 
to detect telomeric DNA and DNA damage foci simultaneously. 
The cell lines used in this investigation were SHSY5Y, an adherent neuroblastoma 
cell line which has telomere lengths of -4-5 kbp and 1301, a non adherent acute 
lyrnphoblastic T cell line with telornere lengths of -80 kbp. Both cell lines are 
telomerase positive. The p53 status of the SHSY5Y is wildtype but it is thought to be 
not fully functional and the 1301 cell line has not been tested specifically but it is 
thought to be mutant for p53. 
5.3 Outline of Results 
5.3.1 Cisplatin 
The details of how cisplatin kills cancer cells are not fully understood but there is 
evidence to suggest that cisplatin binding to form DNA adducts is the central process 
(Section 1.10). The adducts so formed might act by blocking replication or by directly 
triggering a variety of DNA damage responses. Therefore one of the primary 
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objectives of this study was to determine whether cisplatin induces growth arrest/ 
apoptosis via the telomere/ telomerase complex which previous studies had suggested 
(Ishibashi and Lippard, 1998). In the present study the nature of the cytotoxic effect 
was confin-ned and the relationship between drug exposure and cytotoxicity of 
cisplatin on the SHSY5Y cells was defined. As expected, cisplatin induced apoptosis 
and an S phase arrest was detected after high concentrations of cisplatin with either 
short or continuous treatment. Cisplatin treatment did not induce strand breaks after 
initial drug exposure but strand breaks and DNA damage foci were detected 24 hours 
after treatment in the SHSY5Y cells. The H2A. X phosphorylation and strand damage 
detected in cisplatin treated cells over time may be associated with DNA repair, which 
has also been suggested by others who have seen H2A. X phosphorylation after 
cisplatin exposure (Huang et al., 2004). This possibility could be investigated by 
inhibiting ATM and measuring the effect on apoptosis i. e. to determine whether there 
is a delay. 
Telomere restriction fragment lengths, single stranded G rich overhang lengths and 
single strand breaks on the G rich telomeric strand after cisplatin treatment were 
measured and no deteetable telomeric DNA damage was observed in the SHSY5Y 
cells. This does not confinn the work of others which is fully discussed in Chapter 3 
Section 3.4 (Ishibashi and Lippard, 1998; Zhang et al., 2002). 
In the present study a decrease in telomerase activity was detected in the SHSY5Y 
cells at the highest concentrations and after the longest time points, where a large 
majority of the cells were in apoptosis in line with others (Akiyama et al., 1999; 
Cressey et al., 2002) and discussed in Chapter 3 Section 3.4. 
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The examination of DNA damage foci formation simultaneously with a telorneric 
DNA PNA probe in the 1301 cells after cisplatin treatment showed no localisation of 
DNA damage foci on telorneric DNA. 
5.3.2 Etoposide 
Etoposide, a topoisomerase 11 poison stabilises cleavable complex formation, 
inducing double strand breaks into a cell. In Chapter 4 the role of the telomere/ 
telomerase complex in etoposide induced cell death was examined, as previous work 
had suggested a link (Yoon et al., 1998). The cytotoxic effect of etoposide on the 
SHSY5Y and 1301 cells were confirmed with the induction of apoptosis. SHSY5Y 
cells were arrested in S phase, 48 hours after etoposide treatment and cells at this time 
point also had a senescence like phenotype. Etoposide treatment induced strand 
breaks after initial drug exposure and DNA damage foci were detected 24 hours after 
treatment. 
Telomere restriction fragment lengths, single stranded G rich overhangs and the G 
rich telomeric strand after cisplatin treatment were measured in both the SHSY5Y and 
1301 cells and no detectable specific, telomeric DNA damage was observed. This is 
not in accordance with another study (Yoon et al., 1998) and is fully discussed in 
Chapter 4 Section 4.4. 
Previous studies on telomerase activity after etoposide treatment have been somewhat 
contradictory (Section 4.1). In this investigation telomerase activity after a continuous 
etoposide treatment in the SHSY5Y cells was upregulated at low doses and at the 
same time decreased at the high concentrations. This upregulation of telomerase 
activity could be due to a protective factor of telornerase working in a telornere 
independent mechanism (Section 1.8.3) and the cells initial response to the cytotoxic 
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drug treatment. The decrease in telomerase activity levels is a consequence of high 
drug treatments and high apoptosis levels rather than a cause and js discussed fully in 
Chapter 4 Section 4.4. 
The examination of DNA damage foci formation simultaneously with a telomeric 
DNA PNA probe in the 1301 cells after etoposide treatment showed no colocalisation 
of DNA damage foci to telomeric DNA. 
5.4 Summary 
Under conditions where exposure to etoposide or cisplatin was shown to induce 
general DNA damage and H2A. X foci , at no time after drug exposure were there any 
detectable changes in lengths of telorneres or telomeric overhangs and no detectable 
level of single strand breaks in the G-rich telomeric DNA. This was shown to be true 
for cells with either long or short telomeres and for cells exposed to a wide range of 
drug concentrations. Exposure to the drugs generated both growth arrest and apoptosis 
in a concentration and time-dependent manner. Telomerase activity decreased only 
after onset of apoptosis. 
Although there was induction of genome wide DNA strand breaks but no strand 
breaks in telorneric DNA (telomere lengths, single stranded G rich overhang lengths, 
single strand breaks in G rich telomeric strand) were detected, there is no 
contradiction in the data. This is because the sensitivity of the telomere restriction 
fragment measurements to detect telomeric strand breaks (single or double strand) is 
in the order of I break per Mb. This is significantly lower than the sensitivity of the 
FADU assay where one strand break per chromosome can be detected (Birnboim and 
Jevcak, 1981). This may suggest that we are unable to detect the telornere damage 
which may lead to growth arrest/ apoptosis due to the low sensItivIty of the procedure 
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for telomere restriction fragment length analysis. Though in senescence studies any 
effect on telomere length which has been induced were large and easily measurable 
using the southern hybridisation technique. Also, cisplatin and etoposide induced 
DNA damage foci did not localise at the telorneres. 
The two cell lines, SHSY5Y and 1301 showed some differences in IC50 values and in 
levels of drug-induced apoptosis. Overall however, the telomeres/ telomerase 
complex in the SHSY5Y and 1301 cell lines generally displayed similar 
characteristics in response to cisplatin and etoposide treatment, in the sense that there 
is no role of the telomeres/ telomerase complex in cisplatin or etoposide induced cell 
death. 
5.5 Conclusions 
This study has extensively investigated the role of the telomere/ telomerase complex 
in drug induced DNA cell death by investigating two types of conventionally used 
anti-cancer drugs, cisplatin and etoposide whose mode of action target DNA through 
contrasting mechanisms. Furthermore, the response was evaluated on cell lines with 
either short (SHSY5Y) or long telomeres (13 0 1). 
In conclusion, this thesis has demonstrated that there was no preferential damage to 
telomeres as a result of exposure to cisplatin or etoposide. Consequently, telomeres do 
not play an exceptionally important role as signal transducers towards apoptosis and/ 
or growth arrest in these cell lines following exposure to these drugs, unless low 
levels of damage in telomeres triggers a particularly important type of damage 
response. The cell lines responded to the drug treatments by a combination of S phase 
arrest and apoptosis. A transient activation of telomerase was evident after some 
conditions of etoposide treatment which might be part of an attempted survival 
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response. However, the main drug induced changes in telomerase activity were 
decreases in activity levels following high drug exposures and long treatment times. 
These decreases were rather a consequence of than a cause of, apoptosis. 
The thesis studies suggest that DNA strand breaks are not occurring on telomeric 
DNA and the cytotoxicty observed must therefore have resulted from damage in other 
regions of the genome, inducing DNA damage foci formation and leading to 
apoptosis and/ or cell cycle arrest. 
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